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Abstract 
Two closely related bovine lentiviruses have been described, Jembrana disease virus 
(JDV) and Bovine immunodeficiency virus (BIV), that produce very different clinical 
manifestations in infected cattle. JDV causes an acute disease with a case fatality rate 
of about 21% in Bos javanicus (Bali cattle) and is endemic in the cattle population of 
parts of Indonesia. BIV produces a subclinical infection in Bos taurus and buffalo 
and serological evidence has shown that this virus has a worldwide distribution, 
possibly including Indonesia. 
Attempts were made to confirm a previous report that BIV was present in the 
B. javanicus population in Indonesia. BIV proviral DNA was not detected in any of 
the animals although JDV proviral DNA was detected in 12 of 171 animals, only one 
of which was seropositive.  
To define the kinetics of BIV infection in B. javanicus and determine the optimal 
time for sampling to detect BIV infection, 13 animals were experimentally infected 
with the R29 strain of BIV. No clinical effects were detected but proviral DNA was 
detected from 4-60 days post-infection (dpi) with peak titres 20 days dpi, and a 
transient viraemia from 4 to 14 dpi. An antibody response to TM was detected 12 dpi 
but an anti-capsid (CA) antibody response was detected in one animal only and not 
until 34 dpi. The results indicated that detection of BIV in infected Bali cattle using 
PCR would have a greater chance of success soon after infection and prior to the 
onset of a CA antibody response. 
To determine the effect of BIV infection on subsequent JDV infection in 
B. javanicus, 15 cattle were infected with BIV-R29 and 9 of these were subsequently 
infected 42 days later with JDV. The response to BIV was typical of that observed     ii 
previously but BIV infection did not markedly modify the response to subsequent 
infection with JDV. In response to JDV infection, all cattle previously infected with 
BIV still developed an acute disease process typical of Jembrana disease. The results 
suggested that despite the close genetic and antigenic relationship between BIV and 
JDV, BIV infection does not confer protection against subsequent JDV infection. 
The close antigenic relationship between BIV and JDV is a problem in the 
development of specific serological tests and immunosurveillance of JDV infection. 
To develop reagents capable of differentiating between antibody to BIV and JDV 
infections, peptide mapping was used to define linear B cell epitopes on the matrix 
(MA), CA and surface unit (SU) proteins of JDV. Short overlapping peptides that 
spanned these regions were synthesised and used in an ELISA format to screen their 
reactivity with a panel of bovine sera from animals experimentally infected with 
JDVTab87, JDVPul01 or BIV-R29. Peptides representing potential immunoreactive 
epitopes were identified that appeared to offer promise in the development of JDV-
specific serological tests and need to be tested further with a panel of sera taken from 
naturally infected cattle.  
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Chapter 1: Introduction 
Two bovine lentiviruses have been described, Jembrana disease virus (JDV) and 
Bovine immunodeficiency virus (BIV). The 2 viruses, although genetically and 
antigenically related, have been reported to have very different pathogenic effects in 
cattle. JDV causes a severe, acute disease in Bali cattle (Bos javanicus) and a mild 
disease or subclinical infection in other breeds of cattle, including B. taurus 
(Soeharsono et al., 1990). The disease in Bali cattle is acute and associated with a 
marked febrile response, very high titres of infectious virus in the blood and a case 
fatality rate of about 21% (Soesanto et al., 1990). BIV infection is generally not 
associated with significant clinical changes in B. taurus breeds of cattle, although 
they have been reported: one study found an association between BIV and decreased 
milk yield in dairy cattle (McNab et al., 1994) and another associated BIV infection 
with marked weight loss and concurrent infections, suggesting immunosuppression 
(Snider et al., 2003b). JDV appears to have a limited geographic distribution and is 
restricted to Indonesia where Bali cattle are found (Hartaningsih et al., 1993), while 
serological surveys have provided evidence for a worldwide distribution of BIV in 
both cattle and buffalo (Bubalus bubalis) (Gonzalez et al., 2008; McNab et al., 1994; 
Meas et al., 1998; Meas et al., 2000a; Meas et al., 2000b; Suarez et al., 1993). There 
is also serological evidence of infection with a related non-pathogenic BIV-like virus 
in Bali cattle in Indonesia on the island of Sulawesi and also in Bali (Barboni et al., 
2001; Desport et al., 2005). Although infection with a BIV-like virus has been 
suspected in Bali cattle in Indonesia, this has not been confirmed. There is no 
evidence of the nature of BIV infection in this cattle species and what effect BIV 
infection might have on subsequent JDV infection.       2 
This thesis describes the development of a serological diagnostic assay to 
differentiate JDV and BIV infection, the effects of BIV in Bali cattle and the 
interaction between BIV and JDV infections in Bali cattle. As a background to these 
investigations, a review of the literature relating to JDV and the other lentiviruses has 
been undertaken and is reported in Chapter 2. The review includes the key features of 
the various lentiviruses, comparing their genome arrangement, replication and host 
immune responses to infection. It also includes the various techniques that have been 
described for diagnosis of lentivirus infections, methods of differentiating between 
closely-related lentivirus infections and the effects of infection with multiple strains 
of closely related lentiviruses. 
Chapter 3 describes an attempt to detect JDV and BIV in Bali cattle on the island of 
Bali. Two quantitative PCR (qPCR) assays were developed to detect JDV and BIV 
proviral DNA within peripheral blood mononuclear cells (PBMC) of naturally 
infected animals.  
Despite serological evidence for the presence of BIV in the Bali cattle population on 
the island of Bali, the investigations reported in Chapter 3 failed to detect evidence of 
BIV in the cattle that were sampled. Investigations were therefore undertaken to 
determine the susceptibility of Bali cattle to BIV infection in an effort to better 
understand the nature of the infection in this species, and these investigations are 
reported in Chapter 4. Nineteen cattle were experimentally infected with the R29 
strain of BIV and monitored for up to 65 days after infection. The presence of virus 
in plasma and other tissues, the presence of proviral DNA in the PBMC and other 
tissues, and the immune response to virus antigens was examined and is reported.        3 
The possibility that BIV infection of Bali cattle might modify the effect of 
subsequent JDV infection was also investigated and these results are presented in 
Chapter 5. These studies were undertaken to determine what might happen on the 
island of Sulawesi, where BIV infection is suspected to occur in Bali cattle, if JDV 
were to spread through the Bali cattle population of that island. If prior BIV infection 
were to inhibit subsequent JDV infection, it was hypothesised that this might form 
the basis of a method of vaccination for the control of Jembrana disease. 
Due to the presence of cross-reactive epitopes between JDV and BIV proteins, 
current serological assays are not capable of discriminating between antibody to the 
2 bovine lentiviruses. During the studies undertaken and reported in Chapters 3, 4 
and 5, the difficulty of distinguishing antibody to BIV and JDV made it difficult to 
monitor the serological response to the individual virus infections. An attempt was 
therefore made to develop a peptide antigen capable of differentiating between 
antibody to the 2 viruses. Overlapping virus peptides were synthesized and used in 
an enzyme linked immunosorbent assay (ELISA) format with serum samples taken 
from JDV and BIV infected cattle to determine their reactivity to the peptides. The 
results are reported in Chapter 6. 
A general discussion of the results obtained and reported in the thesis is presented in 
Chapter 7.      4 
Chapter 2: Literature Review 
This review covers the general biological features of the retroviruses and 
lentiviruses, in particular the lentiviruses that cause disease in animals. Also 
reviewed are the various immune responses to animal lentivirus infection (including 
cross-reactive epitopes) and the phenomenon of lentivirus superinfection resistance.  
The nomenclature used in this thesis for viral genes and proteins is that suggested by 
(Fauquet, 2005) where gene names are in lower case and italicised, eg. env, and 
where the abbreviations for the encoded proteins have the initial letter in uppercase 
and are not italicised, eg. Env and TM.   
Retroviruses 
Physiochemical characteristics of retroviruses 
The key feature of the family Retroviridae is their mode of replication, involving 
reverse transcription of the virion RNA into linear double-stranded DNA (Baltimore, 
1970; Temin et al., 1970), and the integration of this double-stranded proviral DNA 
into the genome of the cell. This reverses the normal flow of genetic information 
from DNA to RNA, hence the name retrovirus (Coffin, 1997).  
Retrovirus taxonomy 
Many viruses have been classified within the family Retroviridae with a significant 
proportion of them associated with disease (Coffin, 1997). On the basis of 
evolutionary relatedness, retroviruses are separated into 7 genera: Lentivirus, 
Spumavirus, Alpharetrovirus, Betaretrovirus, Gammaretrovirus, Deltaretrovirus and 
Epsilonretrovirus (Buchschacher, 2001). The lentiviruses and spumaviruses are 
distinct from the other 5 genera in that they do not have oncogenic potential. Some of 
the well known oncogenic retroviruses include Rous sarcoma virus, Human T-      5 
lymphotropic virus (HTLV-1) and Mouse mammary tumour virus. Less well 
understood and researched are the spumaviruses which cause no known disease, of 
which Human spumavirus is the type species (Coffin, 1997; Goff, 2001). The 
lentiviruses have been studied extensively since the discovery of Human 
immunodeficiency virus (HIV). 
Lentiviruses 
Most lentivirus infections are characterised by a long asymptomatic period before the 
onset of chronic clinical disease with a slow but inevitable progression to death 
(Campbell et al., 1998). Examples of lentiviruses inducing this type of chronic 
infection include Visna maedi virus (VMV), HIV and Caprine arthritis encephalitis 
virus (CAEV). Some, however, induce a rapidly progressive acute disease, including 
JDV, Equine infectious anaemia virus (EIAV) and the Simian immunodeficiency 
virus (SIV) SIVsmm-PBj. This section will review features of lentiviruses that are 
common to the majority of members of the genus, including genome structure and 
organisation, their mode of replication and common clinical features of infection. 
General structure of lentiviruses 
Lentiviruses are roughly spherical in shape with an average virion diameter of 
approximately 100 nm including the surrounding bilayered lipoprotein envelope 
(Fauquet, 2005). They are sensitive to heat, detergent and formaldehyde (Goff, 
2001). The envelope contains 2 types of surface projections, the surface unit (SU) 
and transmembrane (TM) glycoproteins (Fauquet, 2005; Wagner, 1999). The internal 
virion is composed of the distinctively cone-shaped capsid (CA) which surrounds the 
nucleocapsid (NC) and contains protease (PR), integrase (IN) and reverse 
transcriptase (RT) enzymes (Figure 2.1). The RNA genome is located within the 
nucleocapsid (Goff, 2001).          6 
 
The lentivirus genome 
Lentiviruses have 2 identical linear, positive-sense, single-stranded RNA genomes 
which range in size from 7-10 kb (Goff, 2001; Peterlin, 1995). Reverse transcription 
takes place from one strand at a time. There are 3 major open reading frames (ORF) 
in each strand that transcribe and translate 3 polyproteins which are then cleaved by 
proteases into approximately 8 proteins. The 3 polyproteins are Gag, Pol and Env 
(Figure 2.2). The gag ORF produces the structural proteins MA, CA and NC. The pol 
ORF encodes the intravirion enzymes: RT responsible for copying the single-
stranded RNA genome into the double-stranded DNA, IN which is required to 
incorporate the double stranded DNA into the host genome forming the provirus, and 
PR, required to cleave the encoded polyproteins into smaller proteins (Miller et al., 
2000; Tobin et al., 1994). The env gene produces the 2 envelope proteins, SU and 
TM, which play a vital role in receptor recognition and entry of the virus into the cell 
(Fauquet, 2005; Wagner, 1999). 
 
Figure 2.1. (A) Schematic representation of a mature HIV-1 virion, showing the location of the 
major viral proteins, the lipoprotein envelope and genomic RNA. (B) Tomogram of a mature HIV-1 
particle derived by electron cryotomography. Images from Ganser-Pornillos et al. (2008).       7 
In addition to the obligatory gag, pol and env ORF common to every retrovirus, 
lentiviruses also have a number of accessory genes (Table 2.1), including rev, tat, vif, 
vpr, vpu and nef (Fauquet, 2005), which modulate the replication of the virus and 
probably contribute to clinical latency and pathogenic mechanisms (Clements et al., 
1996). Rev plays an essential role in the replication cycle of all lentiviruses as it 
facilitates the export from the nucleus of unspliced RNAs whose translated products 
are later utilised in virus replication (Malim et al., 1989). Like Rev, Tat is produced 
early in the replication cycle and plays a role in the expression of viral transcripts 
from a promoter within the long terminal repeat (LTR) (Miller et al., 2000). HIV Tat 
has also been shown to modulate the expression of cellular genes and has numerous 
other roles in viral replication and pathogenesis (Chen et al., 2000). FIV is the only 
lentivirus without the tat ORF but ORF2 encoded by orf2 is predicted to have Tat-
like activity and to act via cellular transcription factors during the expression of viral 
transcripts from the promoter within the viral LTR (Chatterji et al., 2002; Miller et 
al., 2000; Miyazawa et al., 1994) but requires additional elements within the LTR, 
unlike other lentivirus Tat proteins (Chatterji et al., 2002). It has been proposed that 
VMV and CAEV lack a tat ORF and that the ORF that is designated tat in these 
viruses (named tat because of its similar position in the genome to the tat ORF in the 
primate lentiviruses) instead encodes a Vpr-like accessory protein (Villet et al., 
2003).        8 
 
Figure 2.2. Genome organisation of lentiviruses. The location of the structural and accessory genes 
are indicated, orientated 5’ to 3’. Each virus has 3 major open reading frames, gag, pol and env, which 
transcribe and translate 3 polyproteins. Image from Craigo et al. (2010).        9 
The vif ORF is transcribed and translated to Vif (viral infectivity factor), thought to 
aid in the infectivity and spread of virus, although its mechanism of action is still 
unclear (Clements et al., 1996; Miller et al., 2000). Vif has recently been implicated 
in protecting virions against the actions of Apolipoprotein B mRNA-editing enzyme-
catalytic polypeptide-like (APOBEC) proteins. APOBEC3G and APOBEC3F are 
cytidine deaminases which are packaged into HIV-1 virions and result in the 
production of non-infectious virions due to the hypermutation of HIV proviral DNA. 
Vif protects the virus against lethal incorporation of the APOBEC proteins by 
marking them for ubiquitin-dependent degradation (Goila-Gaur et al., 2008, Romani 
et al., 2009).  
Vpr encodes Vpr (viral protein R) which, in HIV-1, mediates the nuclear import of 
viral RT complexes in non-dividing cells and alters the cell cycle and proliferation 
status of the infected host cell. In HIV-2 and SIVsm, Vpr inhibits cell cycle 
progression while Vpx (encoded by vpx) is responsible for the nuclear import of the 
viral RT complex (Fletcher et al., 1996; Stivahtis et al., 1997). The vpu ORF encodes 
Vpu (viral protein U) that enhances the efficiency of virion production and induces 
rapid degradation of CD4 (Maldarelli et al., 1993). The nef ORF encodes Nef 
(negative factor) whose function is to decrease the expression of CD4 on T-cells; it is 
thought to have this effect by increasing the rate of endocytosis of CD4 on the cell 
surface which would ultimately prevent re-infection of cells that already harbour the 
virus (Benson et al., 1993; Goff, 2001; Peterlin, 1995). The accessory ORF s2 is 
unique to EIAV and its role in virus replication is unclear but it is thought to play a 
part in replication and virulence of EIAV (Li et al., 1992; Nilsen et al., 1996). 
       10 
Table 2.1. Accessory genes of each lentivirus, presence indicated by Ö (Chakrabarti 
et al., 1987; Chatterji et al., 2002; Clements et al., 1996; Dewhurst et al., 1990; 
Freed, 2001; Li et al., 1992; Miller et al., 2000; Nilsen et al., 1996; Stivahtis et al., 
1997; Tobin et al., 1994). SIVsm has a gene encoding the Vpx protein, other SIVs 
lack this gene (Stivahtis et al., 1997). The presence of tat within the VMV and 
CAEV genomes has been debated (Villet et al., 2003). 
 
 
 
HIV-1  HIV-2  SIV  FIV  VMV  CAEV  EIAV  BIV  JDV 
vif  Ö  Ö  Ö  Ö  Ö  Ö    Ö  Ö 
vpx    Ö  Ö             
vpr  Ö  Ö  Ö             
tat  Ö  Ö  Ö    Ö  Ö  Ö  Ö  Ö 
rev  Ö  Ö  Ö  Ö  Ö  Ö  Ö  Ö  Ö 
vpu  Ö    Ö             
nef  Ö  Ö  Ö             
tmx               Ö  Ö  Ö 
Other 
ORF 
      2/A      S2 
vpw, 
vpy 
 
 
 
Lentivirus replication 
Infection of a cell by a lentivirus commences at the surface of the host cell (Figure 
2.3). The SU interacts with specific receptors on the target cell. For example, HIV-1 
SU interacts with the CD4 receptor located on the surface of T-lymphocytes and 
monocytes/macrophages. The interaction brings about a conformational change in 
the TM glycoprotein and ultimately leads to the fusion of the viral envelope with the       11 
membrane of the target cell (Clapham et al., 2002; Clements et al., 1996). The virus 
then moves into the cytoplasm where it is partially uncoated and virion enzymes 
encoded by pol are released. The virion enzymes RT and RNase H copy the viral 
RNA within the partially uncoated virion, generating a double-stranded DNA copy 
of the viral RNA genome, referred to as the provirus. The provirus forms a complex 
with a number of viral proteins including IN, MA, NC, RT, and possibly others, to 
form the pre-integration complex, which translocates to the nucleus. Integrase then 
catalyses the insertion of the linear, double-stranded viral DNA into the host cell 
chromosome (Freed, 2001). At this point, the proviral DNA may remain integrated 
and the cell can remain latently infected, or a productive infection may result. It 
remains unclear as to what causes a cell to become productively infected, although it 
is thought that the presence of specific transcription factors present in mature cells 
may stimulate transcription of viral genes. For example, it has been proposed that the 
binding of the transcription factor NF-kB, which is found in activated T-
lymphocytes, to the HIV-1 LTR, is important for transcriptional activation in vitro of 
HIV-1 in T-cell lines (Clements et al., 1996; Wagner, 1999). Others have proposed 
that defective HIV-1 particles preferentially activate CD4+ T-cells which render 
them permissive for HIV replication and help to drive HIV pathogenesis (Finzi et al., 
2006). 
Once transcription has been activated, expression of viral mRNA begins when RNA 
polymerase II binds to the U3 region of the 5' LTR and transcription then proceeds 
towards the 3' end of the provirus and into the host DNA. The RNA is cleaved and 
polyadenylated at the R-U5 border of the 3' LTR (Figure 2.4), which yields a 
complete unspliced viral genomic RNA suitable for incorporation into the virion 
particle. A portion of the RNA produced at this level is then spliced by the cellular       12 
splicing machinery to give rise to one or more subgenomic RNAs. Both the 
unspliced and spliced RNAs are exported from the nucleus for translation (Goff, 
2001).  
Once in the cytoplasm, the RNAs transcribed from gag, pol and env are translated by 
ribosomes into polyproteins (large precursor protein molecules). In HIV, the gag 
ORF encodes a polyprotein precursor of 55 kDa, designated Pr55
Gag, that is cleaved 
by viral PR to produce MA (p17), CA (p24), NC (p7) and p6. The pol-encoded 
enzymes are initially synthesised as part of a large polyprotein precursor, Pr160
GagPol 
that is cleaved by the virus encoded protease into PR, RT and IN. The Env precursor, 
gp160, is cleaved by cellular protease into SU (gp120) and TM (gp41) (Egberink et 
al., 1992; Freed, 2001). 
Gag and Gag-Pol precursors assemble beneath the plasma membrane and incorporate 
viral genomic RNA during the process of budding, while SU and TM glycoproteins 
are also inserted into the viral envelope at this stage. After the virion has been 
released, it matures when PR cleaves Gag precursors into their functional subunits. 
The mature virion is then able to infect other cells (Tobin et al., 1994).       13 
 
 
 
Figure 2.4. Schematic illustration of the changes to lentivirus long terminal repeats during the change 
from viral RNA to proviral DNA to viral mRNA (transcript). Illustrations are orientated 5’ to 3’. The 
positions of the R (repeat), U3 and U5 regions are shown. Viral mRNA is expressed when RNA 
polymerase II binds to the U3 region of the 5’ LTR. Image from Coffin et al. (1997).  
 
Figure 2.3. Schematic illustration of the lentivirus replication cycle depicting the major events in 
the replication cycle. Image from Ganser-Pornillos et al. (2008).        14 
 
Common characteristics of lentiviruses  
Members of the genus Lentivirus share a number of features. They all replicate in 
non-dividing terminally differentiated cells, have the ability to integrate their 
genomes into the chromosomal DNA of non-dividing infected cells and they are 
highly species-specific in terms of their ability to cause disease. Common clinical 
features of infection shared by the majority of lentiviruses include long 
asymptomatic incubation periods before the onset of a usually chronic disease, 
persistence of virus infection in the face of vigorous immune responses including 
neutralising antibody and cytotoxic T-lymphocytes (CTL), multi-organ disease and 
replication in cells of the immune system and brain (Clements et al., 1996; Mealey et 
al., 2004; Trautwein, 1992). It is often the immune response of the host against the 
infected cells that results in the wide range of disease symptoms observed (Gonda, 
1992).  
The ability of the viruses to persist in the infected host is, at least in part, associated 
with the capacity of lentiviruses to exhibit a wide array of genetic and antigenic 
variations, particularly in env. Variations are produced in response to biological and 
immunological selective pressures as the virus (usually) successfully avoids 
clearance by defence mechanisms (Leroux et al., 2001; Mealey et al., 2004).        15 
Primate lentiviruses 
HIV and SIV cause disease in primates and it is the study of these lentiviruses that 
has resulted in most of our knowledge of the molecular biology and mechanisms of 
disease associated with lentivirus infections. This section will review HIV and SIV 
with a particular focus on their genome organisation, cell tropism, clinical features of 
diseases they induce, and species specificity.  
Human immunodeficiency virus 
Arguably the most studied virus in the world today, HIV was first identified in 1983 
as the agent responsible for an acquired immunodeficiency syndrome (AIDS) which 
led to opportunistic infections and eventually death (Barre-Sinoussi et al., 1983; 
Gallo et al., 1984). It has assumed very significant pandemic proportions and it is 
estimated that about 33 million people are infected with the virus (UNAIDS, 2008).  
Based on epidemiological and genetic studies, HIV isolates form two clusters, HIV-1 
and HIV-2, which are distinguished by variations primarily in env. They also show 
differences in transmission rate and pathogenicity (Levy, 2009). HIV-1 is the type 
species of the genus Lentivirus and although the published literature describing 
aspects of the molecular biology of HIV-1 and the associated infection is very large, 
a brief overview only will be given in this review.  
Many lentiviruses evade the host immune system via their genetic variability (Lopez 
et al., 2006). Phylogenetic analyses of HIV-1 isolates from around the world indicate 
that more than 10 major groups of distinct genetic subtypes or clades of HIV-1 can 
be distinguished. Clades are differentiated by genomic differences in env of 15% or 
greater (Barker, 1995). The distribution of the clades tends to have a geographic 
basis: Subtype C (clade C) infections are most commonly found in south Africa, 
India, Ethiopia and east Africa. Subtype A clades are found in eastern Europe,       16 
central Asia, west, east and central Africa while subtype B is present in the 
Americas, western Europe and east Asia. Subtype D is present in north Africa, the 
middle east, east and central Africa (Hemelaar et al., 2006).  
In HIV the major determinants of cell tropism are the cell surface receptors used to 
gain entry into the cell. HIV-1 uses the CD4 receptor and a co-receptor to enter the 
host cell (Sattentau et al., 1988). The main cells that have the 2 receptors needed for 
HIV-1 to gain entry are the CD4+ T-helper subset of lymphocytes, the CD4+ cells of 
macrophage lineage and some dendritic cells (Clapham et al., 2002; Freed, 2001). 
Major co-receptors for  HIV-1 include the 2 chemokine receptors CCR5 (expressed 
on macrophages) and CXCR4 (expressed on T-cells) but other co-receptors are used 
(Deng et al., 1996; Doranz et al., 1996; Feng et al., 1996). CCR5-utilising HIV-1 
variants dominate the early phases of HIV-1 infection while CXCR4-utilising HIV-1 
variants dominate the latter phases of HIV-1 infection, and the switch from CCR5-
utilising to CXCR4-utilising is associated with accelerated disease progression (Ito et 
al., 2003). 
HIV-1 will establish infection in both humans and chimpanzees but will only cause 
disease in humans, with a few rare exceptions (Freed, 2001, Keele et al., 2009). 
There are 3 phases to the course of HIV infections. In the initial phase, there is a 
period of rapid virus replication associated with influenza-like symptoms, 
commencing about 2 weeks post infection (pi) and lasting for 2-3 weeks. 
Subsequently, there is a variable asymptomatic period of weeks to years during 
which lymphadenopathy can develop. In the third phase, the destruction of the T-cell 
population causes the onset of AIDS, seen in about 30% of infected people within 5-
7 years and later in others (Campbell et al., 1998). The loss of T-cells results in the 
body being unable to overcome opportunistic infections, and the immune system       17 
finally fails, which without anti-viral therapy will ultimately lead to death (Wagner, 
1999). The loss of CD4+ T-cells and the changes in HIV RNA levels are shown in 
Figure 2.5. Key clinical manifestations of HIV-1 infection are immunodeficiency, 
lymphadenopathy, opportunistic infections, encephalopathy, emaciation, Kaposi's 
sarcoma and other cancers (Gonda, 1992).  
 
Simian immunodeficiency viruses 
Simian lentiviruses have been identified in several species of non-human primates by 
epidemiological studies using serological assays and virus isolation. Each SIV is 
named with a subscript that denotes the species from which the virus was first 
isolated, for example those from sooty mangabeys as SIVsmm, from macaques as 
SIVmac and from chimpanzees as SIVcpz (VandeWoude et al., 2006). In their natural 
host to which they have adapted they do not normally cause disease but when they 
infect species in which they do not normally occur, disease frequently results. These 
 
 
Figure 2.5. The progression from infection with HIV to death in a victim. The patient was infected 
at or near week 0. The diagram illustrates the levels of HIV RNA, the gradual decline in CD4+ T-
cells and the onset of clinical signs. Image from Pantaleo et al. (1995).       18 
viruses share many features in common with HIV, particularly nucleotide homology, 
genome organisation, size (approximately 9 kb in length), receptor usage as well as 
the clinical manifestations of disease they induce in non-natural hosts (Clements et 
al., 1996; Sattentau et al., 1988).  
All SIV have a tropism for CD4+ macrophages or T-cells. Macrophage-tropic (M-
tropic) SIV can efficiently replicate in macrophages, primary CD4+ T-cells and a 
variety of T-cell lines whereas T-cell-tropic (T-tropic) SIV replicate in primary 
CD4+ T-cells and in T-cell lines but not macrophages (Edinger et al., 1999). Both M- 
and T-tropic SIV strains use CCR5 to gain entry into CD4+ cells (Edinger et al., 
1997). The locations of viral replication are thought to be responsible for the varying 
clinical manifestations of SIV infection: replication in cells of the 
monocyte/macrophage lineage results in disease manifestations in the central nervous 
system and lungs; replication in lymphocytes results in a loss of CD4+ lymphocytes 
which in turn results in immunodeficiency and increased susceptibility to 
opportunistic infections (Sharma et al., 1992). 
While the majority of SIV cause disease after a relatively long period of infection, 
there are strains which cause disease after only a short incubation period, such as 
SIVsmmPBj14. This strain causes an cute disease and death within 6 to 10 days after 
intravenous inoculation into pig-tailed macaques and rapidly replicates to high titres 
(Fultz et al., 1994, Tao et al., 1995). The lethal nature of this phenotype is possibly 
associated with insertions within the V1 region of env and within the NF-κB 
enhancer element in the LTR, which enhances transcription and replication kinetics 
(Tao et al., 1995).       19 
SIV that originate in African primate hosts are thought to be relatively ancient 
viruses that result in non-pathogenic infections in their native hosts. A similar 
situation is seen with lentivirus infections of non-domestic cats (Hahn et al., 2000; 
Terwee et al., 2005).  
Non-primate lentiviruses 
Feline immunodeficiency virus 
FIV is associated with acquired immunodeficiency in cats and was first isolated in 
California (Pedersen et al., 1987). Since its initial isolation, similarities in the disease 
syndrome induced in cats to that of HIV in humans have created considerable interest 
in the virus as a potential animal model for HIV infection (Dandekar et al., 1992; 
Dua et al., 1994; Gardner et al., 1989; Olmsted et al., 1989). The virus infects several 
species of Felidae, including the domestic cat Felis cattus, throughout the world but 
particularly in Europe, East Asia, Australasia and North America (Brown et al., 
1994; Duarte et al., 2006; Little et al., 2009; Olmsted et al., 1992). Circumstantial 
evidence suggests that the most efficient mode of virus transmission is horizontally 
by biting (Yamamoto et al., 1989). Other studies have shown that it can be 
transmitted through semen and vertically during pregnancy (Jordan et al., 1998; 
Wasmoen et al., 1992). 
FIV has a broader target cell range than HIV and replicates in both CD4+ and CD8+ 
lymphocytes, macrophages and immunoglobulin G-positive lymphocytes (Beebe et 
al., 1994; Brown et al., 1991; English et al., 1993). The primary receptor of FIV is 
CD134, a T-cell-activation antigen and co-stimulatory molecule (Shimojima et al., 
2004).  Known co-receptors include CXCR4 (Willett et al., 1997). The progression 
from infection to immunosuppression to death in domestic cats is well characterised 
and mirrors HIV-1 infection in humans. There is a transient acute stage of the illness       20 
a few weeks pi that is characterised by fever and lymphadenopathy. The next phase 
is asymptomatic, lasting up to 5 years. The third and final phase of infection is 
characterised by a gradual decline in CD4+ T-lymphocytes leading to 
immunodeficiency. This stage, like AIDS in HIV-infected humans, is characterised 
by the occurrence of opportunistic infections, neurological disorders and tumours of 
various aetiologies, resulting in death usually within a few months (Dean et al., 1996; 
Egberink et al., 1992; Ryan et al., 2003; Sauter et al., 2001).  
Analogous to SIVsmmPBj14 inoculation into pig-tailed macaques, FIV-CPGammar also 
causes an acute disease with a high case fatality rate. Mortalities range from 50 to 
100% in kittens ≤12 weeks of age after a short incubation period following 
intravenous inoculation However, in contrast to SIVsmmPBj14, acute phase virulence 
was induced by acute-phase virus passage (Diehl et al., 1995) and the severe and 
rapidly progressive disease could not be induced in young adult cats (Pedersen et al., 
2001).        21 
FIV in non-domestic feline species 
Serological surveys of a number of non-domestic feline species have revealed at least 
17 species with FIV-like virus infection (Brown et al., 1994; Olmsted et al., 1989; 
VandeWoude et al., 2006; VandeWoude et al., 2002). Isolates from pumas (also 
referred to as cougar, mountain lion and panther; Puma concolor), lions (Panthera 
leo), Pallas cat (Felis manul) and bobcats (Lynx rufus) have been genetically 
characterised (Poss et al., 2006; Poss et al., 2008), and these isolates are distinct from 
each other and are related to, but distinct from FIV of the domestic cat (Olmsted et 
al., 1992). The standard nomenclature for designation of strains originating from 
different species is to append genus and species identifiers for the feline species as a 
subscript to FIV. For example FIV isolated from a lion is referred to as FIVple and 
domestic cat as FIVfca (Brown et al., 1994; VandeWoude et al., 2006). 
The available evidence indicates these viruses have been endemic within cat families 
for a long period (Biek et al., 2006). Although the clinical effects of FIV from non-
domestic cat populations have not been well studied, it appears that infections due to 
these viruses do not cause widespread disease (Biek, 2006; Brown et al., 1994; 
VandeWoude et al., 2002; VandeWoude et al., 2003). The asymptomatic nature of 
infection is most probably because of a long evolutionary association between virus 
and host (Biek, 2006). Signs of neurologic disease have been reported in captive 
lions (Brennan et al., 2006) but this may be attributed to the animals outliving their 
“normal” life span. FIVpco from pumas is able to establish a productive infection in 
domestic cats but does not cause T-cell dysregulation (unlike FIVfca) or clinical signs 
and is able to be cleared from PBMC rapidly (Terwee et al., 2005; VandeWoude et 
al., 2003). These cats also generate humoral and cell-mediated immune responses       22 
reactive against both FIV and non-domestic cat isolates of FIV (VandeWoude et al., 
2003).  
Equine infectious anaemia virus 
EIAV, the cause of a chronic relapsing or intermittent anaemia in horses, was the 
first lentivirus to be identified and the first non-plant virus to be discovered (Leroux 
et al., 2004; Ligné, 1843; Vallée, 1904). The virus causes a persistent infection in 
horses and closely related equids, such as donkeys and mules (O'Rourke et al., 1988; 
Spyrou et al., 2003). It is transmitted mechanically mainly by blood-feeding biting 
arthropods such as tabanids, or iatrogenically on contaminated needles, but contact 
infection can also occur (Hawkins et al., 1976; Kemen et al., 1978; Li et al., 2003; 
Williams et al., 1981). Because of its transmission by arthropods, the infection is 
most common in geographic areas with long vector seasons (Issel et al., 1988).  
EIAV is an exclusively tissue macrophage-tropic lentivirus which utilises the equine 
lentivirus receptor-1 to gain entry into macrophages (Sellon et al., 1992; Zhang et al., 
2005). The virus causes a relapsing disease characterised by periods of depression, 
fever, diarrhoea, anaemia, thrombocytopenia and haemorrhaging due to severe 
depletion of platelets, which are associated with a high level viraemia (Hammond et 
al., 1997; Harrold et al., 2000; O'Rourke et al., 1988; Oaks et al., 1998). The disease 
cycles begin approximately 1-3 weeks pi, last 3-5 days and occur at irregular 
intervals of weeks to months. The periodic disease cycles occur for 8-12 months pi, 
after which infected horses normally progress to a subclinical infection lasting for the 
life of the infected animal; these persistently infected animals serve as a source of 
infection for other animals (Hammond et al., 1997; Issel et al., 1982; Montelaro et 
al., 1984; Oaks et al., 1998; Payne et al., 1998; Salinovich et al., 1986). Between the 
clinical episodes of disease, viral loads are greatly reduced (of the order of 4- to 733-      23 
fold) and viral transcription within macrophages is restricted (Oaks et al., 1998). In 
response to immune pressure, rapid genomic variations occur during replication 
which results in altered glycoprotein structures and antigenic changes. Variants have 
been detected within 28 days and this variation is responsible for the cyclical nature 
of the disease, new antigenic variants having a replication advantage as they are not 
susceptible to pre-existing immunity (Ball et al., 1992; Montelaro et al., 1984; Payne 
et al., 1984; Salinovich et al., 1986).  
Small ruminant lentiviruses 
It was initially thought that VMV and CAEV were specific for sheep and goats, 
respectively, but recent evidence has shown that VMV and CAEV are capable of 
infecting both sheep and goats as well as some small ruminant species living in the 
wild (Guiguen et al., 2000; Leroux et al., 1997; Narayan et al., 1980; Pisoni et al., 
2005; Ravazzolo et al., 2006; Shah et al., 2004). As a result, VMV and CAEV are 
now collectively referred to as small ruminant lentiviruses (SRLV). The 2 viruses 
share many similarities at both the genomic and antigenic level, particularly in gag 
and pol (Brinkhof et al., 2007; Jolly et al., 1989; Pasick, 1998; Pyper et al., 1986; 
Zanoni, 1998), and there is antigenic cross-reactivity between their CA proteins 
(Clements et al., 1980). Some SRLV, however, show significant differences in their 
LTR, env and regulatory genes (Jolly et al., 1989; Pyper et al., 1986; Zanoni, 1998). 
They also differ phenotypically, with the prototypic Icelandic VMV strains inducing 
syncytia and lysis of infected cell cultures whereas the prototypic CAEV-Cork strain 
induces syncytia with a persistent but non-lytic infection of cell cultures (Narayan et 
al., 1980; Pisoni et al., 2007; Querat et al., 1984).       24 
Visna maedi virus 
VMV is a natural pathogen of sheep (Zhang et al., 2000; Zink et al., 1987) and has 
been isolated from the majority of sheep-rearing areas of the world, excluding 
Australia and New Zealand (Dawson, 1988). VMV was initially reported as a cause 
of progressive pneumonia of sheep in South Africa in 1915, then in Montana in the 
1920's, then in sheep in Iceland in the 1950’s (Dawson, 1988; Jolly et al., 1989; 
Sigurdsson et al., 1952; Sigurdsson et al., 1957). The virus name is derived from the 
Icelandic language where “maedi” can be translated as “dyspnoea” (difficult 
breathing due to pneumonia) and “visna” as “fading away” (due to a demyelinating 
leukoencephalomyelitis), representing the 2 forms of the disease (Pepin et al., 1998).  
The main route in which the virus is transmitted is thought to be via ingestion of 
infected colostrum and/or milk or via the respiratory tract, involving direct inhalation 
of infected respiratory secretions, including the inhalation of infected alveolar 
macrophages (McNeilly et al., 2008; Pepin et al., 1998; Preziuso et al., 2004). 
Monocytes, lung tissue macrophages and spleen tissue macrophages (but not T-
lymphocytes) are the major cell targets in vivo for VMV replication and viral 
expression is greatly increased when the monocytes mature into macrophages 
(Gendelman et al., 1986). In PBMC populations, dendritic cells are the most 
permissive for viral replication (Gorrell et al., 1992; Zhang et al., 2000).  
Clinical disease can take months to years to develop (Nilsen et al., 1996) and consists 
of a multi-system disease characterised by a chronic infiltration and proliferation of 
mononuclear cells in the lungs (chronic interstitial pneumonia, maedi) and the central 
nervous system (affected by a chronic and progressive, paralytic disease 
characterised by inflammatory and demyelinating lesions in the CNS leading to 
wasting and paralysis, visna) (Narayan et al., 1980). Organs less commonly affected       25 
include the joints (arthritis) and mammary glands (Bird et al., 1993; Deng et al., 
1986; Gorrell et al., 1992; Zink et al., 1987). 
Caprine arthritis encephalitis virus 
CAEV causes an economically significant disease in infected goats, particularly in 
Europe, the Americas, Asia and Australia (Campbell et al., 1998; Herrmann et al., 
2003b; Mselli-Lakhal et al., 2007; Zanoni, 1998). The main route of virus 
transmission is via colostrum but horizontal spread is also achieved via infected 
secretions if there is direct contact between infected and susceptible animals 
(Ravazzolo et al., 2006) or from doe to foetus either prior to or during the birth 
process (East, 1993).  
The virus, like VMV, infects cells of the monocyte/macrophage lineage and dendritic 
cells and virus expression is activated during maturation of monocytes to 
macrophages (Narayan et al., 1983). It does not infect lymphocytes and so does not 
directly result in immunosuppression, unlike SIV and HIV. Infection results in a 
chronic inflammatory disease affecting the joints, central nervous system, lungs and 
mammary glands, and depending on the organs affected, can result in emaciation, 
respiratory distress, mastitis, paralysis or arthritis (Dawson, 1988; Herrmann et al., 
2003b; Narayan et al., 1983) (Ravazzolo et al., 2006). Up to 40% of infected goats 
develop chronic arthritis (Cheevers et al., 1997).  
Bovine lentiviruses 
Currently there are 2 lentiviruses known to infect cattle, BIV and JDV. The first 
bovine lentivirus discovered was BIV (Tobin et al., 1994; Van der Maaten et al., 
1972) while JDV has more recently been identified as a lentivirus (Chadwick et al., 
1995b).        26 
While the clinical and pathological syndromes associated with the 2 bovine 
lentiviruses are markedy different, the viruses share a very close genetic and 
antigenic relationship (Chadwick et al., 1995b). These are shown in Table 2.2.  
 
Table 2.2. Comparison of putative protein products of JDVTab87 and BIV127. 
  JDV  BIV   
Protein 
Amino 
acids 
Mol. Mass 
(kDa) 
Amino 
acids 
Mol. Mass 
(kDa) 
Amino acid 
identity 
gag precursor  436  48.8  476  53.4  62% 
MA  125  14.3  126  14.6  60% 
p2L  -  -  22  2.5   
CA  226  25.3  219  24.6  75% 
p3  -  -  25  2.7   
NC  85  9.2  66  7.3  63% 
p2  -  -  18  1.9   
gag/pol precursor  1432  163  1475  168  66% 
pol precursor  1027  118  1035  118  68% 
env precursor  781  88.8  904  102  31% 
SU  422  47.8  555  62.1  24% 
TM  359  41.1  349  40.2  39% 
vif   197  22.9  198  22.8  55% 
tat   97  10.7  103  11.7  54% 
(alt. tat)
a  (114)  (12.5)  -  -   
rev   213  23.8  186  20.7  35% 
(alt. rev)
a  (201)  (22.4)  -  -   
tmx  164  18.5  159  18.0  29% 
vpw   -  -  54  6.6   
vpy   -  -  80  9.5   
aAlternate forms of tat and rev generated by utilisation of alternative splice donor 
site.  Data sourced from Chadwick et al. (1995b). 
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Bovine immunodeficiency virus 
BIV is a naturally-occurring lentivirus found in cattle and based on serological 
surveys, infections occur worldwide (Campbell et al., 1998; McNab et al., 1994; 
Meas et al., 2000a; Suarez et al., 1995). The virus may be transmitted horizontally by 
iatrogenic routes, blood-sucking arthropods, via natural or artificial insemination or 
via milk from infected cows (Egberink et al., 1992; Meas et al., 1998; Meas et al., 
2000a). BIV is best known as a virus infection of B. taurus but New Zealand white 
rabbits (Oryctolagus cuniculus) and sheep have been infected experimentally, 
resulting in a persistent infection (Gonda, 1992; Jacobs et al., 1994; Pifat et al., 
1992).  
Genome structure 
The first isolation of BIV was from a cow in Louisiana and this isolate, designated 
R29 (Van der Maaten et al., 1972), has since been cloned (Braun et al., 1988) and 
sequenced (Garvey et al., 1990). BIV-R29 is antigenically and genetically stable 
during long-term, persistent infection (Carpenter et al., 2000). 
The BIV proviral genome is 8.96 kb in size and consists of the 3 main ORF gag, pol 
and env and 6 accessory genes rev, tat, vif, tmx, vpw and vpy (Figure 2.2). The 
functions of vif, tmx, vpw and vpy in BIV are yet to be described (Egberink et al., 
1992; Gonda et al., 1987; Miller et al., 2000; Tobin et al., 1994). The BIV Gag 
polyprotein that is translated is processed into a number of proteins, the 3 major 
proteins found in all lentiviruses (MA, CA and NC) and 3 smaller proteins (p2L, p3 
and p2) (Tobin et al., 1994). 
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Cell tropism and clinical signs associated with disease 
Two studies have indicated that BIV may be pantropic. An initial in vivo study with 
BIV isolate FL112 found proviral DNA in CD3+, CD4+ and CD8+ cells, B cells, 
monocytes and WC1 cells in both the acute and chronic stages of infection 
(Whetstone et al., 1997). A subsequent study involving the R29 isolate detected 
proviral DNA and infectious virus within CD2+ (located on CD4+ and CD8+ T-
cells), WC1+ (located on gd T-cells), mature B cells and monocytes during the early 
stages of infection (Heaton et al., 1998). However, it is not clear from either study 
whether these cell types were productively infected, as only proviral DNA was 
detected. BIV-R29 is able to productively infect primary cultures of embryonic 
bovine spleen and lung, Madin-Darby bovine kidney cells and embryonic rabbit 
epidermal cells producing syncytia, cell lysis and infectious virus (Ferens et al., 
2007; Gonda, 1992; Heaton et al., 1998; Pifat et al., 1992; Suarez et al., 1993; 
Whetstone et al., 1990; Zhang et al., 1997a; Zhang et al., 1997b). 
BIV is most efficiently transmitted via infected blood and cell-free and cell-
associated tissue culture-derived virus (Pifat et al., 1992). The re-use of contaminated 
needles during vaccination and blood collection, communal sharing of colostrum fed 
to calves and the failure to cleanse contaminated instruments, have also been 
suggested to play a role in the spread of BIV (Gonda, 1992). Inoculation usually 
results in a subclinical infection without significant clinical effects (Flaming et al., 
1993) but clinical signs have been reported and include a transient leucocytosis, 
lymphoid hyperplasia, lymph node enlargement, wasting and in some cases immune 
suppression (Carpenter et al., 1992; Egberink et al., 1992; Zhang et al., 1997b). The 
impact of BIV infection to the overall health of herds has not been established (Tobin 
et al., 1994), although there is one Canadian study which suggested BIV infection       29 
had a significant effect on milk yield (McNab et al., 1994). Other studies have 
suggested that persistent BIV infection plays a role in reducing functional immune 
competence as shown by the frequent development of concurrent infections in BIV-
infected animals (Meas et al., 2000a; Snider et al., 2003a; Zhang et al., 1997b). It 
would seem, however, that a direct role for BIV in chronic progressive disease or as 
a cofactor in a specific disease is unlikely (Jacobs et al., 1994; Suarez et al., 1995).  
Jembrana disease virus 
In contrast to BIV, JDV causes a significant acute disease process in Bali cattle (Bos 
javanicus) in Indonesia (Dharma, 1997; Kertayadnya, 1997). The first reported 
outbreak of Jembrana disease occurred in Sangkargung, a village in the Jembrana 
district of the island of Bali in Indonesia (Figure 2.6) in December 1964. The disease 
only affected Bali cattle and while reference is sometimes made to an effect on 
buffalo (Bubalus bubalis) this was anecdotal and has not been confirmed. The 
disease spread through all districts of Bali by August 1965 with an estimated 20,000 
to 70,000 deaths. The disease then disappeared but subsequent smaller outbreaks 
were detected in 1972 in the Tabanan district and in 1981 in the Karangasem district 
of Bali (Ramachandran, 1996; Soeharsono, 1997b). 
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Figure 2.6. (A) The location of Bali in relation to other Indonesian islands (D.F.A.T., 2008). Districts of 
Bali province, adapted from Streetdirectory.com (2009). Jembrana disease was first reported in the district 
of Jembrana. Antibodies to JDV have since been detected in Sumatra, Java and Kalimantan. Clinical 
disease and virus have also been detected in Sumatra and Kalimantan. 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
       31 
Early investigators proposed Rinderpest virus and then a rickettsia as probable causes 
of Jembrana disease (Soeharsono, 1997b). A viral aetiology was subsequently 
demonstrated, a conclusion based on filtration studies that suggested the infectious 
agent in blood was too small for a rickettsia (Ramachandran, 1996). Based on its 
estimated size of 50-100 nm, the probable presence of a lipid-containing envelope, 
electron microscopic observations and reverse transcriptase activity, the agent was 
then considered as a probable member of the family Retroviridae (Kertayadnya, 
1997; Wilcox et al., 1992) and was subsequently identified, based on genome 
structure and genomic nucleotide sequence analysis, as a lentivirus (Chadwick et al., 
1995b). 
Significance of Jembrana disease 
The case fatality rate resulting from experimentally induced Jembrana disease is 
approximately 21% (Desport et al., 2009a). During the original outbreak 
commencing in 1964, it was retrospectively estimated that 60% of the Bali cattle and 
buffalo population on Bali island were affected in the following 12 months, of which 
98.9% died (Ramachandran, 1996); this high prevalence and high case fatality rate is 
unlikely and the evidence is obscure as at the time there were no veterinary services 
on the island. The effect of JDV is widespread throughout Bali, as a consequence of 
the important role that Bali cattle play in society. They are a source of employment 
and help to sustain and generate profit in the agricultural system via the provision of 
draught power and manure which in turn helps to improve soil fertility 
(Wiryosuhanto, 1997).  
Transmission and distribution of Jembrana disease 
The probable modes of transmission of JDV include mechanical and contact 
transmission. Virus can be mechanically transferred from infected cattle to       32 
uninfected cattle by iatrogenic means or by arthropods. Examples of iatrogenic 
routes include multi-use needles during vaccination programs, as has been shown to 
occur in EIAV (Li et al., 2003). Arthropod transmission is thought to be limited to 
the acute viraemic episode when there is a high titre of virus in blood of affected 
cattle, but it requires reasonably close contact between animals and the restriction of 
movement of infected animals by quarantine has helped to reduce the spread of the 
virus. The likelihood of contact transmission is supported by the detection of the 
virus in secretions such as saliva, urine and milk and the ability to reproduce the 
disease by conjunctival and oral inoculation of the virus (Hartaningsih et al., 1993; 
Soeharsono et al., 1995b).  
The disease has now been detected in 4 Indonesian islands: Bali, Kalimantan 
(Indonesian Borneo), West Sumatra and East Java (Figure 2.6). There are no reports 
of JDV infection of Bali cattle in any other area of Indonesia and clinical Jembrana 
disease has not been reported in other cattle types which has led to the belief that the 
disease is specific to Bali cattle (Hartaningsih et al., 1993; Wilcox et al., 1995). 
However, other cattle types and buffalo can be infected experimentally and become 
infected under field conditions (Soeharsono et al., 1995a) although they do not seem 
to develop clinical disease. Bos taurus, B. indicus, crossbred Bali cattle (B. javanicus 
x B. indicus) and buffalo can be infected and develop viraemia (Soeharsono et al., 
1990; Soeharsono et al., 1995a). The clinical changes and lesions that occur in these 
cattle types are consistent with those observed in Bali cattle, but they are much 
milder and would be difficult to detect under field conditions.       33 
The JDV genome 
The genome of JDV is 7732 bp in length and is the smallest of all lentivirus 
genomes. It contains the 3 major ORF typical of all retroviruses, gag, pol and env, as 
well as accessory genes, vif, tat, rev and tmx (Figure 2.2) (Chadwick et al., 1995b; 
Chen et al., 1999; Nilsen et al., 1996). 
JDV is a unique lentivirus in that it is genetically stable, and there is a high level of 
nucleotide conservation in gag, pol and env sequences taken from isolates throughout 
Indonesia. Gag sequences in isolates from Bali and Sumatra had 97 to 100%, 
nucleotide identity. Env sequences were also unexpectedly conserved with 96-99% 
nucleotide identity, and 95 to 99% amino acid identity. The largest divergence was 
seen in an isolate from South Kalimantan with only 88% identity to that of the 
original JDVTab87 isolate (Desport et al., 2007).   
This high level of nucleotide conservation is similar to the LTR regions of EIAV that 
have been reported to be highly conserved during persistent infection of horses 
(Maury et al., 2005; Reis et al., 2003). It is in contrast to other lentiviruses such as 
HIV-1 (Balfe et al., 1990; Lamers et al., 1993; Wolfs et al., 1990), FIV (Brown et al., 
1994; Duarte et al., 2006) and CAEV (Valas et al., 2000) which exhibit greater levels 
of genetic variation, particularly in envelope glycoprotein regions, in sequences 
obtained from within one individual (Lamers et al., 1993; Simmonds et al., 1990), 
between individuals and between different geographic locations (Balfe et al., 1990; 
Maki et al., 1992).        34 
Cell tropism and clinical signs associated with Jembrana disease 
It has been suggested that during the early stages of JDV infection, initial rounds of 
virus replication occur in lymphoid tissue before a rapid and widespread 
dissemination of virus to other tissues during the second phase of replication 
(Chadwick et al., 1995a). JDV has a tropism for mature IgG-containing cells 
(Desport et al., 2009a) and JDV-infected cells are found within spleen, lymphoid 
tissues, bone marrow, lung, liver and kidney, as shown by in situ hybridisation 
techniques for the detection of JDV genomic RNA (Chadwick et al., 1998).  
JDV is not a typical lentivirus in that it causes an acute disease syndrome after a 
short incubation period (Chadwick et al., 1995a). The incubation period before the 
onset of clinical signs is 4-12 days and the clinical signs continue for 5-12 days 
(Soeharsono, 1997a). Major clinical signs include a febrile response, lethargy, 
anorexia and enlargement of superficial lymph nodes. Less frequently observed 
clinical signs include erosions of oral mucous membranes, hypersalivation, nasal 
discharge, diarrhoea and blood in the faeces. JDV has also been implicated in the 
suppression of the humoral immune response in infected cattle, perhaps not 
surprising as the histopathological changes reflect a disease primarily affecting the 
lymphoid system (Dharma et al., 1994; Wareing et al., 1999). The major 
haematological changes associated with JDV infection include leucopenia, 
lymphopenia, eosinopenia and a slight neutropenia. In addition to these changes, a 
mild thrombocytopenia, a normocytic normochromic anaemia, elevated blood urea 
concentrations and reduced total plasma protein are also observed during the acute 
disease (Soesanto et al., 1990).       35 
Immune response to infection with a lentivirus 
The immune response to lentiviruses frequently takes longer to develop than in many 
other virus types. For example, ponies infected with EIAV do not seroconvert to 
envelope glycoproteins and CA until 3 weeks pi, with Env antibodies being 
predominant. However, it requires 6-8 months for the EIAV humoral immune 
response to fully mature into a high avidity, conformational epitope-specific response 
(Hammond et al., 1997). The EIAV-specific CTL activity develops 3-4 weeks pi and 
this correlates with the resolution of the primary viraemia (Hammond et al., 1997). 
Studies involving the depletion of CD8+ lymphocytes in rhesus monkeys 
subsequently infected with SIVmac support the role of these cells in controlling 
viraemia (Schmitz et al., 1999) as do other studies of natural HIV-1 infections in 
humans (Koup et al., 1994). Neutralising antibody is detected 2-3 months pi 
(Hammond et al., 1997). In sheep infected with VMV, the seroconversion to CA also 
occurs about 3 weeks pi (Singh et al., 2006) although serum neutralising antibodies 
are not detectable until 1-3 months pi (Petursson et al., 1976), slightly earlier than in 
EIAV. The time course of the immune response to HIV infection is summarised in 
Figure 2.7 and its relationship to the development of other features of the virus 
infection are shown in Figure 2.8.        36 
Also of importance in limiting infection with lentiviruses are non-adaptive immune 
responses. Studies of HIV and FIV have shown that natural killer cells have an 
important role in controlling acute infection (Howard et al., 2010) while cytidine 
deaminases such as the previously mentioned APOBEC family of proteins restrict 
viruses shortly after they have entered the cell by interfering with viral DNA 
formation (Goila-Gaur et al., 2008, Romani et al., 2009). Other important innate 
immune responses include TRIM5α which is thought to inhibit HIV-1 transduction 
in rhesus macaque cells, non-coding RNAs such as micro RNAs and silence inducing 
RNAs (Strebel et al., 2009), anti-viral cytokines such as interferon and dendritic cells 
(Williams et al., 2009). 
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Figure 2.8. Estimated time course for maturation of the host immune response in EIAV-infected 
animals. Image from Leroux et al. (2004). Env-specific cytotoxic T-cells appear within the first month 
after infection as do Env- and p26 (CA)-specific IgG. Neutralising antibodies appear after 2-3 months 
after infection.  
 
Figure 2.7. Estimated time course for host immune response to acute HIV infection. Image from 
Levy (2007).       38 
Humoral immune response to infection with bovine lentiviruses 
A number of assays have been used to detect and quantify the immune response to 
the bovine lentiviruses, most commonly Western immunoblotting (WIB) and ELISA. 
Antigen can be prepared using cell culture systems (Burki et al., 1992; Hammond et 
al., 1997; O'Rourke et al., 1988; Whetstone et al., 1991; Whetter et al., 1990), 
sucrose-gradient purified plasma from infected animals (Hartaningsih et al., 1994) or 
recombinant protein production (Bird et al., 1993; Burkala et al., 1999; Burkala et al., 
1998). Other techniques have been used to monitor the immune response to bovine 
lentivirus infections, including immunofluorescent assays (O'Rourke et al., 1988), 
agar gel immunodiffusion (AGID) (Burki et al., 1992; Coggins et al., 1972; 
Hartaningsih et al., 1994; Whetter et al., 1990) and radioimmunoprecipitation (Beyer 
et al., 2001; Morin et al., 2003; O'Rourke et al., 1988). Western immunoblot assays 
were more sensitive than AGID tests for detection of antibody to BIV (Whetstone et 
al., 1991) and for JDV an ELISA was also more sensitive than AGID (Hartaningsih 
et al., 1994). 
Experimental infection of Bali cattle with JDV results in the production of antibodies 
detectable by ELISA and WIB to the CA protein 6-11 weeks pi, although 
occasionally animals can seroconvert as early as 2 weeks pi (Desport et al., 2009a; 
Hartaningsih, 1997). The antibody response to JDV peaks 23-33 weeks pi and 
persists beyond 59 weeks (Hartaningsih et al., 1994). As JDV has not been cultured 
in vitro, there have been limited investigations of the neutralising antibody response 
to JDV. There is only a single report available of a neutralising antibody response to 
JDV, which relied on the infection of cattle to determine virus neutralisation. The 
evidence from this study suggested that neutralising antibody to JDV developed only 
after a prolonged period following recovery, and therefore that neutralising antibody       39 
did not seem essential in the recovery from acute Jembrana disease. Antibodies 
capable of neutralising JDV were detected in cattle 4 and 28 months after cattle had 
recovered from clinical disease and titres were low, in the range of 1:2 to 1:20 
(Hartaningsih et al., 2001). 
In experimental BIV infections, antibody develops earlier than in JDV infections. 
Antibody to the CA protein can be detected as early as 14 days post infection (dpi) 
with titres peaking 6-8 weeks pi. Multiple studies have confirmed the early CA 
antibody response and determined that it persists for up to 2.5 years after initial 
infection (Heaton et al., 1998; Suarez et al., 1995; Whetstone et al., 1990; Whetstone 
et al., 1991) although there is a single report that found the CA response to BIV 
infection decreased dramatically by 40 weeks pi (Isaacson et al., 1995). Antibodies 
capable of neutralising BIV have been detected as early as 17 weeks pi and persist 
for 44 months pi (Carpenter et al., 2000). Antibodies against BIV TM could be 
detected 4 weeks pi, peaking 10-30 weeks pi and persisted for at least 50 weeks pi 
(Scobie et al., 1999); in some cattle they were detected 4 years pi (Isaacson et al., 
1995). The antibody response to the SU protein of BIV was reported to take many 
months to develop (Suarez et al., 1995). 
The CA and TM proteins of BIV and JDV contain cross-reactive epitopes which has 
made serological differentiation between infections with JDV and BIV impossible 
(Desport et al., 2005; Kertayadnya et al., 1993; Lu et al., 2002). Attempts have been 
made to develop reagents capable of differentiating between these infections but 
these have been unsuccessful (Desport et al., 2005).       40 
Assays for the detection of lentivirus infections in ruminants 
Small ruminant lentiviruses 
Serological methods such as ELISA (using whole virus, recombinant proteins or 
synthetic peptides as antigens), competitive ELISA (using monoclonal antibodies), 
AGID, radio-immunoprecipitation and WIB are most commonly performed to detect 
SRLV infection and there are a number of kits available commercially (Brinkhof et 
al., 2007; Brodie et al., 1993; de Andres et al., 2005; Herrmann et al., 2003a; Pasick, 
1998).  It is important to note, however, that no “gold standard” method of diagnosis 
exists (Brinkhof et al., 2007; de Andres et al., 2005).  
Of a number of assays recently evaluated by Brinkhof and van Maanen (2007) for 
the serodiagnosis of SRLV infections in sheep and goats, the best performing assay 
was an ELISA. This assay involved the sensitisation of the solid phase with a 
combination of recombinant VMV CA protein produced in E. coli and a TM derived 
peptide. The performance of this assay may be due to the simultaneous detection of 
antibodies against CA and TM. Antibodies to CA are produced early after infection 
but decline once clinical signs appear and TM antibodies are produced later but 
persist into the clinical phase. Therefore any assay which combines the detection of 
antibodies to these 2 proteins could be expected to cover a greater proportion of the 
infection period (Boshoff et al., 1997; Brinkhof et al., 2007).  
A number of supplementary tests are often performed to confirm or resolve 
indeterminate ELISA results, including AGID, WIB and radioimmunoprecipitation, 
and these can be supplemented by PCR assays for the detection of proviral DNA or 
viral RNA in PBMC or plasma (Barlough et al., 1994; Brinkhof et al., 2007; Brodie 
et al., 1993; de Andres et al., 2005; Wagter et al., 1998; Zanoni et al., 1992).        41 
Large ruminant lentiviruses  
Diagnosis of BIV infection plays a crucial role in controlling the spread of infection 
and the pathogen-free preparation of vaccines prepared using cattle, for example tick 
fever vaccines (Lew et al., 2004). Assays used for detecting BIV infection include 
qPCR (Lew et al., 2004), nested PCR, cell culture syncytium assays, WIB assays 
(Meas et al., 1998; Meas et al., 2000a; Snider et al., 2003b; Suarez et al., 1995; 
Zhang et al., 1997a), and ELISA using recombinant CA and TM protein antigens 
(Barboni et al., 2001; Burkala et al., 1999). Techniques to quantify proviral and viral 
BIV loads in tissues have not been described. 
All attempts to culture JDV in vitro have failed and it has not been possible to detect 
JDV infections using virus isolation techniques (Kempster et al., 2002; Wilcox et al., 
1992). Two techniques have been described that enable the detection and 
quantification of JDV virus load, the JDV gag quantitative Reverse Transcriptase-
PCR  (qRT-PCR) assay and a JDV p26 antigen capture ELISA (Stewart et al., 2005). 
The qRT-PCR technique was optimised with plasma samples taken from animals 
experimentally infected with JDV, and it was found to be robust and sensitive, with 
an apparent sensitivity 100-fold greater than that of a standard RT-PCR. The capture 
ELISA was relatively insensitive when compared to the qRT-PCR, although it 
provided an economical method for monitoring of virus in the absence of more 
sensitive techniques (Stewart et al., 2005).        42 
Difficulties with serological testing 
A number of factors have been reported to be critical in the interpretation of 
serological assays. In lentivirus infections, one problem encountered is the delayed 
nature of the antibody response. For example, in donkeys experimentally infected 
with EIAV, the animals respond weakly and produce antibodies 42 dpi while horses 
produce antibodies which can be detected as early as 16 dpi (Spyrou et al., 2003). 
Hence, testing donkeys less than 42 dpi will yield a false-negative result. Problems 
with delayed antibody responses have also occurred in CAEV (Brinkhof et al., 2007; 
Rimstad et al., 1993) and JDV infections (Desport et al., 2009a; Hartaningsih et al., 
1994). Another problem in lentivirus infections is that antibody titres to viral proteins 
may fluctuate between positive and negative after infection, though reasons for this 
are unclear (de Andres et al., 2005).  
Problems can occur in the detection of neutralising antibody in non-primate 
lentivirus infections (Pozzetto et al., 1986; Sahu et al., 1994). Some North American 
strains of VMV do not appear to induce neutralising antibodies (Zink et al., 1987). In 
other VMV infections, the time required to develop detectable levels of neutralising 
antibody after infection may vary considerably, from 12-14 dpi (Bird et al., 1993) 
through to 1-3 months (Petursson et al., 1976). The titre of neutralising antibody 
reported in response to lentivirus infections has also varied considerably in different 
systems: in response to CAEV in goats it was reported to be of low titre and low 
affinity (Kennedy-Stoskopf et al., 1986; Pisoni et al., 2007) as was the response of 
horses to EIAV infection (O'Rourke et al., 1988) but the titre of neutralising antibody 
in sheep in response to VMV infection was reported to be as high as 1:640 (Narayan 
et al., 1978).       43 
Another important factor which should be considered in lentivirus serological tests is 
cross-reactive epitopes on viral proteins, which can make serological differentiation 
of antigenically related viruses difficult. Antigenic cross-reactivity between structural 
proteins of lentiviruses, particularly the CA protein, is well known (Cheevers et al., 
1988; Gnann et al., 1987a). Cross-reactivity has been reported between the CA 
protein of JDV and BIV (Burkala et al., 1998; Desport et al., 2005; Kertayadnya et 
al., 1993), between the TM glycoprotein of BIV and JDV (Burkala et al., 1998) and 
the SU glycoprotein of CAEV and VMV (Gogolewski et al., 1985; Valas et al., 
2000), among others. 
Techniques to identify epitopes and distinguish between viral infections  
Peptide mapping is a useful technique to identify specific epitopes that differ 
between 2 viruses that cross-react antigenically (Valas et al., 2000; Van 
Regenmortel, 1999b). The reactivity to peptides produced in this manner provides 
information on the antigenic characteristics of similar viruses infecting an animal, 
which permits differentiation between the virus infections (Gnann et al., 1987a; 
Mordasini et al., 2006; Pisoni et al., 2007). Peptide mapping involves the generation 
of a panel of overlapping peptides which cover the entire amino acid sequence of the 
protein of interest. These peptides are chemically synthesised and used in immune 
binding assays, usually in an ELISA format for high throughput, against a panel of 
reference sera taken from natural and experimental infections (Ball et al., 1992; 
Bertoni et al., 1994). Synthetic peptides have been used, for example, to identify 
epitopes that differentiate HIV-1 and HIV-2 infections (Gnann et al., 1987a; Gnann 
et al., 1987b). 
Another technique to identify unique epitopes is phage display (Xiao et al., 2008). 
This technique is made possible by the expression of peptide libraries on the surface       44 
of filamentous phage particles. The first step in the process involves the insertion of 
one random oligonucleotide into one phage. The peptide encoded by the 
oligonucleotide is then expressed within the pIII or pVIII coat protein of the 
filamentous phage fd or M13 (D'Mello et al., 1999). These random phage display 
libraries are subsequently screened for reactive epitopes with an antibody of interest. 
The peptide sequence can be determined after amplifying the DNA from the selected 
phage by PCR and sequencing techniques (D'Mello et al., 1999; Van Regenmortel, 
1999a; Westwood, 2000; Williams, 2000).  
Another technique suitable for defining epitopes is the use of protein expression 
libraries. To construct expression libraries, DNA from a coding sequence of interest 
is digested with DNase I to generate random DNA fragments with an approximate 
average of 200 bp in length. These fragments, which can encode peptides, are ligated 
into vector DNA (for example lgt11) whilst preserving the reading frame of a fusion 
protein such as b-galactosidase. Ligations are packaged into Escherichia coli and the 
cloned fragments are expressed as fusion proteins from the recombinant phages. The 
random libraries are subsequently screened for reactive epitopes with an antibody of 
interest. The peptide sequence can be determined after amplifying the DNA from the 
selected phage by PCR and then sequencing this product (Bertoni et al., 2000; 
Bertoni et al., 1994; Pancino et al., 1993; Van Regenmortel, 1999a). 
One traditional method of defining epitopes is the limited fragmentation of proteins 
by chemical cleavage, using cyanogen bromide or enzymatic digestion. 
Fragmentation is then followed by immunoblotting of protein fragments (Westwood, 
2000). Other methods that have been used include crystallographic analysis of 
antigen-antibody complexes and the binding of anti-peptide antibodies to either 
natural or chemically modified proteins (Van Regenmortel, 1999a).       45 
Lentivirus superinfection 
Dual infection of an animal with 2 viruses can be the result of coinfection or 
superinfection. Coinfection occurs when 2 viruses infect at or near the same time 
prior to seroconversion. Superinfection is the infection of an animal (or a cell) by 2 
genetically distinct viruses where the infection with one virus precedes infection with 
the second virus, sometime after seroconversion (Blackard et al., 2002; Gottlieb et 
al., 2004; Jurriaans et al., 2008). 
A natural case of superinfection of goats with CAEV and VMV has recently been 
documented (Pisoni et al., 2007). Several studies have reported superinfection of 
HIV-1 infected individuals (Gottlieb et al., 2004; Jurriaans et al., 2008; Piantadosi et 
al., 2007; Smith et al., 2006). Between 2002 and 2005, 16 cases of HIV-1 
superinfection in humans were reported (Smith et al., 2005). Although this number 
seems small, natural cases of superinfection have generated considerable interest as 
they challenge the assumption that HIV-1 specific immune responses generated 
against primary infection are protective against subsequent infection by different 
strains of the same virus (Allen et al., 2003).  
Benefits of superinfection - superinfection resistance 
Experimental studies have shown that pre-infecting an animal with a relatively less 
pathogenic virus protects against challenge with a second, more pathogenic 
lentivirus, a situation referred to as superinfection resistance (Table 2.3). This has 
been demonstrated in FIV (Terwee et al., 2008; VandeWoude et al., 2002), SIV 
(Cranage et al., 1998; Nilsson et al., 1998; Stebbings et al., 2004) and heterologous 
SHIV infections (Sealy et al., 2009). 
Domestic species of cats that have been asymptomatically infected with non-
pathogenic lion lentivirus (FIVple) or puma lentivirus (FIVpco) have shown resistance       46 
to subsequent challenge with pathogenic FIV (Brown et al., 1994). All cats became 
infected with the pathogenic FIV but prior exposure to FIVple or FIVpco ameliorated 
the normal clinical effects of FIV infection: CD4+ cell depletion was reduced and, in 
some cases, plasma and PBMC FIV loads were reduced (Terwee et al., 2008; 
VandeWoude et al., 2002).  
Infection with live attenuated SIVmacC8 of cynomolgus macaques ameliorated the 
effects of subsequent infection with pathogenic wild-type SIVmacJ5 (Stebbings et al., 
2004), its derivative SIVmac220 (Cranage et al., 1998) and SIVsm (Nilsson et al., 1998). 
This was shown by a significant decrease of cell-associated virus and plasma viral 
RNA loads (Cranage et al., 1998; Stebbings et al., 2004) and negative virus isolation 
in a proportion of animals (Nilsson et al., 1998). Indian rhesus macaques infected 
with SIVmacC8 also resisted superinfection with the virulence-reverted form of 
SIVmacC8 (Sharpe et al., 1997). Likewise, Indian rhesus macaques infected with 
SIVmacGX2 were completely protected against challenge with SIVmac220 (Sharpe et al., 
2004) and macaques infected with SIVmac239Dnef were protected against challenge 
with SIVmac251 (Connor et al., 1998; Daniel et al., 1992).  
Superinfection resistance holds promise as a way to ameliorate the effects of 
lentivirus infection and disease, in effect to act as a potential vaccine. It has been 
proposed that if the mechanism of protection conferred could be better understood, 
then a safe and effective HIV vaccine, for example, could be developed (Cranage et 
al., 1998; Stebbings et al., 2004). The effect of challenge with a non-pathogenic virus 
on the course of infection with a pathogenic virus also offers an opportunity to 
examine host-virus and virus-virus interactions and their effect on pathogenicity and 
resistance to virulent lentivirus infections (VandeWoude et al., 2003).        47 
Mechanisms of superinfection resistance 
The mechanisms responsible for protection against superinfection are not well 
defined. Protection has not been directly correlated with humoral or cellular immune 
responses including virus neutralising activity (Connor et al., 1998; Cranage et al., 
1998; Daniel et al., 1992; Nilsson et al., 1998; Sharpe et al., 1997; Stebbings et al., 
2004; Stebbings et al., 2002; VandeWoude et al., 2002) and in some cases protection 
is not dependent on challenge-driven expansion of immunodominant epitope-specific 
CD8+ T-cells (Sharpe et al., 2004). While CD8+ T-cells are important for control of 
primary viraemia, they do not seem to play a central role in protection against 
superinfection (Stebbings et al., 2005). Non-immunological phenomena such as virus 
interference or antiviral factors such as CD8 suppression factors induced by defective 
particles have been suggested as playing a role in superinfection resistance (Cranage 
et al., 1998; Stebbings et al., 2004; Stebbings et al., 2002). Virus interference has 
been detected in vitro when cell cultures were infected with a retrovirus and were 
relatively resistant to infection by a related retrovirus; the phenomenon occurs only 
when both viruses share the same receptor and results from a restricted penetration 
into the cell (Corbin et al., 1993).   
Adverse consequences of superinfection 
While the positive effects of superinfection, namely resistance, have been well 
described, superinfection or mixed infection of animals with 2 viruses has resulted in 
potentially adverse effects. Goats infected naturally with both CAEV and VMV were 
shown to contain chimeric viruses with CAEV-VMV envelope glycoproteins; this 
was expected to have dramatic effects on the species specificity of the viruses and 
their capacity to cross species barriers (Pisoni et al., 2007).      48 
Table 2.3. Experimental superinfection studies conducted in a range of lentivirus animal model systems.  
Model system  Primary virus 
infection 
Secondary 
pathogenic 
virus strain 
Time between 
primary and 
secondary 
infections (weeks) 
Effect on pathogenic virus  Reference 
FIVpco  FIV-C  4   Reduced CD4+ T-cell depletion.  (Terwee et al., 2008) 
FIVpco or FIVple  FIV-B  27  
Reduced CD4+ T-cell depletion, 
reduced plasma and PBMC FIV 
load. 
(VandeWoude et al., 2002)  FIV in 
domestic cat 
FIVPetaluma  FIV-M2  28   Reduced total viral load, reduced 
CD4+ T-cell depletion.  (Pistello et al., 1999) 
SIVmac251 or 
SIVsmE660 
Reciprocal 
infection    Reduction in peak viraemia, 
amelioration of infection.  (Yeh et al., 2009) 
SIV in rhesus 
macaques 
SIVmacGX2 (nef-
disrupted)  SIVmac220  89 or 122   Complete resistance (determined by 
negative virus isolation).  (Sharpe et al., 2004) 
SIVmacC8  SIVmac32H/L28  3 or 20  Reduction of viral RNA and DNA 
load.   (Berry et al., 2008) 
SIV in 
cynomolgus 
macaques  Attenuated 
SIVmacC8  SIVmacJ5  3  Reduced cell-associated virus loads, 
reduced plasma virus load.   (Stebbings et al., 2004) 
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Chapter 3: Attempts to detect Bovine immunodeficiency virus infection in 
Bali cattle in Indonesia with a PCR-based assay 
Summary 
Attempts were made to provide evidence for the occurrence of BIV in cattle in Indonesia. 
One hundred and seventy one genomic DNA and serum samples were taken from Bali 
cattle in the Bangli and Tabanan regions on the island of Bali. Genomic DNA samples 
extracted from PBMC were screened for the presence of BIV or JDV proviral DNA using 
both real time and conventional PCR methods and direct sequencing of any amplified 
products to confirm their identity. Serum samples were screened for antibodies against 
JDV using a range of antigens in a WIB or ELISA format and 21 of the 171 animals were 
identified as being seropositive by a positive WIB reaction with the p26 CA protein of 
JDV and at least one other positive serological test. BIV proviral DNA was not detected in 
any of the cattle but JDV proviral DNA was detected in 12 animals, only one of which 
was seropositive.      50 
 
Introduction 
Two bovine lentiviruses are suspected to circulate in the Bali cattle population of 
Indonesia. The presence of Jembrana disease virus (JDV) is well documented and both 
the disease and antibodies to the virus have been detected in cattle on the islands of Bali, 
Sumatra and Java (Hartaningsih et al., 1993). The disease also now occurs in all 
Kalimantan provinces in Indonesian Borneo (Hartaningsih, personal communication). 
Despite the widespread distribution of Bali cattle in the eastern islands of Indonesia, 
clinical Jembrana disease has not been reported in these areas.  However, there are reports 
of JDV antibody-positive cattle in some of the regions of Indonesia that are free of clinical 
Jembrana disease, including on the island of Sulawesi (Desport et al., 2005), suggesting 
the presence of a second non-pathogenic virus that is antigenically related to JDV, 
possibly BIV. Serological evidence was also presented for the presence of a BIV-like 
virus in Bali cattle in Bali where JDV is endemic (Barboni et al., 2001) although this has 
not been confirmed by virus isolation. 
The objectives of the investigations reported in this thesis were to attempt confirmation of 
the presence of non-pathogenic BIV-like viruses in Bali cattle in Bali, to develop 
methodology for the detection and differentiation of infection by these viruses and JDV, 
perhaps enabling the determination of the distribution of each virus in Indonesia, and to 
investigate the interaction between the 2 viruses in infected Bali cattle. Ideally, these 
investigations required the isolation of the non-pathogenic BIV-like virus that is reputedly 
present in Indonesia, that would then enable its experimental inoculation into animals not 
only to determine the effects of these viruses in Bali cattle but also for the production of 
reagents. Use of the local non-pathogenic virus would eliminate the need to import an     51 
 
exotic strain of BIV for these investigations. Unsuccessful attempts were made previously 
to isolate a non-pathogenic bovine lentivirus from cattle in Sulawesi: blood samples were 
obtained from antibody-positive Bali cattle in Sulawesi, the samples were transported by 
air to Bali and inoculated into Bali cattle on arrival. The inoculated cattle did not 
seroconvert to BIV or JDV, suggesting the virus was not present in the inoculum.  Further 
attempts to detect the Sulawesi virus were abandoned due to political unrest in the area 
from where cattle had been sampled and the expense involved (Hartaningsih, personal 
communication).  
This Chapter describes the results of attempts to confirm the report of Barboni et al. 
(2001) that Bali cattle on the island of Bali were infected with BIV, and from which 
attempts to isolate the virus could be made.  
Materials and methods 
Field samples  
Peripheral blood samples were taken from 171 Bali cattle (Bos javanicus) in 2 districts 
(Bangli and Tabanan) on the island of Bali, Indonesia. They were collected from the 
jugular vein, into sterile 10 ml vacutainer tubes containing 15% EDTA (BD) for 
extraction of genomic DNA, and into plain tubes for preparation of serum samples for 
serological tests.   
Preparation of PBMC genomic DNA  
After collection into vacutainer tubes containing EDTA, the Bangli samples were 
centrifuged (900 g for 10 min at 4°C) and the buffy coat was subsequently transferred into 
10 ml tubes containing 6 ml distilled H2O, then mixed by inverting 3 times. Three ml of 
2X PBS was then added and mixed by inverting 3 times after which tubes were     52 
 
centrifuged again (250 g for 10 min at 4°C). The resulting supernatant was discarded and 
the pellet washed twice with 10 ml PBS before the pellet was gently resuspended in 1 ml 
Hank’s medium supplemented with 20% v/v heat inactivated foetal calf serum and 6% v/v 
DMSO (Sigma) and stored in 200 ml aliquots at -20°C until required. Genomic DNA was 
extracted from PBMC using the FlexiGene DNA Kit (Qiagen) according to the 
manufacturer’s instructions and stored at -20°C until used. The concentration of PBMC 
genomic DNA in each sample was determined using a spectrophotometer (Nanodrop ND-
1000). 
After collection into vacutainer tubes, the Tabanan blood samples were centrifuged (900 g 
for 10 min at 4°C) and the buffy coat was collected and mixed with 2 ml of PBS, then 
overlayed onto 6 ml Ficoll (Amersham) in a sterile 10 ml tube and centrifuged at 400 g for 
20 min at 4°C. The cells at the interphase were collected and washed 3 times in PBS by 
mixing with PBS followed by centrifugation (400 g for 20 min at 4°C). The washed cells 
were then resuspended with 1 ml PBS and stored at -20°C until required. Genomic DNA 
was extracted from the purified PBMC using the QIAamp DNA Mini Kit (Qiagen) 
according to the manufacturer’s instructions and the DNA was stored at -20°C until used. 
The concentration of PBMC genomic DNA in the samples was determined using a 
spectrophotometer. 
Verification of DNA quality 
Extracted DNA samples were initially tested by PCR using gene-specific glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) primers to test for integrity of the DNA. If no PCR 
product was obtained with these primers then the sample was discarded. The GAPDH 
primers used were as described previously (Mohan et al., 2001) and the reaction consisted     53 
 
of 200 ng of PBMC genomic DNA, 1X PCR buffer, 1.25 mM MgCl2, 0.2 mM of each 
dNTP, 0.8 mM of each primer (GAPDH F, 
CCTTCATTGACCTTCACTACATGGTCTA, GAPDH R, 
GCTGTAGCCAAATTCATTGTCGTTACCA; Invitrogen), 0.687 U Taq polymerase, and 
ultrapure water to a final volume of 25 µl. All reagents were sourced from Fisher Biotec 
unless otherwise stated. Thermal cycling conditions were 1 cycle of 94°C for 3 min, 35 
cycles at 94 °C for 30 s, 60°C for 30 s and 72°C for 45 s, a final extension step of 72°C 
for 7 min and they were then held at 14°C in a Bio-Rad thermal cycler. 
qPCR for detection of JDV proviral DNA 
The JDV proviral DNA genome copy number was quantified using a DNA plasmid-based 
standard curve derived using JDV plasmid clone #139 as a template as previously 
described (Stewart et al., 2005). The JDV sequence within the pT7T3 vector spanned JDV 
nucleotides 19 to 2881 (U21603). The qPCR assay specifically amplified 118 bp in JDV 
gag. All reactions consisted of 1X iQ Supermix (100 mM KCl, 40 mM Tris-HCl (pH 8.4), 
1.6 mM dNTPs, 50 U/ml of iTaq DNA polymerase, 6 mM MgCl2, undefined stabilisers, 
Bio-Rad), 0.6 mM of each primer (gag1f-GGGAGACCCGTCAGATGTGGA, gag1r- 
TGGGAAGCATGGACAATCA; Invitrogen) prepared as described previously (Stewart et 
al., 2005), 0.1 mM fluorogenic probe (Geneworks), 200 ng of extracted PBMC genomic 
DNA and made up to a final volume of 10 ml using ultrapure water (Bio-Rad). Thermal 
cycling conditions were the same as previously described (Stewart et al., 2005), except 
that the reverse transcriptase step was omitted.  
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Conventional PCR for detection of JDV proviral DNA 
A number of DNA samples which were tested by qPCR but provided results below the 
cut-off for a positive result but where the results were clearly greater than that for the 
JDV-negative control DNA, were re-analysed using conventional PCR. The primer pair 
for detecting JDV proviral DNA by conventional PCR (JDV 1: 
GCAGCGGAGGTGGCAATTTTGATAGGA, JDV 3: 
CGGCGTGGTGGTCCACCCCATG) were located within the gag open reading frame 
and specifically amplify a 360 bp fragment (Desport et al., 2007). Reactions conditions 
consisted of 1X buffer, 1 mM MgCl2, 0.2 mM of each dNTP, 0.88 mM of each primer 
(Invitrogen), 1.374 U Taq polymerase, 400 ng PBMC genomic DNA and made up to a 
final volume of 50 µl with ultrapure water. Unless otherwise stated, all reagents were from 
Fisher Biotec. Thermal cycling conditions were the same as those described (above) for 
the GAPDH primer pair. Reaction conditions in the second round of amplification, where 
necessary, were the same as the first except 1 µl of first round PCR product was added 
into 25 µl reaction volumes.  
Sequence analysis of PCR products 
Direct DNA sequencing was performed to confirm and compare the proviral DNA 
detected in the 2 cattle populations. If one band was produced by conventional PCR 
amplification, the PCR product was purified using a PCR Purification Kit (Qiagen) 
according to the manufacturer’s instructions. If multiple bands were produced, the PCR 
product of the correct size was excised from the agarose gel and purified using a Gel 
Extraction Kit (Qiagen) according to the manufacturer’s instructions. Ten ng of purified 
product was sequenced using 1 µl of Big Dye Terminator (Applied Biosystems), 1.5 µl of     55 
 
Big Dye Terminator sequencing buffer (Applied Biosystems), 3.2 pmoles of JDV 1 or 
JDV 3 primer and made up to a volume of 10 µl using ultrapure water (Fisher Biotec). 
The sequencing reaction consisted of a 2 min hold at 96°C and 25 cycles of 96°C for 10 s, 
60°C for 30 s and 60°C for 4 mins. The sequencing reaction was purified by ethanol 
precipitation according to the protocol supplied by Applied Biosystems. Samples were 
then sequenced using an ABI 3730 48 capillary machine at the State Agricultural 
Biotechnology Centre, Murdoch University.  
Sequences were edited using Chromas Lite and aligned using the ClustalW program 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html). Phylogenetic analysis was performed 
using Phylogeny.fr (http://www.phylogeny.fr/version2_cgi/index.cgi) and phylogenetic 
trees were edited using MEGA (http://www.megasoftware.net/index.html).  
qPCR for BIV proviral DNA 
All animals were tested for the presence of BIV proviral DNA using a qPCR assay as 
described previously (Lew et al., 2004), with the following modifications: 1X iQ 
Supermix (Bio-Rad), 100 ng of each primer (BIVF1- 
ACAAAAACTACGGGAATACCCTACA, BIVR1- 
TCTTTTAGATCTCTGTGGGCTCTTTC; Invitrogen), 0.1 mM of probe (6FAM 
CCACAATCCCAGGGAGT; Applied Biosystems) and 200 ng of PBMC genomic DNA. 
The reaction volume was made up to 10 µl using ultrapure water (Fisher Biotec). The 
qPCR assay specifically amplified 73 bp in BIV pol. The limit of quantification of the 
assay was 20 copies per reaction (determined by amplification of specific known 
quantities of cloned viral DNA). 
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Serological tests 
Serum samples were tested for the presence of antibodies to JDV using ELISA or WIB 
with a range of antigens.  The assays were conducted by Dr J. Lewis (this laboratory) 
using antigens that included a recombinant JDV p26-his, recombinant fused JDV 
p26/TM-his, JDV TM peptide and plasma-derived JDV native antigen (kindly provided 
by N. Hartaningsih). The WIB assay that utilised native JDV antigen derived from the 
plasma of infected cattle was conducted as described previously by Hartaningsih et al. 
(1994); results were recorded as positive if there was reactivity with the 26 kDa CA 
protein. All other ELISA and WIB assays were conducted and interpreted as described 
previously (Lewis, 2009). 
The recombinant JDV p26-his construct expressed full-length JDVTab87 CA (Barboni et 
al., 2001). The construct was kindly supplied by Dr. Margaret Collins, transformed into 
BL21 (DE3) E. coli for protein expression and was purified using Ni-NTA agarose resin 
in chromatography columns. The fused p26/TM construct was generated in a previously 
described manner (de Andres et al., 2005; Rosati et al., 2004) whereby JDV capsid was 
fused directly to the putative TM principle immunodominant domain (PID) epitope, 
transformed into E. coli BL21 and purified as described for the recombinant JDV p26-his. 
The JDV TM peptide ELISA was prepared as previously described (Ditcham et al., 2009) 
and encompassed the PID of JDV TM (Barboni et al., 2001). 
As there was no “gold standard” test for JDV antibody detection, samples were considered 
“positive” when a positive result was obtained in WIB using the plasma-derived JDV 
antigen and at least one other assay was also positive. Antibody to JDV and BIV cannot 
be differentiated due to the presence of numerous cross-reactive epitopes on the CA     57 
 
(Desport et al., 2005; Kertayadnya et al., 1993) and TM proteins (Burkala et al., 1998). 
Therefore, the use ofthese antigens in WIB assays will equally detect antibody to both 
JDV and BIV. 
Results 
Serology  
Twenty one of the 171 cattle from which DNA was also analysed were seropositive for 
antibody to the p26 CA of JDV by WIB utilising native JDV antigen and at least one other 
assay (Table 3.1).  
PCR 
The GAPDH gene was detected by PCR in PBMC genomic DNA samples from 171 cattle 
and these were deemed to have DNA of sufficient quality to test using qPCR or 
conventional PCR. These 171 samples were then screened for the presence of JDV 
proviral DNA by PCR and JDV-specific PCR products were detected in 12 of the 171 
PBMC genomic DNA samples tested (Table 3.1). The sequences had between 99 and 
100% homology with the reference JDVTab87 strain. The sequences generated are shown in 
Figure 3.1.  
With the exception of one animal (Tabanan Y26), all cattle in which JDV proviral DNA 
was detected were seronegative (Table 3.1). In the 11 seronegative and PCR positive 
cattle, 10 (83%) were negative in every serological assay and one (Bangli 35) was positive 
in one of the 5 serological assays.  
BIV proviral DNA was not detected in any of the 171 PBMC genomic DNA samples 
tested.      58 
 
Table 3.1. Results of PCR diagnostic assays and serological assays (ELISA and WIB) in 
171 samples taken from Bali cattle (B. javanicus) in the Bangli and Tabanan region of 
Bali, Indonesia. The results shown are those from 52 cattle where any assay provided a 
positive result, and where samples provided negative results in all assays the results are 
not shown. Italics indicate the sample was positive by both JDV PCR and serology.  
Animal 
identification 
Age 
(years)
a 
BIV 
PCR  
JDV 
PCR
b  Antigen and serological assay 
Final 
serological 
result
c 
 
 
   
CA 
ELISA 
CA 
WIB 
Fused 
CA/TM 
ELISA 
Fused 
CA/TM 
WIB 
Native 
antigen 
WIB 
 
Bangli 5    -  -  -  -  +  -  -  - 
Bangli 9    -  +  -  -  -  -  -  - 
Bangli 15    -  -  -  -  +  -  -  - 
Bangli 17    -  -  -  -  +  -  -  - 
Bangli 18    -  -  -  -  +  -  -  - 
Bangli 20    -  -  -  -  +  -  -  - 
Bangli 27    -  +  -  -  -  -  -  - 
Bangli 35    -  +  -  -  +  -  -  - 
Bangli 50    -  +  -  -  -  -  -  - 
Tabanan R3  5  -  -  +  +  -  +  +  + 
Tabanan R4  4  -  -  +  +  -  +  +  + 
Tabanan R9  6  -  -  +  +  -  +  +  + 
Tabanan R10  6  -  -  +  +  +  +  +  + 
Tabanan R12  6  -  -  -  +  -  +  -  - 
Tabanan R16  5  -  -  +  +  -  +  +  +     59 
 
Animal 
identification 
Age 
(years)
a 
BIV 
PCR  
JDV 
PCR
b  Antigen and serological assay 
Final 
serological 
result
c 
 
 
   
CA 
ELISA 
CA 
WIB 
Fused 
CA/TM 
ELISA 
Fused 
CA/TM 
WIB 
Native 
antigen 
WIB 
 
Tabanan R17  4  -  -  -  +  -  +  -  - 
Tabanan R18  4  -  -  +  +  -  +  +  + 
Tabanan R21  4  -  -  +  -  -  -  -  - 
Tabanan R26  5  -  -  +  -  -  +  +  + 
Tabanan R28  8  -  -  +  +  -  +  +  + 
Tabanan R33  10  -  -  +  -  +  +  +  + 
Tabanan R39  7  -  -  -  -  -  +  -  - 
Tabanan R43  6  -  -  +  +  -  +  +  + 
Tabanan R46  3  -  -  -  -  -  +  -  - 
Tabanan R48  5  -  -  -  -  -  +  -  - 
Tabanan Y5  4  -  -  +  -  -  -  +  + 
Tabanan Y15  1.6  -  -  -  -  -  +  -  - 
Tabanan Y21  6  -  -  +  +  -  -  +  + 
Tabanan Y22  5  -  -  +  +  -  +  +  + 
Tabanan Y26  5  -  +  +  +  +  -  +  + 
Tabanan Y31  7  -  -  +  +  -  -  +  + 
Tabanan Y43  8  -  -  +  +  -  -  +  + 
Tabanan Y45  7  -  -  +  +  +  -  -  - 
Tabanan B5  5  -  +  -  -  -  -  -  - 
Tabanan B6  4  -  -  +  -  -  +  +  + 
Tabanan B11  8  -  -  -  +  -  -  -  -     60 
 
Animal 
identification 
Age 
(years)
a 
BIV 
PCR  
JDV 
PCR
b  Antigen and serological assay 
Final 
serological 
result
c 
 
 
   
CA 
ELISA 
CA 
WIB 
Fused 
CA/TM 
ELISA 
Fused 
CA/TM 
WIB 
Native 
antigen 
WIB 
 
Tabanan B16  9  -  -  -  -  -  +  -  - 
Tabanan B26  8  -  -  +  -  +  +  +  + 
Tabanan B35  2  -  -  +  -  +  -  -  - 
Tabanan B37  7  -  -  +  -  +  +  +  + 
Tabanan G1  12  -  -  +  -  +  -  +  + 
Tabanan G4  7  -  +  -  -  -  -  -  - 
Tabanan G6  7 months  -  +  -  -  -  -  -  - 
Tabanan G7  7 months  -  -  -  -  +  -  -  - 
Tabanan G8  7  -  +  -  -  -  -  -  - 
Tabanan G11  6 months  -  +  -  -  -  -  -  - 
Tabanan G15  10  -  -  +  -  -  -  -  - 
Tabanan G16  14  -  -  +  -  +  -  +  + 
Tabanan G26  4  -  -  -  -  +  -  -  - 
Tabanan G29  3  -  +  -  -  -  -  -  - 
Tabanan G31  5  -  +  -  -  -  -  -  - 
Tabanan G49  8  -  -  +  -  +  -  -  + 
Total    0  12  26  17  18  21  21  21 
a Age data not available for Bangli cattle.  
b Positive status given where a positive result was obtained in the qPCR or conventional 
PCR assay and confirmed by direct sequencing. 
c Positive status given where a positive result was obtained with the JDV plasma-derived 
antigen WIB and at least one other serological assay.  
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Bangli 27       CTGCTGGCGGGCCACCACCCAGAAAATTCAGATATGGCAGAAAAGTATTGGGAAGCATGG 60 
Bangli 35       CTGCTGGCGGGCCACCACCCAGAAAATTCAGATATGGCAGAAAAGTATTGGGAAGCATGG 60 
Bangli 50       CTGCTGGCGGGCCACCACCCAGAAAATTCAGATATGGCAGAAAAGTATTGGGAAGCATGG 60 
G31             CTGCTGGCGGGCCACCACCCAGAAAATTCAGATATGGCAGAAAAGTATTGGGAAGCATGG 60 
Y26             CTGCTGGCGGGCCACCACCCAGAAAATTCAGATATGGCAGAAAAGTATTGGGAAGCATGG 59 
G29             CTGCTGGCGGGCCACCACCCAGAAAATTCAGATATGGCAGAAAAGTATTGGGAAGCATGG 60 
G11             CTGCTGGCGGGCCACCACCCAGAAAATTCAGATATGGCAGAAAAGTATTGGGAAGCATGG 60 
G8              CTGCTGGCGGGCCACCACCCAGAAAATTCAGATATGGCAGAAAAGTATTGGGAAGCATGG 60 
G6              CTGCTGGCGGGCCACCACCCAGAAAATTCAGATATGGCAGAAAAGTATTGGGAAGCATGG 60 
B5              CTGCTGGCGGGCCACCACCCAGAAAATTCAGATATGGCAGAAAAGTATTGGGAAGCATGG 60 
G4              CTGCTGGCGGGCCACCACCCAGAAAATTCAGATATGGCAGAAAAGTATTGGGAAGCATGG 60 
Bangli 9        CTGCTGGCGGGCCACCACCCAGAAAATTCAGATATGGCAGAAAAGTATTGGGAAGCATGG 60 
JDV/Tab 87      CTGCTGGCGGGCCACCACCCAGAAAATTCAGATATGGCAGAAAAGTATTGGGAAGCATGG 60 
JDV/Pul 01      CTGCTGGCGGGCCACCACCCAGAAAATTCAGATATGGCCGAAAAGTATTGGGAAGCATGG 60 
BIV127          CTGCTGGCGGGGTACAAACCAGAGAGTACAGAAACGGCCCTAGGATATTGGGAGGCCTTT 60 
                 **********  ** * ***** * * **** * ***   *   ******** ** *   
 
Bangli 27       ATAATCAGAGAAAGGGAGTCCCAAAAGGAGGAGGAAGGAGAAATTACCAGCATCTACCCA 120 
Bangli 35       ATAATCAGAGAAAGGGAGTCCCAAAAGGAGGAGGAAGGAGAAATTACCAGCATCTACCCA 120 
Bangli 50       ATAATCAGAGAAAGGGAGTCCCAAAAGGAGGAGGAAGGAGAAATTACCAGCATCTACCCA 120 
G31             ACAATCAGAGAAAGGGAGTCCCAAAAGGAGGAGGAAGGAGAAATTACCAGCATCTACCCA 120 
Y26             ACAATCAGAGAAAGGGAGTCCCAAAAGGAGGAGGAAGGAGAAATTACCAGCATCTACCCA 119 
G29             ACAATCAGAGAAAGGGAGTCCCAAAAGGAGGAGGAAGGAGAAATTACCAGCATCTACCCA 120 
G11             ACAATCAGAGAAAGGGAGTCCCAAAAGGAGGAGGAAGGAGAAATTACCAGCATCTACCCA 120 
G8              ACAATCAGAGAAAGGGAGTCCCAAAAGGAGGAGGAAGGAGAAATTACCAGCATCTACCCA 120 
G6              ACAATCAGAGAAAGGGAGTCCCAAAAGGAGGAGGAAGGAGAAATTACCAGCATCTACCCA 120 
B5              ACAATCAGAGAAAGGGAGTCCCAAAAGGAGGAGGAAGGAGAAATTACCAGCATCTACCCA 120 
G4              ACAATCAGAGAAAGGGAGTCCCAAAAGGAGGAGGAAGGAGAAATTACCAGCATCTACCCA 120 
Bangli 9        ACAATCAGAGAAAGGGAGTCCCAAAAGGAGGAGGAAGGAGAAATTACCAGCATCTACCCA 120 
JDV/Tab 87      ACAATCAGAGAAAGGGAGTCCCAAAAGGAGGAGGAAGGAGAAATTACCAGCATCTACCCA 120 
JDV/Pul 01      ACAATCAGAGAAAGGGAGTCCCAAAAGGAGGAGGAAGGAGAAATTACCAGCATCTACCCA 120 
BIV127          ACATATAGAGAAAGGGAGGCCAGAGCTGATAAGGAAGGCGAAATTAAGAGTATTTACCCT 120 
                * *   ************ **  *   **  ******* *******  ** ** *****  
 
Bangli 27       CAACTTAGAAAGAACT------------------------------------ 136 
Bangli 35       CAACTTAGAAAGAACT------------------------------------ 136 
Bangli 50       CAACTTAGAAAGAACT------------------------------------ 136 
G31             CAACTTAGAAAGAACT------------------------------------ 136 
Y26             CAACTTAGAAAGAACT------------------------------------ 135 
G29             CAACTTAGAAAGAACT------------------------------------ 136 
G11             CAACTTAGAAAGAACT------------------------------------ 136 
G8              CAACTTAGAAAGAACT------------------------------------ 136 
G6              CAACTTAGAAAGAACT------------------------------------ 136 
B5              CAACTTAGAAAGAACT------------------------------------ 136 
G4              CAACTTAGAAAGAACT------------------------------------ 136 
Bangli 9        CAACTTAGAAAGAACT------------------------------------ 136 
JDV/Tab 87      CAACTTAGAAAGAACT------------------------------------ 136 
JDV/Pul 01      CAACTTAGAAAGAACT------------------------------------ 136 
BIV127          TCCCTAACACAGAACACACAGAATAAGAAGCAGACATCGAATCAGACAAACA 172 
                   ** * * *****                                      
 
Figure 3.1. Sequence alignment of gag nucleotide sequences from 12 animals with JDV 
taken from Bangli and Tabanan. Reference sequences JDVTab87 (accession number 
U21603), JDVPul01 (accession number DQ229295) and BIV127 (accession number 
NC_001413.1) are included for comparison. Sequences were aligned using ClustalW2. 
“*” indicates all nucleotides are identical in that column.       62 
 
Discussion 
Although JDV proviral DNA was detected in the PBMC of 12 of 171 cattle examined, 
which included cattle from 2 adjacent districts of Bali, BIV proviral DNA was not 
detected in any of the animals tested. The result does not provide proof of the absence of 
BIV in the Bali cattle population of Bali but it also does not provide any support for the 
serological evidence reported by Barboni et al. (2001) that cattle within Bali are infected 
not only by JDV but with a second antigenically related but presumably non-pathogenic 
bovine lentivirus. The methodology used by Barboni et al. (2001) involved the production 
of recombinant BIV CA and JDV CA and their use in a WIB format or a combination of 
the recombinant CA with a BIV or JDV TM peptide in an ELISA format. Sera were 
screened initially using the JDV antigens, then JDV antibody negative sera were screened 
using the BIV antigens; if the serum reacted in the second set of assays the sample was 
declared BIV seropositive and JDV seronegative. Given the high level of cross-reactivity 
between JDV and BIV CA and TM antigens (Desport et al., 2005; Kertayadnya et al., 
1993), including the cross-reactivity of the antigens used in the study, these findings 
should be interpreted with considerable caution. Results from this laboratory (Desport et 
al., 2005) have shown that the reagents used by Barboni et al. (2001) would not 
differentiate between JDV and BIV antibody. 
The attempt to identify cattle infected with BIV by the detection of proviral DNA was 
unsuccessful but not surprising. It is difficult to detect BIV in naturally infected cattle and 
with the exception of the reports describing 3 successful attempts in the USA and Japan 
(Suarez et al., 1993; Van der Maaten et al., 1972) and one from Japan (Meas et al., 1998), 
this has not been reported, although there have been limited reports of the detection of     63 
 
proviral BIV DNA in naturally infected cattle (Lew et al., 2004; Meas et al., 1998; Meas 
et al., 2000b; Snider et al., 2003b). In the current study, both antibody-positive and 
antibody-negative cattle were examined, and 2 specific PCR assays were used. Either both 
assays lacked the sensitivity to detect the level of provirus present in cattle, or maybe 
BIV-like viruses are present in Bali but were not present in the populations sampled, or 
possibly BIV-like viruses do not occur in the cattle population of Bali. Modifications to 
the PCR assays, such as degenerate primers and less stringent PCR reaction conditions, 
may have assisted in the detection of proviral DNA. However, based on previous 
experience in this laboratory, alterations such as these have a tendency to produce false 
positive results. Further investigation of the pathogenesis of BIV infection in Bali cattle is 
needed to examine the kinetics of virus replication and persistence after infection and the 
optimal time for sampling.  
JDV proviral DNA was detected in 12 animals sampled, suggesting recent infection, even 
though there was no evidence of clinical Jembrana disease immediately preceding and 
following the sampling. This is the first reported detection of JDV in clinically normal 
cattle. The lack of variation between the PCR amplicons suggests a common virus strain 
was circulating in the cattle, although the lack of variation is also consistent with previous 
studies reporting a high level of nucleotide conservation in gag sequences of JDV detected 
in Bali (Desport et al., 2007) and they may not have arisen from a single source. All the 21 
JDV-seropositive cattle were 4 years or older indicating minimal transmission of JDV 
between the cattle in the preceding 4 years, and this is consistent with the lack of reports 
of Jembrana disease outbreaks in Bali during this period (Hartaningsih, personal 
communication).      64 
 
Proviral DNA positive-seronegative animals are rare but not uncommon after natural 
lentivirus infections, and have been reported in cattle infected with BIV (Meas et al., 
2000a), cats infected with FIV (Dandekar et al., 1992) and sheep infected with VMV 
(Leginagoikoa et al., 2009). These observations, and the detection of JDV provirus in 12 
cattle, only one of which was seropositive, highlights the difficulty associated with 
conclusively detecting natural lentivirus infections. There are a number of possible 
reasons for the lack of concordance between serological and PCR assays. Firstly, the 
antibody response to JDV is delayed and has been reported to be detectable only from 11 
weeks post infection (Hartaningsih et al., 1994), hence serological assays would only 
detect antibodies in the period after this time and this is a period of active virus replication 
(Stewart et al., 2005). The detection of JDV proviral DNA in seronegative animals 
suggests recent infection with JDV, prior to seroconversion. Secondly, there are a 
proportion of animals infected with JDV that do not mount an antibody response to the 
CA antigen (Desport et al., 2009a; Ditcham et al., 2009). These animals are referred to as 
atypical responders and account for 15% of all animals experimentally infected but it 
seems unlikely that this would account for the lack of antibody in 11 of the 12 
PCR-positive animals detected. Thirdly, JDV proviral DNA levels in the PBMC are 
hypothesised to persist at very low levels in naturally infected cattle, similar to SRLV 
infections (de Andres et al., 2005). JDV proviral DNA has been readily detectable in 
experimentally infected cattle, even many months after infection but is normally detected 
only with difficulty in naturally infected cattle (Desport, personal communication).  
Further studies are required to characterise the response of Bali cattle to inoculation with 
BIV, including whether the animals can become actively infected and whether the virus     65 
 
will persist in the animals over time. It will also be of interest to determine if and at what 
level BIV proviral DNA and viral RNA loads occur. The development of reagents that are 
able to distinguish between BIV and JDV infections in an ELISA will help in the 
identification of BIV infections and in Indonesia may clarify discrepancies between 
genomic and antibody based assay results.      66 
 
Chapter 4: Bovine immunodeficiency virus produces a transient 
viraemic phase soon after infection in Bos javanicus  
Summary 
Infection of Bali cattle in Indonesia with a non-pathogenic bovine lentivirus similar 
to BIV is suspected but efforts to detect the virus have been unsuccessful. To define 
the kinetics of BIV infection and seroconversion in Bali cattle and determine the 
optimal time for sampling for detection of virus in infected cattle, 13 cattle were 
infected with the R29 strain of BIV and monitored for up to 65 days. No clinical 
signs were observed in the infected cattle following infection. Proviral DNA was 
detected in PBMC from 4-60 days with peak titres 20 dpi. There was a transient 
viraemia from 4 to 14 dpi with a maximum titre of 1 x 10
4 genome copies/ml plasma. 
An antibody response to the TM glycoprotein commenced 12 dpi but an antibody 
response to the CA protein was detected in one animal only and not until 34 dpi. The 
results indicated that detection of BIV in infected Bali cattle is similar to B. taurus 
with levels of proviral DNA detectable during the early stage of infection. Based on 
these results, a CA based serological assay would not identify the majority of 
infected cattle.      67 
 
Introduction 
Bali cattle are particularly susceptible to JDV and develop an acute disease process 
soon after infection. The acute disease is characterised by a transient febrile 
response, enlargement of superficial lymph nodes, high virus titres in the plasma and 
a number of haematological changes including leucopenia and thrombocytopenia. 
The case fatality rate is about 21% and recovered animals are resistant to re-
challenge with the virus (Desport et al., 2009a; Soeharsono et al., 1990; Soesanto et 
al., 1990). In contrast, breeds such as B. taurus (Fresian cattle) and B. indicus 
(Ongole cattle) develop a mild febrile response but no other clinical signs of disease 
(Soeharsono et al., 1990). 
The effects of BIV in Bali cattle are unknown but the pathogenesis of BIV in 
B. taurus has been investigated by several groups. Many of the studies that were 
undertaken assumed that the virus would produce effects long after infection, akin to 
many other lentiviruses, and they therefore followed the infections for long time 
intervals. In experimentally infected B. taurus, the original R29 isolate caused no 
major clinical signs in the period up to 27 months after infection (Flaming et al., 
1993; Zhang et al., 1997b) although subclinical changes in experimentally infected 
cattle were reported by others. Subclinical changes reported have included 
lymphocytosis and follicular hyperplasia (Carpenter et al., 1992) and immune 
suppression at 3-7 weeks post-infection (Zhang et al., 1997b). Other isolates of BIV 
(FL491 and FL112) were reported to cause a transient increase in PBMC (Suarez et 
al., 1993). The FL112 isolate caused a transient B-cell lymphocytosis that peaked 14 
dpi (Whetstone et al., 1997) and is also reported to cause lymphadenopathy and non-
suppurative meningoencephalitis 12 months post-infection (Munro et al., 1998). 
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changes but one study based in North America found associations between BIV and 
decreased milk yield in dairy cattle (McNab et al., 1994) while another reported 
marked weight loss with frequent and severe concurrent infections (Snider et al., 
2003b). 
This Chapter reports the experimental infection of Bali cattle with BIV that was 
conducted with 2 objectives. First, to determine if Bali cattle were more susceptible 
to infection with BIV than B. taurus, similar to their greater susceptibility to JDV 
than other cattle species (Soeharsono et al., 1995a). Second, to determine the kinetics 
of virus replication and persistence of BIV and the development of the antibody 
response after infection, so as to provide insights into the optimal periods in which to 
sample naturally infected cattle to detect the virus.  The experiments were conducted 
with the R29 strain of BIV as attempts to detect BIV in Indonesian cattle were not 
successful (Chapter 3).   
Materials and methods 
Animals 
Nineteen cattle were obtained from Nusa Penida, an island adjacent to Bali where 
Jembrana disease has never been detected and the cattle have been consistently 
negative for antibody to JDV and BIV.  The cattle were housed indoors as previously 
described (Soeharsono et al., 1990). Six weeks prior to infection with BIV the cattle 
were vaccinated against Bovine viral diarrhoea virus using Pestigard (Pfizer) twice 
at 0 and 4 weeks apart as the FBL cell culture was contaminated with BVDV. BVDV 
is a common contaminate of BIV cell cultures and foetal bovine serum (Makoschey 
et al., 2003).      69 
 
Virus 
BIV-R29 was obtained from J Brownlie and M Collins, Royal Veterinary College, 
UK, passaged in primary bovine foetal lung (BFL) cell cultures grown in RPMI 
medium (Invitrogen) supplemented with 10% foetal bovine serum (Thermo 
Scientific) and antibiotics in 75 cm
2 flasks (Nunc). For inoculation into cattle, 
infected cells exhibiting marked syncytium formation were scraped from the surface 
of flasks 24 h after infection and the cells suspended in RPMI medium.  The titre of 
the virus was retrospectively estimated by titration in BFL cell cultures and the total 
inoculum administered to each animal determined to be 1.38 x 10
6 50% tissue culture 
infectious doses (TCID50). 
Experimental infection and sampling of cattle 
The infectious inoculum was divided into 2 equal amounts, one administered 
intravenously and the other subcutaneously.  Seven virus infected cattle (CB169-
CB175) were monitored for 42 days after infection and 6 (CB177-CB182) for 65 
days after infection. An additional 6 cattle (CB183-CB189) were inoculated with an 
equivalent volume of uninfected BFL cells in RPMI medium and monitored for 65 
days as controls.  
Animals were observed daily for the development of clinical signs of disease. Rectal 
temperatures were measured daily for the duration of the study. Blood samples were 
obtained as required by venipuncture of the jugular vein and used for determination 
of total leukocyte counts, extraction of DNA from PBMC, extraction of RNA from 
plasma and serum for serological tests.   
The 6 cattle monitored for 65 days were killed and a complete post-mortem 
examination conducted.  Tissue samples (retropharyngeal and prescapular lymph     70 
 
nodes, spleen, bone marrow, kidney, lung and thymus) were collected into RNAlater 
(Ambion) for DNA and RNA extraction.  
Extraction of DNA and RNA from tissues  
Total DNA was extracted and purified from tissue samples using a DNeasy Tissue 
Kit (Qiagen) according to the manufacturer’s instructions. 
Total RNA was extracted and purified from tissues using the RNeasy Mini Kit 
(Qiagen) according to the manufacturer’s instructions. Disruption and 
homogenisation was performed using the TissueLyser (Qiagen) and an optional on-
column DNase digestion step using an RNase-Free DNase Set (Qiagen) was included 
to remove any contaminating genomic DNA.  
A Ficoll-PaqueÔ Plus (GE Healthcare) gradient was used to purify PBMC from 
heparinised blood according to the manufacturer’s directions. Genomic DNA was 
subsequently extracted from the cells using a QIAamp
 DNA Mini Kit (Qiagen).  
Viral RNA was extracted from plasma using the QIAamp Viral RNA Extraction Kit 
(Qiagen) as recommended by the manufacturer. 
Quantitation of BIV proviral DNA 
Extracted DNA samples were initially tested by PCR using gene-specific (GAPDH) 
primers to test for sample integrity. If no product was obtained then the sample was 
not used in the analysis. The GAPDH primers used were as described in Chapter 3.  
Proviral DNA loads were determined with GAPDH-positive samples by a qPCR 
assay as described in Chapter 3.  
BIV Proviral DNA loads were normalised to GAPDH copy number according to 
previously published methods (Terwee et al., 2008). Briefly, the number of cell 
equivalents (CE) in 200 ng of PBMC genomic DNA or 200 ng of tissue DNA was     71 
 
determined by qPCR using GAPDH-specific primers. All reactions consisted of 1X 
iQ SYBR
® Green Supermix (Bio-Rad), 400 mM of each primer (GAPDH156F: 
GGTGATGCTGGTGCTGAGTA, GAPDH342R: GGCACTGCTGACAATCTTGA; 
Invitrogen), 200 ng of extracted DNA and were made up to a final volume of 10 ml 
using ultrapure water (Fisher Biotec). Thermal cycling conditions were 1 cycle of 
95°C for 3 min, 40 cycles of 95°C for 15 s, 60°C for 30 s, 72°C for 30 s and a final 
extension step of 72°C for 10 min. The DNA-based plasmid standard was generated 
using the Mohan et al. (2001) GAPDH primers. The BIV proviral DNA copy number 
generated using the protocol from Lew et al. (2004) was then expressed as the 
number of BIV proviral DNA copies/100 000 cell equivalents (CE). The number of 
CE was determined using the GAPDH qPCR protocol.  
When DNA yields from PBMC were less than 50 ng/ul and insufficient for qPCR, 
samples were tested by conventional PCR using primers (Heaton BIV F, 5’ 
CCCCAGGTCCCATCAACATTCATC and Heaton BIV R, 5’ 
GTCTTCCCACATCCGTAACATCTCC) as previously described (Heaton et al., 
1998).  
Quantification of BIV RNA  
Viral RNA loads were determined using qRT-PCR with primers and probes as 
described for the qPCR for provirus except that 2 ml of viral RNA, 0.2 ml iScript 
Reverse Transcriptase for One-Step RT-PCR (Bio-Rad) and 1X iScript RT-PCR 
reaction mix for probes was included per reaction and a 10 min reverse transcription 
incubation step at 50°C was included at the start of the reaction. To determine viral 
loads within the tissues, the above protocol was followed except 200 ng of tissue 
RNA was included in each reaction instead of 2 µl of viral RNA. Results were 
expressed in BIV viral RNA genome copies/µg of total RNA.      72 
 
Enzyme linked immunosorbent assays 
The BIV TM antibody response was determined by ELISA with 1:25 dilutions of 
sera and a peptide antigen as previously described (Barboni et al., 2001; Ditcham et 
al., 2009), except that the 36 amino acid TM peptide 
RVSYLEYVEEIRQKQVFFGCKPHGRYCHFDFGPEEV (Proteomics 
International) of BIV-R29 was converted from linear to cyclic form (TM
c) as 
described previously (Scobie et al., 1999). BIV hyperimmune serum was included as 
a positive control and serum from uninfected cattle was used as a negative control in 
every plate. 
The CA antibody response was determined by ELISA using a recombinant protein 
antigen. To produce the CA protein, full length BIV CA protein was cloned into the 
pTrcHisB vector and transformed into JM109 chemically competent E. coli. Bacteria 
were grown overnight at 37°C at 225 rpm in a 50 ml culture of standard 2X YT 
medium with ampicillin (50 µg/ml, Sigma). Forty ml of overnight culture was added 
to 1 L of 2X YT medium plus ampicillin and grown at 37°C for 4 h at 225 rpm. 
Protein production was induced by the addition of 1 mM isopropyl-beta-D-
thiogalactopyranoside (Sigma) for 4 h. The protein was purified as recommended in 
the QIAExpressionist Handbook (Qiagen) and an ELISA protocol was optimised. 
One hundred ng of protein was coated onto each well of a Maxisorp 96-well plate 
(Nunc) and incubated overnight at 4°C. Plates were then washed 3 times with PBS-T 
(137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, 0.05% Tween 20). 
One hundred µl of serum diluted 1:100 in PBS-T with 5% w/v skim milk (Fonterra) 
was added to each well for 1 h at 37°C. Plates were then washed 3 times with PBS-T 
and 100 µl of a 1:2 000 dilution of anti-bovine IgG-HRP (ICN) in PBS-T-skim milk 
was added to each well for 1 h at 37°C after which they were washed 3 times with     73 
 
PBS-T and once with PBS. Colour development was induced by the addition of 
peroxidase substrate (Bio-Rad) and the reaction stopped by the addition of 2% w/v 
oxalic acid and absorbance read at 405 nm. BIV hyperimmune serum was included 
in every plate as a positive control and serum from uninfected cattle was used as a 
negative control. 
Results  
Clinical observations 
The 13 Bali cattle infected with BIV-R29 and the 6 BFL-only controls did not 
develop any clinical signs of disease during the observation period. Rectal 
temperatures and total leukocyte counts remained normal throughout the experiment 
and no gross lesions were observed during post-mortem examination of the 7 cattle 
killed 65 days after infection.  
Quantification of BIV proviral DNA load 
Proviral DNA was detected in PBMC of all cattle inoculated with virus during the 65 
days after infection. Proviral DNA was first detected 8 dpi in 4 of the 13 animals 
(Table 1), it was detected in all 13 cattle 20 dpi but in only 2/13 at 40 dpi and 3/6 at 
60 dpi. Maximum proviral DNA titres were 6.2 x10
2 proviral genome 
copies/100 000 CE.  
Quantification of BIV RNA load 
Plasma viral RNA was detected in 8 of the 13 cattle from 4 to 14 dpi (Table 4.2). 
Viral titres ranged from 4.2 x 10
1 to 1.0 x 10
4 genome copies/ml plasma.      74 
 
Table 4.1. BIV proviral DNA detection and quantification by conventional and 
qPCR in cattle inoculated with BIV-R29.  
 
  Days after infection 
Animal  
Identification 
0  2  4  6  8  12  14  20  40  56  60 
CB169  -  -  -  NT
a  +
b  +   1.6x10
1  4.5 x10
1  -  NA
d  NA 
CB170  -  -  -  -  -  -  +  5.1 x10
1  -  NA  NA 
CB171  -  -  -  NT  -  +   +  +  -  NA  NA 
CB172  -  -  NT  NT  +  -  +  +  -  NA  NA 
CB173  -  -  -  -  -  4.9x10
1 c  -  4.0 x10
2  +  NA  NA 
CB174  -  -  -  NT  -  -  6.6x10
1  1.6 x10
2  -  NA  NA 
CB175  -  -  NT  -  -  -  +  1.9 x10
2  +  NA  NA 
CB177  -  -  NT  NT  +  +  +  3.3 x10
1  -  NT  - 
CB178  -  -  -  -  -  -  1.2x10
2  3.2 x10
1  -  +  - 
CB179  -  -  -  -  NT  -  +  +  -  +  - 
CB180  -  -  -  -  -  -  -  +  -  -  + 
CB181  -  -  -  -  -  +  7.7x10
1  6.2 x10
2  -  -  + 
CB182  -  -  NT  NT  +  +  6.8x10
1  2.2 x10
1  -  +  + 
Percent 
positive  
0  0  0  0  33.3  46.1  84.6  100  15.3  60.0  50.0 
 
aNT, not tested.  
b+, positive result by conventional PCR.  
cNumber of BIV proviral genome copies/100 000 peripheral blood mononuclear cell-
equivalents. 
dNA, not available 
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Table 4.2. BIV viral RNA genome copies/ml of plasma determined by qPCR in cattle inoculated with BIV-R29. 
 
  Days after infection 
Cattle  0-2
a  4  6  7  8  9  10  11  12  14  15-34
b  15-62
c 
CB169  -  -  -  -  -  -  -  -  -  -  -   
CB170  -  -  -  -  -  -  -  -  -  -  -   
CB171  -  -  -  -  -  -  -  -  -  -  -   
CB172  -  -  -  -  -  -  -  -  -  -  -   
CB173  -  -  -  -  4.7 x10
3  -  5.9 x10
3  -  -    -   
CB174  -  -  -  -  -  5.7 x10
3  -  5.4 x10
3  -  -  -   
CB175  -  -  -  -  4.2 x10
1  2.1 x10
1  -  3.2 x10
1  -  -  -   
CB177  -  -  -  -  -  -  -  -  -  -    - 
CB178  -  -  -  -  2.0 x10
2  -  -  3.2 x10
2  -  -    - 
CB179  -  -  -  6.1 x10
1  -  -  2.6 x10
2  6.3 x10
2  1.3 x10
2  -    - 
CB180  -  -  -  -  -  4.8 x10
2  -  -  -  -    - 
CB181  -  1.0 x10
4  -  4.4 x10
1  1.0 x10
3  3.1 x10
3  6.5 x10
2  8 x10
1  -  -    - 
CB182  -  -  -  -  -  -  -  3.4 x10
3  5.6 x10
3  6.0 x10
2    - 
 
arepresents results from days 0,1 and 2 p.i. 
brepresents results from days 15, 16, 18, 20, 27 and 34 p.i. 
crepresents results from days 15, 16, 18, 20, 27, 34, 40, 41, 43, 45, 47 to 53, 55 to 58, 60 and 62 p.i.     76 
 
Virus RNA and proviral DNA in tissues 65 days after infection 
Proviral DNA and/or viral RNA were detected in all 6 cattle killed 65 dpi 
(Table 4.3).  Proviral DNA was detected in at least 1 tissue type of each animal and 
most commonly in lymphoid tissues. Viral RNA was detected less frequently than 
proviral DNA and only in the spleen and prescapular lymph nodes. The levels of 
viral RNA detected by qRT-PCR were very low, bordering on undetectable.  
Serological response to BIV-R29 infection 
Antibody to the BIV TM
c and CA antigens were detected by ELISA (Figures 4.1 and 
4.2). Increased ELISA absorbance readings with the BIV TM
c peptide were detected 
12 dpi and were detected in most cattle by 20 dpi. The antibody response to the CA 
antigen was markedly less than to the TM
c peptide and a strong antibody response to 
this protein was detected in one animal only between 34 and 56 dpi (Figure. 4.2).  
None of the control group developed detectable TM or CA antibody. 
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Table 4.3. Viral RNA and proviral DNA quantification in tissues after necropsy of 
experimentally infected Bali cattle. 
 
Cattle  
Tissue 
 
CB177  CB178  CB179  CB180  CB181  CB182 
Provirus
a  + (<20
c)  + (<20)  + (<20)  -  21.8  21.1 
Spleen 
Viral RNA
b  + (<20)
  + (<20)  204.0
e  -  -  - 
               
Provirus  -  + (<20)  + (<20)  + (<20)  -  + (<20) 
Lung 
Viral RNA  -  -  -  -  -  - 
               
Provirus  -  -  -  36.6  -  - 
Thymus 
Viral RNA  -  -  -  -  -  - 
               
Provirus  -  -  -  3849.4  -  - 
Bone marrow 
Viral RNA  -  -  -  -  -  - 
               
Provirus  -  + (<20)  3086.4  -  + (<20)  + (<20)  Retropharyngeal 
lymph node  Viral RNA  -  -  -  -  -  - 
               
Provirus  -  6800.6
d  + (<20)  + (<20)  + (<20)  -  Prescapular lymph 
node  Viral RNA  + (<20)  63.5  -  -  -  - 
               
Provirus  -  29.28  -  -  -  - 
Kidney 
Viral RNA  -  -  -  -  -  - 
               
 
aProviral genome in tissues quantified using qPCR.  
bViral RNA genome copies in tissues quantified using qRT-PCR.  
cSamples with values less than 20 but consistently above the negative control.  
dNumbers refer to BIV proviral genome copies/100 000 cell equivalents. 
eNumbers refer to BIV viral RNA genome copies/µg total RNA.  
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Figure. 4.1. TM IgG in serum of cattle after infection with BIV-R29. Antibody was 
detected by ELISA with a BIV TM
c peptide antigen. Absorbances were normalised 
to day 0 readings. ELISA absorbances from mock infected cattle (CB183 – CB187) 
are also shown. Top: individual results in 17 cattle.  Bottom: box and whisker plot of 
the values in the 13 cattle infected with BIV.  
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Figure. 4.2. CA IgG in serum of cattle after infection with BIV-R29. Antibody was 
detected by ELISA with a BIV CA antigen. Absorbances were normalised to day 0 
readings. ELISA absorbances from mock infected cattle (CB183 – CB187) are also 
shown. Top: individual results in 17 cattle.  Bottom: box and whisker plot of the 
values in the 13 cattle infected with BIV.  
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Discussion 
The detection of BIV provirus in PBMC in all 13 cattle over the course of the 
experiment and within tissues at the end of the experiment 65 dpi, the transient 
detection of viral RNA in plasma from 8 of 13 infected cattle and an antibody 
response to BIV in inoculated cattle, confirm that the Bali cattle were productively 
infected with BIV. 
No clinical signs of infection were observed in any of the infected Bali cattle.  The 
absence of significant clinical effects is similar to other experiments where BIV had 
been inoculated into B. taurus (Carpenter et al., 1992; Heaton et al., 1998; Isaacson 
et al., 1995; Zhang et al., 1997a). The greater susceptibility to JDV of Bali cattle than 
B. taurus is not reflected in their susceptibility to BIV. This absence of clinical signs 
in Bali cattle in response to BIV would be consistent with the presence of a BIV-like 
virus in Bali cattle on the island of Sulawesi in Indonesia where antibody to JDV has 
been detected but there is no evidence of Jembrana disease (Hartaningsih, personal 
communication).  
BIV proviral DNA was detected in PBMC from 8 dpi until the conclusion of the 
experiment at 65 dpi but was not detected in all animals at all sampling occasions.  
The highest proportion of BIV proviral DNA positive animals was at 14 and 20 dpi 
when 84.4 and 100% of animals were positive, suggesting this was a peak period of 
virus replication and indicating an acute phase for BIV infection.  After this period 
the virus appeared to persist in PBMC, at a level that was often undetectable. 
Modifications to the PCR assays may have assisted in the detection of very low 
proviral DNA copy numbers. 
Provirus was detected in a wide variety of tissues at 65 dpi when the experiment was 
concluded, similar to a previous report of infection in B. taurus (Zhang et al., 1997a).     81 
 
The levels of proviral DNA were low but highest in the lymphoid tissues examined, 
spleen and lymph nodes.  The low titres were similar to those reported in other 
lentivirus infections, including African green monkeys persistently infected with 
SIVagm (Gueye et al., 2004) and in horses asymptomatically infected with a cell-
adapted pathogenic EIAV (Harrold et al., 2000).  
Although previous studies involving experimental infection of B. taurus with BIV 
have detected viral RNA within PBMC subpopulations, either by RT-PCR (Baron et 
al., 1995; Wu et al., 2003)  or by in situ hybridisation (Carpenter et al., 1992), this 
study appears to be the first report documenting the transient nature of the plasma 
viraemia in the period soon after infection, similar to that reported in many other 
lentivirus infections (Langemeier et al., 1996; Miyake et al., 2006; Ryan et al., 2003; 
Stewart et al., 2005). While provirus was detected in all 13 infected cattle, viral RNA 
was detected in 8 of 13 cattle and only during the period from 4 to 14 dpi.  The levels 
of virus RNA detected never exceeded 1 x 10
4 genome copies/ml plasma, much less 
than those detected during infection of Bali cattle with the genetically related JDV 
where titres of up to 1.6 x 10
12 genome copies/ml plasma have been detected during 
the acute disease (Stewart et al., 2005).  The transient nature of the plasma viraemia 
could be viewed as escape of the virus from host control. While provirus was 
widespread in the tissues that were tested, viral RNA was detected in the spleen and 
prescapular lymph node only of some animals and was at low levels. Perhaps the 
level of replication of BIV relative to JDV may be associated with the relative lack of 
pathogenicity of BIV compared to JDV. 
There was a rapid and strong response against TM but a poor antibody response to 
the CA protein in most infected cattle.  The TM response to BIV infection was 
similar to that reported by Scobie et al. (1999) in cattle infected with the BIV FL112     82 
 
isolate and an antibody response was detected as early as 2 weeks pi. The weak CA 
response detected in all but one of the 13 infected Bali cattle was surprising as in 
B. taurus there is normally a strong response to CA between 2 and 4 weeks pi 
(Isaacson et al., 1995; Whetstone et al., 1991). Seroconversion to a gag precursor 
also occurred between 2 and 4 weeks pi in rabbits infected with BIV (Pifat et al., 
1992). The reason for the poor antibody response to CA in Bali cattle is unknown. In 
response to infection with the genetically and antigenically related JDV, Bali cattle 
normally mount a strong albeit delayed immune response against CA (Hartaningsih 
et al., 1994) but as in the Bali cattle infected with BIV, a subset of cattle infected 
with JDV mount a poor antibody response to the JDV CA and a strong antibody 
response to JDV TM (Ditcham et al., 2009). A 10 to 100 times greater antibody 
response to envelope proteins compared to CA proteins was also observed in horses 
in response to EIAV (O'Rourke et al., 1988). 
Results from this study indicate not only that BIV is non-pathogenic in Bali cattle but 
that maximum virus replication occurred soon after infection and prior to the onset of 
a significant antibody response, certainly prior to the onset of a significant antibody 
response to the CA protein.  It is likely that future attempts to detect BIV infection in 
Bali cattle and possibly other cattle species using PCR based assays, would have 
greatest chance of success soon after infection and before the onset of a significant 
antibody response.      83 
 
Chapter 5: Bovine immunodeficiency virus infection alters the 
dynamics of subsequent Jembrana disease virus infection  
Summary 
To determine whether BIV infection is capable of protecting against superinfection 
with JDV, 15 animals were infected with BIV-R29 and 42 days after BIV infection, 
9 of the BIV infected and 4 mock BIV infected animals were superinfected with 
JDVTab87. All cattle were successfully infected with BIV, shown by the presence of 
proviral DNA and, in a subset of cattle, a transient viraemia. Strong antibody 
responses against the TM glycoprotein and poor antibody responses against the CA 
protein were also detected. Despite the development of immune responses against 
TM, a region known to contain cross-reactive epitopes, all cattle became infected 
with JDV, as indicated by the development of typical clinical signs of Jembrana 
disease and an acute phase viraemia.      84 
 
Introduction 
The 2 bovine lentiviruses, BIV (Gonda et al., 1987) and JDV (Chadwick et al., 
1995a; Kertayadnya et al., 1993), are genetically and antigenically related but differ 
markedly in pathogenicity. The incidence of clinical Jembrana disease and 
serological surveys indicate JDV is common in the Bali cattle population in parts of 
Indonesia (Hartaningsih et al., 1993). A BIV-like non-pathogenic bovine lentivirus is 
also suspected to occur in the cattle population on Bali island (Barboni et al., 2001) 
and antibody to JDV has been detected in Bali cattle on the island of Sulawesi where 
there is no clinical evidence of Jembrana disease in the Bali cattle population 
(Desport et al., 2005). Antibody to JDV and BIV cannot be differentiated due to the 
presence of numerous cross-reactive epitopes on the CA (Desport et al., 2005; 
Kertayadnya et al., 1993) and TM proteins (Burkala et al., 1998).  
A protective immunity against JDV infection has been induced by vaccination with 
inactivated whole virus antigens (Ditcham et al., 2009). It was considered possible 
that infection of Bali cattle with a non-pathogenic BIV-like lentivirus might also 
induce a protective immune response against Jembrana disease. Non-pathogenic 
strains of other lentiviruses have been shown to induce protective immunity against 
pathogenic strains of the same virus. Infection of domestic cats with non-pathogenic 
lion lentivirus or puma lentivirus ameliorated the effects of subsequent wild-type FIV 
infection (Terwee et al., 2008; VandeWoude et al., 2002). Similar results were 
obtained in domestic cats pre-infected with chimeric FIV (generated by substituting 
part of env of clade A FIVPET with a corresponding region of clade B FIVM2, or vice-
versa) and subsequently inoculated with FIVPET or FIVM2 (Giannecchini et al., 2007). 
Infection of macaques infected with attenuated SIVmac also ameliorated the effects of 
challenge with pathogenic SIVmac (Cranage et al., 1998; Sharpe et al., 2004) and     85 
 
SIVsm (Nilsson et al., 1998) although attenuated SIVmac did not provide protection 
against the more divergent HIV-2 (Nilsson et al., 1998). 
This Chapter describes an experiment to determine whether prior infection of Bali 
cattle with BIV would provide protection against superinfection with pathogenic 
JDV infection 42 days after the initial BIV infection. This experiment was expected 
to provide information that would increase our understanding of the effect JDV 
would have on the Bali cattle population if it were introduced onto the island of 
Sulawesi where BIV is suspected to occur in the cattle population of that island.  
Materials and methods 
Animals 
Nineteen cattle approximately 18 months of age were obtained from Nusa Penida, an 
island adjacent to Bali where Jembrana disease has never been detected and the cattle 
have been consistently negative to antibody to JDV and BIV (Hartaningsih et al., 
1993). The cattle were housed indoors as previously described (Soeharsono et al., 
1990). Cattle were screened by PCR and ELISA to ensure they were not infected 
with bovine lentiviruses prior to challenge (Chapter 3). Six weeks prior to infection 
with BIV the cattle were vaccinated against BVDV with Pestigard
® (Pfizer), as 
previously described (Chapter 4). 
Viruses 
The BIV-R29 for infection of cattle was obtained from J Brownlie and M Collins, 
Royal Veterinary College, UK. The virus was cultured in primary BFL cells and 
titrated in BFL cells as previously described (Chapter 4). An estimated 1.82 x 10
4 
TCID50 was inoculated into each animal, half subcutaneously and half intravenously.     86 
 
The JDVTab87 (Chadwick et al., 1995b) used for infection of cattle was prepared by 
infection of antibody-negative cattle with a suspension of frozen spleen harvested 
from infected cattle as described previously (Soeharsono et al., 1990). Plasma from 
the infected cattle was obtained 2 days after the development of a febrile response 
typical of Jembrana disease, and the approximate ID50 in the plasma determined 
using an antigen-capture ELISA as described previously (Stewart et al., 2005). An 
estimated 1 000 ID50 of the virus was inoculated intravenously into each animal. 
Experimental infection and sampling of cattle 
Nine cattle were inoculated with BIV at day 0 and with JDV 42 days later (CB190–
CB197 and CB205). Six cattle were inoculated with BIV at day 0 and were not 
subsequently inoculated with JDV (CB198–CB202 and CB204). Four cattle were 
inoculated with uninfected BFL cells in RPMI medium at day 0 and subsequently 
with JDV 42 days later (CB203, CB206, CB208 and CB210). 
Animals were observed daily for clinical signs of disease. Rectal temperatures were 
measured daily for the duration of the study. Heparinised blood samples were 
obtained as required by venipuncture of the jugular vein and used for extraction of 
DNA from PBMC, extraction of RNA from plasma and serum for serological tests. 
Extraction of DNA and RNA from peripheral blood 
PBMC were purified from 10 ml of heparinised blood using a Ficoll-Paque Plus
TM 
(GE Healthcare) gradient as recommended by the manufacturer. DNA was extracted 
from the PBMC using a QIAamp DNA Mini Kit (Qiagen) as recommended by the 
manufacturer. Viral RNA was extracted from plasma using the QIAamp Viral RNA 
Extraction Kit (Qiagen) as recommended by the manufacturer.     87 
 
Detection of BIV proviral DNA  
The integrity of genomic DNA was confirmed using gene-specific GAPDH primers 
as previously described (Chapter 4). BIV proviral DNA loads were determined using 
a conventional PCR assay as described previously (Chapter 4).  
Quantification of BIV and JDV RNA in plasma 
BIV RNA was quantified as described previously (Chapter 4) and JDV RNA as 
described by Stewart et al. (2005), with the following exceptions: 1X RT-PCR 
Reaction Mix for Probes (Bio-Rad), 0.2 ml iScript Reverse Transcriptase for One-
Step RT-PCR (Bio-Rad) and 2 ml RNA extracted from plasma was added to each 
reaction. The reaction was made up to 10 ml using nuclease free water (Bio-Rad). 
ELISA  
The BIV TM antibody response was determined by ELISA using a cyclic BIV TM 
(BIV TM
c) peptide as described previously (Chapter 4). The JDV TM antibody 
response was determined by ELISA using a cyclic JDV TM (JDV TM
c) peptide as 
previously described (Ditcham et al., 2009) as while there was extensive cross-
reactivity between JDV and BIV TM antigens, our experience was that the JDV TM
c 
peptide provided greater sensitivity in the detection of JDV TM antibody than did the 
BIV TM
c antigen. The BIV CA antibody response was determined using an ELISA 
with a recombinant BIV CA antigen as previously described (Chapter 4) except that 
100 ng of protein was coated onto each well and serum was tested at a dilution of 
1:100.      88 
 
Analysis of data 
To determine whether prior BIV infection would induce protection against 
subsequent JDV infection, differences between the viral load (VL) on the first and 
second day of the febrile period when the rectal temperature exceeded 39.3°C, the 
peak VL, the duration and magnitude of the VL where the area under the curve 
(AUC) was >10
6 genomes/ml, and the duration of the febrile period, were compared 
in JDV-infected cattle that had been previously infected with BIV and in cattle not 
previously infected with BIV, as described previously (Desport et al., 2009a; 
Ditcham et al., 2009). The AUC where the VL was > 10
6 for each animal was 
estimated and linear interpolation between consecutive observations, in combination 
with the previously described piecewise-linear model was used to supply missing 
data caused by variations in sampling intervals (Ditcham et al., 2009). The duration 
of the infectious period was defined as the period where VL was > 10
6 genomes/ml. 
A baseline of 10
6 was chosen (Ditcham et al., 2009) as bloodmeal residues of 
between 4–10 nl have been reported on the mouthparts of tabanid flies and EIAV at 
10
6 ID/ml in blood can be transmitted by a single fly (Foil et al., 1987). For analysis 
of the febrile response, rectal temperatures were divided into ranges adapted from a 
previously described method (Muraguri et al., 1999) as low fever (>39.3 °C – 40.2 
°C), moderate fever (40.3 °C – 41.2 °C) and high fever (> 41.2 °C). Student’s t-test 
was used for statistical comparison of the magnitude and duration of plasma VL and 
febrile responses and P-values < 0.05 were considered statistically significant. 
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Results 
Clinical and virological observations in cattle after BIV inoculation 
Fifteen BIV inoculated Bali cattle and 4 mock-infected control cattle were monitored 
for 42 days and then superinfected with JDV. During the initial 42 day period after 
BIV infection, the BIV-infected cattle did not exhibit any change in rectal 
temperature or other clinical signs of disease. 
BIV proviral DNA was detected in PBMC initially 7 dpi in one animal and 
subsequently in PBMC of all 15 cattle inoculated with BIV, confirming that all 
animals were infected (Table 5.1). BIV proviral DNA was detected in most cattle 
after 17 dpi but at no single time point was BIV proviral DNA detected concurrently 
in all 15 cattle. BIV proviral DNA was not detected in the mock-infected cattle. 
Plasma viral RNA was detected in 5 of the 15 cattle in the period from 8 to 13 dpi 
(Table 5.2) and plasma viral titres ranged from 1.04 to 4.25 log10 genome copies/ml 
plasma.  
An antibody response to the BIV TM
c and CA antigens was detected by ELISA 
(Figure 5.1). Antibody to the BIV TM
c peptide was detected from 10 dpi and in the 
majority of cattle by 41 dpi (Figure 5.1A). Antibody to the BIV CA antigen was 
detected from 19 dpi (Figure 5.1C) but the CA response was markedly less than the 
response to the BIV TM
c peptide (Figure 5.1A). Only some of the BIV-infected 
cattle developed CA antibody and only one seroconverted strongly in the 42 day 
period after infection. None of the mock-infected cattle developed BIV TM
c or CA 
antibody (Figure 5.1B and 5.1D).  
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Figure 5.1. TM
c and CA IgG response in serum of cattle after inoculation with BIV, 
shown as box and whisker plots of the ELISA absorbance values. (A) Response 
detected by BIV TM
c peptide in all 15 cattle inoculated with BIV at day 0. 
(B) Response detected by His-BIV CA antigen in all 15 cattle inoculated with BIV at 
day 0. (C) Response detected by BIV TM
c peptide antigen in all 8 cattle mock 
inoculated at day 0. (D) Response detected by His-BIV CA antigen in all 8 cattle 
mock inoculated at day 0. 
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Table 5.1. BIV proviral DNA detected by PCR in cattle inoculated with BIV and 
prior to infection with JDV. 
 
Days after BIV infection 
Animal  
0  7  10  17  19  21  42 
Cattle inoculated with BIV at day 0 and then JDV 
at day 42               
CB190  -
a  -  -  +
a  -  +  - 
CB191  -  -  +  +  -  +  - 
CB192  -  -  NT  +  -  +  - 
CB193  -  -  NT  +  +  +  + 
CB194  -  -  -  +  +  -  + 
CB195  -  -  -  +  +  +  + 
CB196  -  -  -  +  +  -  - 
CB197  -  -  -  +  -  +  - 
CB205  -  -  -  +  +  +  + 
               
Cattle inoculated with BIV only at day 0               
CB198  -  -  -  -  -  -  + 
CB199  -  +  +  -  +  -  + 
CB200  -  -  -  NT
b  +  -  + 
CB201  -  -  +  +  +  -  - 
CB202  -  -  -  +  -  -  + 
CB204  -  -  +  +  -  -  + 
               
Cattle inoculated with JDV only at day 42               
CB203  -  -  NT  -  -  -  - 
CB206  -  -  NT  -  NT  -  - 
CB208  -  -  -  -  -  -  - 
CB210  -  -  -  -  -  -  - 
               
Percent BIV-inoculated cattle positive  0  7  15  85  53  47  60 
Cumulative % positive  0  7  15  93  93  93  100 
Percent mock-inoculated cattle positive  0  0  0  0  0  0  0 
 
a - and + denote negative and positive PCR results, respectively, for BIV proviral 
DNA. 
b not tested.     92 
 
Table 5.2. BIV viral RNA genome copies/ml (log10) of plasma determined by qPCR in cattle inoculated with BIV at day 0 (all cattle) 
and JDV at day 42 (CB190 – CB205 only). 
Days after BIV inoculation    Days after JDV inoculation 
Animal 
0 - 1
a  7  8  9  10  11  13 
14-
42
c 
  44-
50
d  51  52  53  54  55 
56-
63
e 
Cattle inoculated with BIV at day 0 and JDV at day 42 
CB190  -
b  -  -  -  1.20  -  4.25  -    -  -  -  -  -  -  - 
CB191  -  -  -  -  -  -  1.89  -    -  1.40  -  -  -  -  - 
CB192  -  -  -  -  -  -  -  -    -  -  -  -  -  -  - 
CB193  -  -  -  -  1.79  -  -  -    -  -  -  -  -  -  - 
CB194  -  -  -  -  -  -  -  -    -  -  -  1.86  -  -  - 
CB195  -  -  -  -  -  -  -  -    -  2.18  -  2.57  2.51  1.48  - 
CB196  -  -  -  -  -  -  -  -    -  -  -  -  -  -  - 
CB197  -  -  -  -  -  -  -  -    -  1.79  -  -  -  -  - 
CB205  -  -  1.04  2.45  -  -  -  -    -  -  -  -  -  -  - 
 
Cattle inoculated with BIV at day 0 only 
CB198  -  -  -  -  -  -  -  -    -  -  -  -  -  -  - 
CB199  -  -  -  -  -  -  -  -    -  -  -  -  -  -  - 
CB200  -  -  -  -  -  -  -  -    -  -  -  -  -  -  - 
CB201  -  -  -  -  -  -  -  -    -  -  -  -  -  -  - 
CB202  -  -  -  -  -  -  -  -    -  -  -  -  -  -  - 
CB204  -  -  -  1.04  -  -  -  -    -  -  -  -  -  -  - 
 
a represent results from 0 and 1 dpi. 
b negative. 
c represents results from 14 - 17, 19, 21, 28, 35 and 41 - 42 dpi. 
d represents results from 44, 46 and 48 - 50 dpi. 
e represents results from 56 - 59, 61 and 63 dpi       93 
Clinical and virological observations after JDV inoculation 
Forty two days after BIV infection, 9 of the 15 BIV-infected cattle and 4 of the 
mock-infected cattle were inoculated with JDV and monitored for a further 15 to 19 
days. All the JDV-inoculated cattle developed a febrile response but there were 
differences in the responses in the previously BIV-infected and non-BIV-infected 
groups (Figure 5.2). Excluding 2 animals CB190 and CB205 that responded 
uncharacteristically to JDV infection and were considered atypical responders (see 
below), the febrile response in the BIV-infected group started 2 days earlier (a mean 
of 7 dpi compared to 9 dpi, P = 0.058), the peak of the febrile response occurred 
earlier (a mean of 10 dpi versus 12 dpi, P = 0.067), the peak VL also occurred 
significantly sooner (a mean of 10 dpi versus 12 dpi, P = 0.008) and there was a 
significantly earlier conclusion of the febrile response (a mean of 13 dpi compared to 
15 dpi, P = 0.033, Table 5.3). There were no significant differences between groups 
in regards to the duration and severity of the febrile response (Table 5.3). The 6 BIV-
only controls did not develop a febrile response or other clinical signs during the 
observation period (Figure 5.2). 
JDV plasma RNA was detected in all cattle inoculated with JDV from 3 to 19 dpi 
(Figure 5.3). The maximum VL was 2.18 x 10
11 genome copies/ml plasma. 
Excluding the 2 atypical responders, the cattle infected with JDV, regardless of 
whether they had been challenged previously with BIV, developed a viraemia typical 
of that reported previously (Desport et al., 2009a; Stewart et al., 2005). As shown in 
Figure 5.3, the pattern and magnitude of the viraemia was also similar between 
groups, but the viraemia started and finished earlier in the cattle infected previously 
with BIV, although these differences were not statistically significant; accordingly, 
in cattle previously infected with BIV there was a reduction in the mean duration of       94 
the JDV viraemia that was >10
6 genomes/ml plasma (P = 0.068).  There were no 
significant differences between previously BIV-infected and non-BIV-infected 
groups in the VL on the first or second day of the febrile period, the peak VL or the 
total AUC when the viraemia was ³10
6 genomes/ml plasma (Table 5.4).  
Two animals, CB190 and CB205, responded atypically to JDV infection. The cattle 
had a late onset fever (Figures 5.2 and Table 5.3) and the dynamics of their viraemia 
were different to those in the other cattle (Figure 5.3), similar to atypical responders 
previously reported (Desport et al., 2009a). These animals had an erratic viraemia 
increasing to a maximum titre of approximately 10
10 genome copies/ml which 
continued through to the conclusion of the experiment. As the viraemia in these 
animals did not decrease before the experiment concluded, the data provided for the 
duration of the viraemia in Table 5.4 is an underestimation of the actual values. 
After inoculation with JDV, plasma BIV RNA was again detected in 4 of the 9 
superinfected cattle (Table 5.2). The titre of BIV RNA during this period ranged 
from 1.40 to 2.57 log10 genome copies/ml plasma.  
Antibody to the JDV TM
c antigen was detected (Figure 5.4) in the 15 day period 
after JDV infection in a majority of cattle previously infected with BIV (Figure 
5.4A), but was not detected in any of the JDV-infected cattle that had not been 
infected previously with BIV (Figure 5.4B). ELISA absorbances to the CA protein 
increased at 4 days after JDV infection in the cattle that had been previously infected 
with BIV (Figure. 5.4D). BIV CA ELISA absorbances remained low in the cattle 
infected with JDV only (Figure 5.4F). 
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Figure 5.2.  Mean rectal temperatures in cattle inoculated with JDV. Y-error bars 
represent the standard deviations of rectal temperatures. Shown are the rectal 
temperatures in cattle which had been previously inoculated with BIV and responded 
to JDV in a typical fashion (○; CB191 – CB197), in cattle which had been 
previously infected with BIV and responded to JDV in an atypical fashion (▼; 
CB190 and CB205), JDV-only control cattle (●; CB203, CB206, CB208 and CB210) 
and BIV-only control cattle JDV (■).       96 
Table 5.3. Effect of previous BIV infection of cattle on the febrile response 
following JDV infection. 
Days after infection  Duration of febrile response 
(days) 
Animal  
Peak 
VL
 
Onset of 
febrile 
response
 
Peak 
febrile 
response
 
End of 
febrile 
response 
Low  Moderate  High  Total 
Cattle infected with BIV 42 days previously 
CB190  18  17  18  21  1  3  0  4 
CB191  8    5    8  13  4  2  2  8 
CB192    9    8  10  12  3  1  0  4 
CB193  12  11  13  16  4  1  0  5 
CB194    9    4  10  12  8  0  0  8 
CB195  11    8  10  15  3  3  1  7 
CB196    9    7  10  12  1  3  1  5 
CB197    9    7    9  13  3  3  0  6 
CB205  18  17  20  21  0  3  1  4 
Mean  11 
(10)
a 
9 
(7)
a 
12 
(10)
a 
15 
(13)
a 
3  2  1  6 
Variance  15.28  22.75  17.75  13.50  5.50  1.36  0.53  2.75 
                 
Cattle not previously infected with BIV
 
CB203  12    8  10  15  2  5  0  7 
CB206  12  10  13  15  4  1  0  5 
CB208  11  10  11  14  1  2  1  4 
CB210  12    9  12  17  4  4  0  8 
Mean  12    9  12  15  3  3  0  6 
Variance  0.25  0.92  1.67  1.58  2.25  3.33  0.25  3.33 
                 
P-value
b  0.441 
(0.008)
c 
0.487 
(0.058)
c 
0.412 
(0.067)
c 
0.449 
(0.033)
c 
0.425
  0.153  0.233  0.376 
a mean calculated excluding atypical responders CB190 and CB205. 
b P-values represent statistical differences between animals infected with BIV and 
then JDV and those infected with JDV only. 
c P-value calculated excluding atypical responders CB190 and CB205.       97 
 
 
0 2 4 6 8 10 12 14 16 18 20
0
2
4
6
8
10
12
Days after JDV inoculation
l
o
g
1
0
 
J
D
V
 
v
i
r
a
l
 
R
N
A
g
e
n
o
m
e
 
c
o
p
i
e
s
/
m
l
 
p
l
a
s
m
a
Figure 5.3. Mean plasma viral loads (JDV RNA genome copies/ml plasma) in 
animals inoculated with JDV at day 0. Y-error bars represent the standard deviations 
of viral loads. Shown are viral loads in cattle which had been previously infected 
with BIV and responded to JDV in a typical fashion (o; CB191 – CB197), JDV-only 
control cattle (●; CB203, CB206, CB208 and CB210), and cattle which had been 
previously infected with BIV and responded to JDV in an atypical fashion 
(▼; CB190 and CB205).   
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Table 5.4. Effect of previous BIV infection on the dynamics of the JDV viral load 
(VL) in plasma after JDV inoculation. 
 
Animal
  VL 1
st day of 
febrile period 
(log10) 
VL 2
nd day of 
febrile period 
(log10) 
Peak VL 
(log10) 
AUC ³10
6 
genome 
copies/ml (log10) 
Total 
days 
VL³10
6 
Cattle infected with BIV 42 days previously 
CB190  6.61  9.77  11.34  10.15  5.60 
CB191  7.35  10.63  10.12  11.76  11.20 
CB192  8.49  9.59  9.59  9.71  7.40 
CB193  8.89  9.26  9.26  9.68  8.60 
CB194  1.91  4.64  9.98  10.25  7.60 
CB195  9.23  10.12  10.57  10.98  10.10 
CB196  9.22  9.25  10.31  10.44  9.60 
CB197  9.36  9.93  10.72  11.00  8.50 
CB205  11.25  10.68  10.68  10.70  9.20 
Mean  8.04  9.06  10.08  10.55  9.00 
Variance  7.00  4.04  0.27  0.57  1.91 
 
Cattle not previously infected with BIV 
CB203  9.98  10.28  10.73  11.18  16.40 
CB206  9.40  10.01  10.18  10.55  10.30 
CB208  7.54  8.95  10.02  10.22  10.70 
CB210  7.46  9.16  10.13  10.60  13.40 
Mean  8.59  9.60  10.26  10.64  12.53 
Variance  1.65  0.41  0.10  0.15  7.77 
           
P-value
a  0.624  0.692  0.931   0.404  0.068
 
 
a P-values represent statistical differences between groups of animals infected with 
BIV 42 days prior to infection with JDV and those infected with JDV only.      99 
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Figure 5.4. IgG response detected by JDV TM
c peptide and His-BIV CA after 
inoculation with JDV, shown as box and whisker plots of the ELISA absorbance 
values. (A) Response detected by JDV TM
c peptide in cattle infected with JDV at 
day 0 and infected with BIV 42 days earlier. (B) Response detected by JDV TM
c 
peptide in cattle infected with JDV at day 0 but not infected previously with BIV. 
(C) Response detected by JDV TM
c peptide in cattle not infected with JDV at day 0 
but infected with BIV 42 days earlier. (D) Response detected by His-BIV CA in 
cattle infected with JDV at day 0 and infected with BIV 42 days earlier. 
(E) Response detected by His-BIV CA in cattle infected with JDV at day 0 only. 
(F) Response detected by His-BIV CA in cattle not infected with JDV at day 0 but 
infected with BIV 42 days earlier.       100 
Discussion 
Under the conditions with which the experiment was conducted, prior BIV infection 
did not prevent subsequent JDV infection or result in significant amelioration of the 
normal response of Bali cattle to JDV infection. Although it did not alter the normal 
clinical response to JDV infection, prior infection of cattle with BIV altered the 
dynamics of their response to JDV and resulted in an earlier onset of Jembrana 
disease.  Although many of the effects were not significantly different, cattle 
previously infected with BIV developed an earlier onset of fever, an earlier peak 
febrile response, a significantly earlier peak VL and a significantly earlier resolution 
of fever following superinfection with JDV.  Although prior BIV infection did not 
cause a difference in the total AUC, there was (in cattle previously infected with 
BIV) a reduction in the duration of the viraemia that exceeded 10
6 genome copies/ml 
of plasma. The differences were only evident when 2 atypical responders, identified 
in a small percentage of all cattle infected with the JDVTab87 strain of JDV (Desport et 
al., 2009a), were removed from the analysis. The lack of statistical significance in 
those animals that responded typically was probably at least partly due to the wide 
variance in the response to JDV of the cattle previously infected with BIV. A case 
fatality rate of about 21% is normally evident in experimentally JDV-infected Bali 
cattle (Desport et al., 2009a) but no fatalities occurred in any of the JDV-infected 
cattle during the 14 day observation period after infection so no effect on the JDV-
associated case fatality rate of prior BIV infection was determined. 
The enhanced early replication of a superinfecting virus seen here has not been 
reported previously in superinfections with other related lentiviruses.  An earlier 
onset of disease has, however, been reported with CAEV, JDV, EIAV and FIV 
following vaccination.  Goats vaccinated with inactivated CAEV developed arthritis       101 
more rapidly after CAEV infection than control animals (McGuire et al., 1986). 
Cattle vaccinated with a tissue-derived JDV vaccine had earlier peak VL than control 
animals (Ditcham et al., 2009). Horses vaccinated with a recombinant EIAV subunit 
vaccine and then challenged with EIAV displayed severe enhancement of viral 
infection and exacerbation of disease (Montelaro et al., 1996). Goats vaccinated with 
a T-cell priming Gag peptide from CAEV had transiently enhanced virus replication 
after CAEV infection compared with control animals, potentially via T-cell 
enhancement of virus replication (Nenci et al., 2007) and similar findings have been 
reported in FIV vaccine studies (Richardson et al., 1997). The presence of an active, 
cross-reactive T-helper cell immune response may explain the earlier start of 
viraemia and accelerated febrile response. JDV has recently been identified as 
replicating in IgG-containing cells (Desport et al., 2009b) and alternatively, the 
earlier replication of JDV in BIV-infected cattle may be related to the B-cell 
stimulatory activity of BIV (Whetstone et al., 1997).  
The lack of amelioration of the febrile response and the replication of JDV in the 
cattle previously infected with BIV occurred despite a strong antibody response to 
the BIV TM and, in a proportion of the cattle, an antibody response to the CA at the 
time of JDV inoculation. Due to the close antigenic relationship between JDV and 
BIV (Desport et al., 2005; Kertayadnya et al., 1993) the result was not expected as 
other lentiviruses have been shown to offer protection against infection with closely 
related heterologous viruses.  Domestic cats infected with non-pathogenic puma or 
lion lentiviruses developed humoral and cell-mediated immune responses against 
both homologous and heterologous FIV isolated from domestic cats (VandeWoude et 
al., 2003), suppressed FIV-induced CD4+ T-cell depletion (Terwee et al., 2008; 
VandeWoude et al., 2002) and FIV-induced plasma and PBMC viral loads       102 
(VandeWoude et al., 2002). Domestic cats pre-infected with a chimeric FIV and 
subsequently infected with fully virulent FIV ameliorated the clinical effects of the 
virulent challenge virus in some challenged cats, and reduced viral RNA and proviral 
DNA loads in others (Giannecchini et al., 2007). A lack of neutralising antibody 
response against the TM glycoprotein could explain why JDV infection occurred 
despite a strong anti-TM antibody response.  
It is possible that the R29 strain of BIV may have become attenuated since its 
isolation in 1969 (Whetstone et al., 1997) and that this may have affected the result 
obtained.  It is also possible that the 42 day period between BIV infection and 
subsequent JDV infection was too short for an effective protective immunity to 
develop. Although there was a strong antibody response to the TM protein of BIV at 
the time of JDV infection, and a rapid antibody response to TM and CA after JDV 
infection, which is normally delayed until at least 6 weeks after infection 
(Hartaningsih et al., 1994), this response may be unrelated to the development of a 
protective immune response which may require a longer period to develop with the 
bovine lentiviruses. However, in a similar experiment, protection against SIV in 
macaques could be achieved within 21 days of infection with a live attenuated SIV, 
with partial protection against wild-type SIV provided within 10 days of inoculation 
(Stebbings et al., 2004). In contrast, after wild-type FIV infection there was no 
protection against the effects of heterologous virus challenge until 2 to 3 years after 
infection when animals exhibited a reduced virus load and sometimes a reduced 
decline of CD4+ T-cells (Pistello et al., 1999). The possibility that longer term 
infections with BIV may induce a protective response to JDV infection needs further 
investigation as it would perhaps offer a low cost means of immunizing cattle against 
Jembrana disease.        103 
The dose of BIV used for infection and the challenge dose of JDV may also be 
factors responsible for lack of resistance to JDV infection following BIV infection. 
Studies of SIVmac in macaques have shown that the dose of primary virus affects the 
level of resistance to infection with a pathogenic virus (Cranage et al., 1998). 
Macaques given higher doses, 2 000 - 20 000 TCID50, of SIVmacC8 were shown to 
completely resist infection with SIVmac, shown by a lack of virus detection by PCR 
and a lack of virus isolation, whereas animals given lower doses of primary virus, 2 – 
200 TCID50, were protected against a loss of CD4 cells only.  
While there was no evidence that prior BIV infection provided protection against the 
pathological effects of subsequent JDV infection, there was also no evidence that the 
prior BIV infection exacerbated subsequent JDV infection, as reported in cases of 
HIV superinfection. Epidemiological observations suggest that infection with a 
second heterologous strain of HIV-1 has in the majority of cases, accelerated disease 
progression after infection, reviewed previously (Smith et al., 2005). It was observed 
in the current experiments that JDV infection in cattle previously infected with BIV 
reactivated replication of the BIV, and this appears to be an observation seen during 
heterologous lentivirus infections. Reactivation of primary infection virus has also 
been seen in HIV-2 infected macaques superinfected with SIVmac (Petry et al., 1995) 
and in HIV-2 infected baboons superinfected with heterologous HIV-2 (Locher et al., 
1997). Reactivation might be associated with the potent transactivation function of 
the JDV Tat protein, which was shown to be a potent transactivator not only of its 
own LTR but also the BIV and HIV LTR in vitro (Chen et al., 2000; Chen et al., 
1999). JDV Tat may function similarly in vivo in Bali cattle.  
There is no evidence of the outcome of mixed infections with JDV and non-
pathogenic BIV-like viruses under field situations in the Bali cattle population of       104 
Indonesia. Although mixed infection with JDV and a second BIV-like virus has been 
reported to occur in Bali cattle on Bali island (Barboni et al., 2001), the difficulty of 
detecting BIV-like virus in cattle and the close antigenic relationship of the 2 viruses 
has so far precluded the epidemiological study of mixed infection by JDV and 
possible non-pathogenic BIV-like viruses. BIV proviral DNA is only transiently 
present within PBMC of experimentally infected Bali cattle (Chapter 4), making the 
virus difficult to detect even when the animals are known to be infected.  
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Chapter 6: Humoral immune responses to Jembrana disease virus 
detected using overlapping synthetic peptides spanning the MA, CA 
and SU regions of JDV 
Summary 
The mapping of linear B-cell epitopes on the MA, CA and SU regions of Jembrana 
disease virus is described. One hundred and fifty five overlapping peptides that 
spanned these regions were synthesised and used in an ELISA format to screen a 
panel of bovine sera from animals experimentally infected with JDVTab87, JDVPul01 or 
BIV-R29. Six immunoreactive (IR) peptides, representing 6 potential epitopes, were 
identified when the set of peptides was screened with sera taken following JDVTab87 
infections; 1 in MA, 1 in CA and 5 in SU. Numerous IR peptides were identified 
when the set of peptides was screened with JDVPul01 sera. BIV-R29 sera also reacted 
with many peptides, including the IR peptides identified with the JDVTab87 sera. 
However, BIV-R29 sera did not react with some peptides and a combination of these 
peptides would enable detection of JDV-only seropositive cattle. These peptides 
include MA18, MA19, SU93, SU95, SU103, SU119 and SU135.        106 
Introduction 
The occurrence of clinical Jembrana disease and serological surveys for antibody 
reactive to JDV indicate that JDV infection is widespread in some islands of 
Indonesia including Bali, Java, Sumatra and Kalimantan (Indonesian Borneo) but the 
absence of clinical Jembrana disease and the occurrence of antibody to JDV suggests 
the occurrence of a non-pathogenic bovine lentivirus, possibly related to BIV, on the 
island of Sulawesi (Hartaningsih, personal communication). A BIV-like, non-
pathogenic bovine lentivirus was also reported to occur in the cattle population on 
Bali island (Barboni et al., 2001) but this has not been confirmed and efforts to detect 
BIV proviral DNA in PBMC of cattle on Bali island were unsuccessful (Chapter 3).  
While JDV and BIV are sufficiently different genetically that they can be 
differentiated utilising a number of PCR assays (Lew et al., 2004; Lewis et al., 2009) 
low proviral DNA loads in PBMC after infection precludes their use as a screening 
tool. They are very similar antigenically and attempts to differentiate antibody to the 
2 viruses using ELISA and WIB procedures have been unsuccessful due to the 
presence of numerous cross-reactive epitopes on the CA, MA and TM proteins 
(Desport et al., 2005). Using recombinant, overlapping JDV Gag proteins, previous 
attempts have been made to define specific epitopes that differentiate between the 2 
bovine lentiviruses antigenically, however these were unsuccessful (Desport et al., 
2005). A number of recombinant proteins were produced and reacted with JDV and 
BIV hyperimmune sera as well as monoclonal antibodies in a WIB. These attempts 
identified at least three epitopic domains within MA and CA, including the Major 
Homology Region (MHR) but could not identify an epitope(s) that differentiated 
between the two viruses (Desport et al., 2005).   A monoclonal antibody directed 
against an epitope which spans the cleavage site between BIV MA and the p2L       107 
protein was reported to differentiate between BIV and JDV antibody using a WIB 
assay (Lu et al., 2002; Zheng et al., 2001) but the epitope involved does not appear to 
be immunogenic in cattle and linear forms of this epitope can not be used to 
differentiate between bovine lentivirus infections (Desport et al., 2005). Reliable 
serological surveillance for JDV infection in cattle in Indonesia requires the use of 
serological techniques that can differentiate the 2 infections. 
Various epitope mapping studies have employed the use of expression libraries and 
recombinant proteins to map epitopes and then fine mapping using synthetic peptide 
strategies (Bertoni et al., 1994; Chong et al., 1991a; Chong et al., 1991b; Rosati et 
al., 1999). These approaches were used to map the antigenicity of the SU 
glycoproteins of EIAV (Ball et al., 1992) and CAEV (Valas et al., 2000) and the 
antigenicity of CAEV TM (Bertoni et al., 1994). In this Chapter, synthetic peptides 
were used to map the epitopes of JDV MA, CA and SU proteins to find epitopes 
which can be used for differentiating the 2 viruses in serological assays.  
Materials and methods 
Source of animal sera 
A panel of bovine sera from experimentally infected Bali cattle was used in this 
study. The cattle were infected with either JDVTab87, JDVPul01 or BIV-R29 during 
various studies of the response of cattle to these viruses (Desport et al., 2009; 
Ditcham et al., 2009; Chapters 4 and 5) and serum samples were acquired at various 
dpi. Pre-infection serum samples from the same cattle were used to test the 
background level of reactivity to each peptide. 
Hyperimmune JDV and BIV sera, a gift from N. Hartaningsih (Indonesia) were also 
tested. JDV hyperimmune serum was created by inoculating a bovine lentivirus-free       108 
animal with plasma taken from an animal during the febrile phase after infection with 
JDVTab87. The animal then received 7 booster inoculations intramuscularly at 2 week 
internals with tissue-derived JDV vaccine. Serum was taken 2 weeks after the final 
inoculation. BIV hyperimmune serum was produced in a bovine lentivirus-free 
animal with cell-culture preparations of BIV-R29 prepared as described in Chapter 4.  
This cell culture material was emulsified in Freund’s incomplete adjuvant and 
inoculated 3 times at 2-week intervals and serum was collected 2 weeks after the 
final inoculation. The first inoculation was from freshly harvested cell culture 
material while the final 2 inoculations were from frozen cell culture material. The 
reactivity of the JDV hyperimmune serum has previously been reported (Desport et 
al., 2005). The BIV hyperimmune serum reacted with JDV CA and BIV CA and SU 
proteins on a WIB.       109 
Overlapping synthetic peptides  
One hundred and fifty five overlapping synthetic peptides were constructed to cover 
the entire amino acid sequence of MA, CA and SU of JDVTab87 (accession number 
U21603). The peptides were designed to be 16 amino acids long and to overlap each 
other by 11 amino acids. This length allows for coverage of the three regions while 
the minimal overlap enables mapping to a fine specificity and takes into account the 
significant expense of peptide production.  The peptides were synthesised by 
automated 9-fluorenylmethyloxycarbonyl chemistry (Mimotopes, Australia) as 
previously described (Valas et al., 2000). An amino-terminal biotinylated 
tetrapeptide (Ser-Gly-Ser-Gly) was added to all peptides to facilitate epitope 
accessibility and absorption to streptavidin-coated wells. All peptides were dissolved 
in 200 µl of cell culture grade, 100% DMSO (Sigma-Aldrich). For use in the ELISA, 
peptides were further diluted 1:200 in PBS-T (PBS containing 0.1% Tween-20 
[Sigma] and 0.1% sodium azide [Sigma]). 
ELISA  
Serum samples were tested at a dilution of 1:50 against each peptide in a standard 
ELISA according to the peptide manufacturer’s instructions. Plates were coated with 
100 µl of 5 µg/ml stock streptavidin (Sigma-Aldrich) and left to evaporate overnight 
at 37°C. Plates were blocked for 2 h with 200 µl of blocking solution (0.01 M PBS 
containing 2.5% gelatin [Bio-Rad], 5% rabbit serum [Invitrogen], 1% sodium 
caseinate [MP Biomedicals], 0.1% Tween 20 [Sigma]). All incubation steps were 
conducted at room temperature (~25°C) on a rocker platform. Plates were then 
washed 4 times with PBS-T. Peptides were further diluted 1:4 in PBS-T and 100 µl 
of peptide solution were added to each ELISA well, in duplicate, and incubated for 
1 h. Plates were again washed 4 times. Serum was diluted 1:50 using PBS-T and       110 
100 µl added to each well. Plates were incubated for 1 h then washed a further 4 
times. Goat anti-bovine IgG HRP-conjugated (MP Biomedicals) was diluted 1:2 000 
in 0.01 M PBS with additional 1% sheep serum (Invitrogen), 0.1% Tween 20 and 
0.1% sodium caseinate, 100 µl was added to each well. Plates were incubated for 1 h 
then washed 4 times with PBS-T and 2 times with PBS only. Substrate (SigmaFast 
OPD; Sigma) was prepared as per the manufacturer’s instructions and 100 µl was 
added to each well. After colour development, the reactions were stopped with 3 M 
H2SO4 and read at 450 nm. 
Statistical analysis 
A model previously developed and described to map linear epitopes in HIV-1 was 
used to analyse the data produced in the ELISA (Loomis-Price et al., 1997). The cut-
off for reactivity of individual peptides was determined as follows: the median and 
first quartile values (of the optical densities) were determined separately for each 
serum sample and for each block of peptides. The data were normalised by 
subtracting the median reactivity of the set from each value in the set and the 
standard deviation was calculated: 
Standard deviation (s) = (median – first quartile)/0.675 
The data were then divided by the calculated standard deviation and expressed as 
normalised reactivity (s) compared to the median. Measurements above a cut-off of 
5 s were considered positive.  
The overlapping peptide set was screened with pre-infection sera to determine the 
level of background binding present for each serum sample. Unless the level of 
reactivity increased over time, the peptide was scored as non-reactive. 
Immunoreactive (IR) peptides were defined as those which reacted with 75% or       111 
greater of the serum samples tested and immunodominant (ID) peptides defined as 
those which reacted with 100% of the serum samples tested, as previously reported 
(Ball et al., 1992). 
Results 
When the overlapping peptides were tested against sera from cattle after infection 
with JDVTab87, a number of peptides were not reactive against any of the sera tested, 
including peptide MA18 in MA (Figure 6.1A), peptides CA34, CA35, CA42 and 
CA62 in CA (Figure 6.2A) and peptides SU78, SU85, SU92, SU121, SU138, 
SU145, SU148 and SU149 in SU (Figure 6.3A). One peptide (MA24) was identified 
as IR in MA (Figure 6.1A), one peptide (CA70) was identified as IR in CA 
(Figure 6.2A) and 4 peptides (SU112, SU152, SU154 and SU155) were as IR in SU 
(Figure 6.3A). The locations of these peptides on the linear amino acid sequence of 
JDVTab87 are shown in Figures 6.5 and 6.6. No peptides were identified as ID in MA, 
CA or SU using the Ball et al. (1992) definitions. Using the less stringent definitions 
reported in a separate study (Valas et al., 2000), whereby IR peptides were defined 
by greater than 20% reactivity with bovine sera and ID peptides defined by greater 
than 58% reactivity, 22 MA peptides were IR and 1 was ID, 27 CA peptides were IR 
and 4 were ID, and 44 SU peptides were IR and 8 were ID. 
When the overlapping peptides were screened with serum taken from cattle 
experimentally infected with JDVPul01, a number of peptides were not reactive 
against the JDVPul01 sera, including peptides MA6, MA10, MA13, MA14 and MA22 
in MA (Figure 6.1B), peptides CA26, CA27, CA38, CA39, CA43, CA44, CA55, 
CA62, CA63, CA67, CA68 and CA70 in CA (Figure 6.2B) and peptides SU78-80, 
SU83, SU84, SU86- 88, SU90, SU94, SU95, SU111, SU112, SU114, SU116, 
SU131, SU135, SU136, SU147 and SU154 in SU (Figure 6.3B). Numerous peptides       112 
were IR against the sera from JDVPul01 infected animals including peptides MA4, 
MA15, MA21 and MA25 in MA (Figure 6.1B), peptides CA41, CA49, CA52 and 
CA69 in CA (Figure 6.2B) and peptides SU100, SU106, SU108, SU110, SU115, 
SU118, SU120, SU121, SU126, SU145 and SU150 in SU (Figure 6.3B). Peptides 
CA53, SU96 and SU102 were ID.  
When the overlapping peptides were screened with serum taken from cattle 
experimentally infected with BIV, peptides not reactive with the BIV sera tested 
included peptide MA10, MA12 and MA18 in MA (Figure 6.1C), CA33, CA42 and 
CA63 in CA (Figure 6.2C) and peptides SU74, SU83, SU85, SU86, SU88, SU92, 
SU93, SU95, SU103, SU105, SU111, SU114, SU119, SU135 and SU137 in SU 
(Figure 6.3C). Peptide 25 in MA (Figure 6.1C), peptides CA29, CA53 and CA55 in 
CA (Figure 6.2C) and peptides SU126, SU129, SU100, SU118 and SU123 in SU 
(Figure 6.3C) were all IR and no peptides were ID against these sera. 
The 2 hyperimmune serum samples tested reacted against different peptides. 
JDVTab87 hyperimmune serum reacted particularly strongly against peptide SU83 as 
well as peptide MA5 (Figure 6.4). In contrast, BIV hyperimmune serum reacted 
strongly to peptides in 3 regions of CA: CA57 and 58, peptides CA44 and CA45, and 
CA65 (Figure 6.4). 
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Figure 6.1. Reactivity to peptides derived from the MA sequence of JDVTab87 to 
serum samples taken (A) 56-159 days after infection of cattle with JDVTab87, (B) 
71-102 days after infection of cattle with JDVPul01 and (C) 35-101 days after infection 
of cattle with BIV.       114 
26 31 36 41 46 51 56 61 66 71
0
25
50
75
100
Peptide number
R
e
a
c
t
i
v
i
t
y
 
(
s
s
s
s
)
25 30 35 40 45 50 55 60 65 70
0
25
50
75
100
Peptide number
R
e
a
c
t
i
v
i
t
y
 
(
s
s
s
s
)
25 30 35 40 45 50 55 60 65 70
0
25
50
75
100
Peptide number
R
e
a
c
t
i
v
i
t
y
 
(
s
s
s
s
)
A
B
C
 
Figure 6.2. Reactivity to peptides derived from the CA sequence of JDVTab87 to 
serum samples taken (A) 56-159 days after infection of cattle with JDVTab87, (B) 56-
159 days after infection of cattle with JDVTab87 and (C) 35-101 days after infection of 
cattle with BIV.        115 
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Figure 6.3. Reactivity to peptides derived from the SU sequence of JDVTab87 to 
serum samples taken (A) 56-159 days after infection of cattle with JDVTab87, (B) 71-
102 days after infection of cattle with JDVPul01 and (C) 35-101 days after infection of 
cattle with BIV.       116 
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Figure 6.4. Reactivity of hyperimmune serum to overlapping peptides spanning the 
MA (peptides MA1-25), CA (peptides CA26-71) and SU (peptides SU72-155) of 
JDV. A: reactivity with JDVTab87 hyperimmune sera. B: reactivity with BIV-R29 
hyperimmune sera. Connecting lines are shown for clarity and are not meant to imply 
continuous data. Horizontal line (-----) indicates the cut-off of 5 s.       117 
JDV             MKLSKLEKALKKVRVTPQRDDTYTIGNVLWAIRMCRLMGLDCCIDEAT-AAEVAILIGRF 59 
      Start gag ► 
BIV             MKRRELEKKLRKVRVTPQQDKYYTIGNLQWAIRMINLMGIKCVCDEECSAAEVALIITQF 60 
                **  :*** *:*******:*. *****: ***** .***:.*  **   *****::* :* 
 
JDV             QSLDLQDSPLKGKDEKAILTTLKVLWSLLAGHHPENSDMAEKYWEAWTIRERESQKEEEG 119 
                   Peptide 24 
BIV             SALDLENSPIRGKEEVAIKNTLKVFWSLLAGYKPESTETALGYWEAFTYREREARADKEG 120 
                .:***::**::**:* ** .****:******::**.:: *  ****:* ****:: ::** 
 
JDV             EITSIYPQLRKN---------------FPAVSTSDGSPRYDPDLTKQLKIWADATEKHGV 164 
    MA¨ ¨ ¨ ¨CA 
         Peptide 24 
BIV             EIKSIYPSLTQNTQNKKQTSNQTNTQSLPAITTQDGTPRFDPDLMKQLKIWSDATERNGV 180 
                **.****.* :*               :**::*.**:**:**** ******:****::** 
 
JDV             DHHAVNILGVITANLTQSEIRLLLQSTPQWRLDIQLIESKLNAREHAHRVWKESHPEAPK 224 
BIV             DLHAVNILGVITANLVQEEIKLLLNSTPKWRLDVQLIESKVREKENAHRTWKQHHPEAPK 240 
                * *************.*.**:***:***:****:******:. :*:***.**: ****** 
 
JDV             TDEIIGKGLTAAEQATLTTQECRDTYRQWVLEAALEVAQGKHDRPGPINIHQGPKEPYPE 284 
BIV             TDEIIGKGLSSAEQATLISVECRETFRQWVLQAAMEVAQAKHATPGPINIHQGPKEPYTD 300 
                *********::****** : ***:*:*****:**:****.**  **************.: 
 
JDV             FVNKLVTALEGMAAPETTKQYLLDHLSVDHANEDCRAVLLPLGPSAPMERKLEACRAVGS 344 
BIV             FINRLVAALEGMAAPETTKEYLLQHLSIDHANEDCQSILRPLGPNTPMEKKLEACRVVGS 360 
                *:*:**:************:***:***:*******:::* ****.:***:******.*** 
 
JDV             SKQKMQFLAEAFAAINVK-------------------GDGEVQRCYGCGKPGHIRRDCKN 385 
     CA¨ ¨ ¨ ¨NC 
    Peptide 70 
BIV             QKSKMQFLVAAMKEMGIQSPIPAVLPHTPEAYASQTSGPEDGRRCYGCGKTGHLKRNCKQ 420 
                .*.*****. *:  :.::                   *  : :*******.**::*:**: 
 
JDV             QKCFKCGKPGHLQRNCKSKNGRRSSAPSGQRS----GYHQEKTS-VTPSAPPLVLD 436 
                  ◄ End gag 
BIV             QKCYHCGKPGHQARNCRSKNGKCSSAPYGQRSQPQNNFHQSNMSSVTPSAPPLILD 476 
                ***::******  ***:****: **** ****    .:**.: * ********:** 
 
Figure 6.5. Linear representation of JDV MA and CA epitopes. A panel of sera 
taken from animals experimentally infected with JDVTab87 were reacted in ELISA 
against the panel of JDV MA and CA synthetic peptides. Bovine humoral epitopes 
are portrayed along the linear amino acid sequence of the JDVTab87 gag precursor 
protein. Grey highlighted sequences delineate immunoreactive peptides which are 
recognized by 75% or more of the bovine sera. The BIV gag precursor protein 
sequence is also shown below the JDV sequence for comparison. The sequences 
were aligned using ClustalW2 (Larkin, 2007).  “*” indicates identical residues, “:” 
indicates conserved substitutions and “.” indicates semi-conserved substitutions.        118 
JDV             MMEEGRKEEPEERGEKSTMRDLLQRAVDKGHLTAREALDRWTLEDHGEIHPWIILFCFAG 60 
      Start env ► 
BIV             MDQDLDGAERGERGGGS--EELLQEEINEGRLTAREALQTWINN--GEIHPWVLAGMLSM 56 
                * ::    *  ***  *  .:***. :::*:*******: *  :  ******::   ::  
 
JDV             AIGVIGGWGLRGELNVCMLIVLVVLVPIYWGIGEAARNIDSLDWKWIRKVFIVIIFVLVG 120 
BIV             GVGML--LGVYCQLPDTLIWILMFQLCLYWGLGETSRELDKDSWQWVRSVFIIAILGTLT 114 
                .:*::   *:  :*   :: :*:. : :***:**::*::*. .*:*:*.***: *:  :  
 
JDV             LLG--------------------------------------------------------- 123 
BIV             MAGTALADDDQSTLIPNITKIPTKDTEPGCTYPWILILLILAFILGILGIILVLRRSNSE 174 
                : *                                                          
 
JDV             ------------------------------------------------------------ 
BIV             DILAARDTIDWWLSANQEIPPKFAFPIILISSPLAGIIGYYVMERHLEIFKKGCQICGSL 234 
                                                                             
 
JDV             ----------------------------------------GCSAQRQHVAMLLSPPGIRL 143 
BIV             SSMWGMLLEEIGRWLARREWNVSRVMVILLISFSWGMYVNRVNASGSHVAMVTSPPGYRI 294 
                                                          .*. .****: **** *: 
 
JDV             P-STVDIPWFCISNAPIPDCVHWTVQK---PDQKHQQIENVMELQEVLDNATFFEVPDLF 199 
BIV             VNDTSQAPWYCFSSAPIPTCSSSQWGDKYFEEKINETLVKQVYEQAAKHSRATWIEPDLL 354 
                  .* : **:*:*.**** *      .    :: :: : : :  * . .. : :  ***: 
 
JDV             DRVYLELARLDANSTGVPVNIPPTGISQVKGDCSTGDIQGMNETLSTRGTLGERTFLSIR 259 
    Peptide 112 
BIV             EEAVYELALLSANDS-----------RQVVVENGTDVCSSQNSSTNKGHPMTLLKLRGQV 403 
                :..  *** *.**.:            **  : .*.  .. *.: ..  .:   .: .   
 
JDV             PGGWFTNTTVWFCVHWPFGFIQRKEN-----LSEGSAQVRNCLDPINVTEPRVANYSYCP 314 
                    Peptide 134 
BIV             SETWIGNSSLQFCVQWPYVLVGLNNSDSNISFNSGDWIATNCMHPITLNKS--------- 454 
                .  *: *::: ***:**: ::  ::.     :..*.  . **:.**.:.:.          
 
JDV             LEYKGKNYINKGLKCVGGRVDLSSNPEQHTDLLACGTFCQNFRNCDMVSRDILIG-YHPS 373 
         Peptide 134 
BIV             AQDLGKNFP--RLTFLDGQLSQLKN-----TLCGHNTNCLKFGNKSFSTNSLILCQDNPI 507 
                 :  ***:    *. :.*::.  .*      * . .* * :* * .: :..:::   :*  
 
JDV             QQKQHIYINHTFWEQANTQWILVQVPNYGFVPVPDTERPWKGGKPRGKRAVGMVIFLLVL 433 
                  SU♦TM 
              Peptide 152 Peptide 154 Peptide 155 
BIV             GNDTFYSLSHSFSKQASARWILVKVPSYGFVVVNDTDTPP-SLRIRKPRAVGLAIFLLVL 566 
                 :. .  :.*:* :**.::****:**.**** * **: *  . : *  ****:.****** 
Figure 6.6. Linear representation of JDV SU epitopes. A panel of sera taken from 
animals experimentally infected with JDVTab87 were reacted in ELISA against the 
panel of JDV SU synthetic peptides. Bovine humoral epitopes are portrayed along 
the linear amino acid sequence of the JDV Env precursor protein. Grey highlighted 
sequences delineate immunoreactive peptides which are recognized by 75% or more 
of the bovine sera. Three immunoreactive peptides are shown at the carboxyl end of 
the protein; these are distinguished by the grey highlighted text (1), the underlined 
text (2) and the bolded text (3). The BIV Env precursor protein sequence is also 
shown below the JDV sequence for comparison. The sequences were aligned using       119 
ClustalW2 (Larkin, 2007).  “*” indicates identical residues, “:” indicates conserved 
substitutions and “.” indicates semi-conserved substitutions.  
Discussion   
The investigations conducted were designed to use synthetic peptides to identify 
antigenic sites on the MA, CA and SU that would react differentially to antibody to 
JDV and BIV. Synthetic peptides have been used previously to map antigenic sites in 
a number of lentiviruses, including EIAV (Ball et al., 1992; Grund et al., 1996; 
Soutullo et al., 2007), the SRLV CAEV and VMV (Mordasini et al., 2006; Rosati et 
al., 1999; Valas et al., 2000) and HIV-1 (Loomis-Price et al., 1997; Neurath et al., 
1990).  They have also been used with other virus systems including human 
cytomegalovirus (Greijer et al., 1999), Foot and mouth disease virus (Geysen et al., 
1987) and Epstein-Barr virus (Middeldorp et al., 1988). The peptides were able to 
identify specific linear sites which were immunogenic in the native protein antigens. 
It is recognised, however, that a limitation of these studies as well as the current 
study is that the use of synthetic peptides cannot identify discontinuous 
conformation-dependent epitopes which may represent important antigenic 
determinants of viral proteins.  
Another limitation of this current study was that it was necessary to use serum from 
BIV-R29 infected animals to screen the peptides and examine for differences in the 
reactions comparative to those in JDV-infected cattle. This BIV strain may not 
necessarily have a close antigenic relationship to the putative non-pathogenic bovine 
lentivirus in Indonesia. However, this was the only BIV serum available and sera 
from antibody-positive cattle in Sulawesi, which would have been a suitable 
alternative, were unavailable for this study.        120 
Sera from cattle experimentally infected with JDVTab87 or JDVPul01 were used to 
screen the peptides for JDV-reactive epitopes as these are 2 reasonably well defined 
strains that have been detected in Indonesia and the samples had a well documented 
history. Of a number of JDV strains sequenced, JDVPul01 is the most divergent from 
JDVTab87 in env and gag regions (Desport et al., 2007) and we sought to determine 
whether the differences extended to the humoral response. The amino acid sequence 
homology between the two strains in the entire env region and part of the gag regions 
is 97% (Desport et al., 2007).  Differences also existed between the reaction of cattle 
infected with these 2 JDV strains in regards to peak viral loads and duration of 
viraemia (Desport et al., 2009a). Differences were detected in the reactivity of the 
peptides between the JDVTab87 and JDVPul01 sera. The JDVPul01 sera had a larger 
number of IR peptides, with 3 ID peptides CA53, SU96 and SU102. These 
differences could be attributed to the fewer number of cattle analysed and it would be 
of interest to screen the peptides with more JDVPul01 sera to confirm these results.  
The synthetic peptides used in this study encompassed the complete JDVTab87 MA, 
CA and SU regions. The MA, CA and SU proteins were chosen for investigation for 
a number of reasons. Firstly, the strongest and earliest immune responses against 
JDV are directed at CA (Hartaningsih et al., 1994; Kertayadnya et al., 1993) although 
a subset of cattle do not mount an immune response against CA (Desport et al., 
2009a; Ditcham et al., 2009). Matrix was chosen as BIV was reported to contain at 
least one unique epitope in the CA that is absent in JDV, at the 6.4-kDa N terminus 
of the 29-kDa CA adjacent to MA (Zheng et al., 2001) and strong antibody responses 
against MA have been previously identified in experimentally infected animals 
(Desport et al., 2005; Kertayadnya et al., 1993). SU was included as anti-Env 
responses have been reported to persist beyond 190 weeks after BIV infection whilst       121 
the Gag response wanes 40 weeks after infection (Isaacson et al., 1995), env 
sequences between JDV strains are reasonable well conserved (Desport et al., 2007) 
and there are a significant number of differences between the sequence of the SU 
regions of JDV and BIV (Chadwick et al., 1995b, Figure 6.6, Table 2.2). Little 
information is currently available detailing the antigenicity of JDV SU due to 
problems expressing recombinant SU. 
In the ELISA used to examine differential reactivity of the peptides, a cut-off of 75% 
and greater positive reactivity to represent a significant B-cell epitope was used, as 
reported by others (Ball et al., 1992). Other studies have utilised lower cut-offs of 
33% (Kusk et al., 1992) and 50% (Valas et al., 2000) but a higher cut-off was used in 
the current study to identify highly reactive B-cell epitopes in the JDV proteins. 
There is potential for the use of IR peptides, those reacting with a high percentage of 
serum samples tested, and ID peptides reacting with all serum samples, to facilitate 
the development of a peptide-based ELISA able to identify most animals infected 
with JDV or both JDV and BIV depending on the peptides used. Several potentially 
useful IR peptides were detected. 
One IR MA peptide was identified which spanned amino acids 116 to 131 of the CA 
and MA proteins. This peptide spanned the MA-CA border and indicates that the 
antibodies which recognise this peptide are produced in response to the uncleaved 
Gag precursor protein.  
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Sera from long-term JDV infections (>12 months after infection) were reported to 
recognise a protein of the same size as MA (Kertayadnya et al., 1993) and these 
findings identify an epitope within MA. Some JDV-infected cattle (CB83-86) have 
been reported not to respond to MA within 175 dpi when tested in an ELISA using 
recombinant MA (Ditcham et al., 2009) but MA24 reacted with sera from all of these 
cattle (Table 6.1). The difference between the responses reported by Ditcham et al. 
(2009) and those in the current study may be due to differences associated with the 
sequences covered by the antigens. The responses reported by Ditcham et al. (2009) 
were those generated when using a full length recombinant MA while MA24 spans 
the MA-CA border, encompassing additional sequence. Peptide ELISA has been 
shown to be more sensitive than an ELISA using recombinant proteins (Rosati et al., 
1999). Coincidentally, most variation in JDV Gag occurs just before the predicted 
cleavage point between the MA and CA proteins (Desport et al., 2007) and this, 
combined with the identification of an IR peptide in this region, suggests this may be 
a region under pressure from the immune system.  
The IR CA peptide reported here is within amino acids 346 – 360 of the Gag 
precursor protein and spans the CA-NC border. Like the MA response, it also 
suggests that the antibodies are produced in response to the uncleaved Gag precursor 
polyprotein. Hyperimmune sera against whole JDV and BIV were reported to not 
recognise recombinant proteins encompassing this region, presumable because of the 
differences in the way hyperimmune sera is raised compared to sera from natural or 
experimental infections (Desport et al., 2005). As shown in Figure 6.1, JDV 
hyperimmune serum did react to this peptide while BIV hyperimmune sera did not. 
A highly immunogenic domain has been reported in a similar location for EIAV 
(Chong et al., 1991b).        123 
There were no IR peptides found within the MHR in CA when the peptides were 
screened with JDVTab87 sera. The lack of an JDVTab87 IR peptide in this region is 
surprising given that previous studies have shown that it is likely to be an epitopic 
domain within JDV (Desport et al., 2005). The MHR is conserved among 
retroviruses and is essential for virus assembly, maturation and infectivity 
(Mammano et al., 1994) and is assumed to account for some of the cross-reactivity 
observed between the Gag proteins of HIV, EIAV and BIV. Previous studies have 
shown cross-reactivity between BIV hyperimmune sera and the JDV MHR (Desport 
et al., 2005), although confirmation is required. Peptides CA52-59 spanned the MHR 
and although they were not identified as IR in the current study, a number of peptides 
had high reactivities against JDVTab87 sera, including CA53–55, 57 and CA58. 
Peptide CA57 had the second highest reactivity of all the CA peptides with a 
reactivity of 62.5%. The CA53 peptide was a JDVPul01 ID peptide and when screened 
with BIV sera, peptides CA53 and CA55 were found to be IR, confirming that this is 
one region of cross-reactivity. The BIV hyperimmune serum used in this study also 
strongly reacted to this region (Figure 6.4). JDV hyperimmune serum also reacted to 
the MHR, albeit more weakly than the BIV hyperimmune serum.  
Surprisingly, the major homology region identified as an immunodominant domain 
in the CA proteins of many of the lentiviruses was not identified as IR or ID using 
this method of analysis.This may indicate that the level of stringency was too high or 
may be due to the characteristics of the sera chosen or the conformation of the 
peptides. Previous studies have shown that conformational changes to peptides, such 
as converting the peptides to a cyclical form, can help to increase reactivity (Scobie 
et al., 1999). Further studies are required to clarify this discrepancy.        124 
Five IR peptides were found within SU. Peptide SU112 spanned amino acids 201–
216 in the central portion of the protein. The most IR peptide, reactive with 87.5% of 
the sera tested, was SU134 and this spanned amino acids 311–326. The remaining 3 
peptides, SU152, SU154 and SU155, clustered around the carboxyl end of SU and 
spanned amino acids 401–430. The reduction in reactivity for peptide SU153 
compared with the reactivity for peptides SU152 and SU154 indicated that there may 
be 2 different epitopes at this location, as reported in CAEV SU (Valas et al., 2000). 
The clustering of IR peptides around the carboxyl end of SU is similar to CAEV 
(Bertoni et al., 2000; Valas et al., 2000), HIV-1 (Palker et al., 1987) and EIAV (Ball 
et al., 1992; Grund et al., 1996), although these viruses also have IR regions at the 
amino end of SU which were not identified in this current study of JDV. FIV also has 
an epitope at the carboxyl end of SU, progressing into the start of TM (Pancino et al., 
1993), similar to the region encompassed by peptides SU154 and SU155 in the 
current study. It was suggested that the antigenicity of terminal segments of proteins, 
including lentiviral SU glycoproteins, is because these regions are frequently surface 
orientated and thus exposed and immunogenic in their native state (Ball et al., 1992; 
Valas et al., 2000; Van Regenmortel, 1999b). 
No ID peptides were identified with the JDVTab87 serum. This might be associated 
with the outbred nature of the Bali cattle population, as has been suggested in the T-
cell epitope mapping in FIV (Dean et al., 2004). A number of ID peptides were 
identified with the JDVPul01 serum including 1 in CA and 2 in SU (Figures 6.2 and 
6.3). Reactivities with the JDVTab°/87 sera to these peptides ranged from 25 to 50% 
(Figures 6.2 and 6.3). Further investigations are required to determine whether the 
differences are attributed to strain variation or to the number of samples analysed.        125 
The differential reaction of some peptides to JDV sera compared to BIV sera 
suggests some of these peptides could be used to form antigens for potential JDV-
specific and broadly reactive bovine lentivirus serological assays. Peptides which 
were reactive against 50% of sera taken from JDVTab87, JDVPul01 and BIV-R29 would 
be useful to include in a bovine lentivirus serological assay as these should detect a 
majority of cattle infected with these bovine lentiviruses. The areas encompassed by 
these peptides are significant regions of cross-reactivity since a majority of both JDV 
and BIV sera reacted to these peptides.  
Peptides that were not recognised by BIV sera are potential candidates for inclusion 
in a JDV-specific ELISA antigen, an approach previously suggested in CAEV (Valas 
et al., 2000). Unfortunately, none of these peptides were IR or ID against the JDV 
sera only. However, a combination of 5 of these peptides, SU93, SU95, SU103, 
SU119 and SU135 from SU, would have reacted with 87.5% of the JDV-only sera, 
although this specific combination would not have detected animals infected with 
JDVPul01. The addition of 2 extra peptides, MA18 and MA19 would provide 
reactivity with the JDVPul01 sera. It is important to note, however, that this approach 
would potentially provide a JDV-specific serological assay and not a BIV-specific 
assay. Previous diagnostic assays have combined multiple antigens in an ELISA 
format (Khan et al., 2006) and it would be practical to combine these peptides in this 
format.  
This study needs to be extended by testing sera from naturally infected cattle as well 
as by testing the longitudinal responses to the IR peptides in experimentally infected 
cattle, and applying the tests in a clinical setting in Indonesia. Consideration could 
also be given to using selected peptides in the formulation of vaccines capable of 
protecting against JDV, as has been reported in a number of lentivirus systems       126 
including SIV (Belyakov et al., 2001; Nehete et al., 2008) and HIV-1 (Hovanessian 
et al., 2004). Due to the persistent nature of the anti-TM antibody response in BIV 
infections (Isaacson et al., 1995, Scobie et al., 1999), the TM glycoprotein may also 
be a promising linear antigenic target and therefore extending this study to the TM 
glycoprotein may yield a potential antigen for inclusion in a differential serological 
assay. It would also be of interest to test the response of cattle superinfected with 
both BIV and JDV and their pattern of reactivity over time.       127 
Chapter 7: General discussion 
The close genetic and antigenic relationship between BIV and JDV raised 2 issues 
that were investigated and are reported in this thesis. First, in animals that are 
infected with both viruses, it was hypothesised that there might be cross-protective 
immunity or other interaction between the 2 viruses that could modify their 
pathogenesis. Second, there is a need for serological tests that will differentiate 
antibody to the pathogenic JDV and other non-pathogenic bovine lentiviruses. The 
presence of a BIV-like virus in cattle on the island of Sulawesi where Jembrana 
disease does not occur could have a marked effect on the events that might occur if 
JDV spreads to that island. In an endemic area, previous infection with a non-
pathogenic bovine lentivirus like BIV might ameliorate the effect of subsequent 
infection with JDV, resulting in subclinical JDV infections. Immunosurveillance for 
JDV infection would be affected by the presence of a second antigenically cross-
reactive but non-pathogenic bovine lentivirus in the cattle population of Indonesia. 
The investigations reported in this thesis have provided information that clarifies 
these issues.  
Evidence was provided previously for the occurrence of a non-pathogenic bovine 
lentivirus in Bali cattle in Indonesia, although this was based on serological evidence 
only and the virus has not been detected. This serological evidence, particularly that 
presented by Barboni et al. (2001), is difficult to evaluate because other 
investigations have demonstrated a very close antigenic relationship between JDV 
and BIV and there are no reagents or tests available that allow differentiation of 
antibody to the 2 types of virus in cattle sera (Desport et al, 2005). Antibody to JDV 
was detected in B. javanicus in Sulawesi where there is no evidence of Jembrana 
disease (Hartaningsih, personal communication) suggesting the presence of a non-      128 
pathogenic bovine lentivirus antigenically related to JDV. Blood from a seropositive 
animal in Sulawesi was inoculated into Bali cattle in an attempt to transmit the non-
pathogenic bovine lentivirus but these attempts were unsuccessful (Hartaningsih, 
personal communication). For further investigation of the effects of the Indonesian 
strain of this non-pathogenic bovine lentivirus in Bali cattle, an attempt was made to 
detect the virus in cattle on the island of Bali (Chapter 3). A large number of cattle 
were screened using PCR and serological assays which detect both BIV and JDV. 
While a number of cattle were identified that contained proviral JDV DNA, BIV 
proviral DNA was not detected and the investigations reported in Chapter 3 therefore 
provide no evidence for the occurrence of a second non-pathogenic bovine lentivirus 
in these cattle. Isolation of virus in cell culture was not attempted in this study due to 
a lack of suitable facilities. 
The lack of evidence of a BIV-like virus reported in Chapter 3, however, was 
insufficient to eliminate the possibility that there is a second non-pathogenic bovine 
lentivirus in the cattle population of Bali as only a limited number of samples from 
one area were screened and the seroprevalence was lower than expected. Previous 
investigators have concluded that BIV is difficult to detect in cattle. While numerous 
studies have reported serological evidence for BIV infection (Barboni et al., 2001; 
Bhatia et al., 2008; Horzinek et al., 1991; Meas et al., 1998; Meas et al., 2000a; 
Whetstone et al., 1990) there have been only 3 reports of isolation of the virus from 
cattle (Meas et al., 1998; Suarez et al., 1993; Van der Maaten et al., 1972). Suarez et 
al. (1993) were only successful in the isolation of virus on 2 occasions from many 
samples and only after 4 blind passages of samples in cell culture. A very exceptional 
result was reported from Japan, where an unusually high isolation rate of BIV in cell 
culture was reported from PBMC and milk-derived leukocytes from BIV-antibody-      129 
positive dairy cattle. These isolates had 99.0 to 99.7% nucleotide sequence identity 
with the R29 strain of BIV within a 258 nucleotide amplicon from the pol region.  
These authors were also able to identify BIV proviral DNA by nested PCR and 
Southern blot in cattle and buffalo samples from Japan, Cambodia and Pakistan 
(Meas et al., 1998; Meas et al., 2000a; Meas et al., 2000b). The reports by Meas and 
colleagues are interesting as they suggest that infection with BIV is widespread and 
reasonably easy to detect in buffalo and cattle in Asian countries, and that virus 
isolation was possible from antibody-positive cattle. 
The study of BIV infection in Bali cattle reported in Chapter 4 is the first report of 
the pathogenesis of BIV infection in this species. Because of the unusual 
susceptibility of Bali cattle to JDV and Malignant catarrhal fever virus (Soesanto et 
al., 1990) it was hypothesised that these cattle might also show a greater 
susceptibility to BIV than do B. taurus but their susceptibility appeared generally 
similar to the effects reported in B. taurus (Scobie et al., 1999; Suarez et al., 1993; 
Whetstone et al., 1990). We also considered that BIV in Bali cattle might have very 
different effects to those observed in B. taurus, as some lentiviruses do not cause 
disease in their natural host (VandeWoude et al., 2006) but do so in heterologous 
hosts, a phenomenon best described with SIV strains (Apetrei et al., 2004) but also 
recognised with other lentiviruses such as puma and lion lentivirus infection in 
domestic cats (VandeWoude et al., 1997). It has been reported that infection of B. 
taurus with JDV resulted in a mild disease only, of much less severity that observed 
in B. javanicus (Soeharsono et al., 1995a), and the reciprocal event, greater 
susceptibility of Bali cattle to BIV was a potential outcome. 
Bali cattle inoculated with BIV did not develop clinical signs within 62 days of 
infection and this suggested that if the putative bovine lentivirus present in Sulawesi       130 
is indeed related to BIV-R29, then it should have no significant effect on animal 
health in the Bali cattle population. A result that is significant in terms of the optimal 
method for detection of natural BIV infection in Bali cattle, and possibly B. taurus, 
was that there was a transient period of viraemia detected after infection and it is 
during this period that the virus would be most easily detected. However, in natural 
infections, the timing of infection is unknown and therefore these results show that 
the choice of assay is an important one. If a recent infection is suspected, then a 
genome based assay would be most likely to detect infection but if a longer term 
infection is suspected then a ELISA using a TM peptide would be more appropriate. 
This transient period of viraemia was analogous to that which occurs in other animal 
lentivirus infections such as JDV infection of Bali cattle (Stewart et al., 2005), EIAV 
infection of horses (Harrold et al., 2000) and SIVsmm-PBj14 infection of pig-tailed 
macaques (Dewhurst et al., 1990; Fultz et al., 1989), although BIV was found to have 
significantly lower titres than these viruses. It is suggested that BIV infection of B. 
taurus should be re-examined using sensitive techniques such as qRT-PCR to see 
whether a similar acute phase viraemia is produced. Sensitive techniques need to be 
used in such an investigation as the level of viraemia in Bali cattle infected with BIV 
was low and virus was not detected consistently in any animal, reflecting the 
difficulty of detecting BIV infection even in experimentally infected cattle. The 
majority of infected cattle had a significant TM antibody response but a poor CA 
response but this occurred after the transient viraemic period, suggesting that 
detection of BIV proviral DNA would be most successful in antibody-negative cattle, 
similar to the result obtained for JDV in field cattle (Chapter 3). The ability to detect 
BIV prior to the onset of an antibody response but not afterwards is in contrast to the       131 
report of the high frequency of isolation of BIV from antibody-positive cattle in Asia 
(Meas et al., 1998). 
A limitation of this current study of BIV-R29 in Bali cattle is that an Indonesian BIV 
isolate was not discovered and could not be used for experimental studies, and the 
BIV-R29 isolate used might not reflect what would occur with the putative BIV-like 
virus present in Indonesia. However, other Asian isolates have been shown to be 
closely related to BIV-R29 (Meas et al., 1998). The R29 strain of BIV may have a 
different pathogenesis to the BIV-like virus present in Indonesian cattle. The results 
obtained may also not be typical of BIV infection under field conditions as it is 
considered by some that the BIV-R29 strain may have, since its isolation in 1969 
(Van der Maaten et al., 1972), become attenuated during its prolonged storage and 
passage in cell culture (Whetstone et al., 1997). However, an unsuccessful attempt 
was made to increase the virulence of BIV-R29 by its serial passage through cattle 
(Whetstone et al., 1990), a technique known to increase the virulence of EIAV 
(Orrego et al., 1982), and perhaps this inability to increase its virulence reflects a 
natural low pathogenicity. Other BIV strains isolated from Florida were thought to be 
more pathogenic than BIV-R29, causing a B-cell lymphocytosis in experimentally 
infected cattle, but the effects of the Florida isolates in cattle were still very mild 
(Suarez et al., 1993; Whetstone et al., 1997). It is possible, however, that the 
inoculation of the Florida isolates into Bali cattle may produce results different to 
that observed with the R29 strain.  
The lower antibody response to the CA versus the TM antigen was an unexpected 
finding in BIV-infected Bali cattle. Animals infected with lentiviruses normally 
develop a strong antibody response to CA and this response is the first to be detected 
(Rosati et al., 2004; Soutullo et al., 2007). A strong response to CA has also been       132 
documented in Bali cattle infected with JDV (Hartaningsih et al., 1994) although 
there is a subset of JDV infected Bali cattle that do not develop a detectable CA 
antibody response (Desport et al., 2009a; Ditcham et al., 2009). A loss of Gag-
reactivity in the presence of a sustained Env response has previously been reported in 
B. taurus infected with BIV (Isaacson et al., 1995).   
In several lentivirus systems, infection with a non-pathogenic lentivirus is able to 
protect against subsequent superinfection with a closely related pathogenic lentivirus 
(Cranage et al., 1998; VandeWoude et al., 2002). An investigation of whether the 
same was true for BIV and JDV in Bali cattle showed that BIV-R29 infection did not 
induce a protective immune response against subsequent infection 42 days later with 
JDV. All BIV-infected animals inoculated with JDV became infected and had a 
viraemic phase and a febrile response typical of JDV infection. However, while 
previous BIV infection did not protect against subsequent JDV infection, there was 
no enhancement of JDV infection even though it did cause an earlier onset and 
resolution of fever that was associated with JDV infection. The result suggests that if 
BIV-R29 is related to the BIV-like lentivirus circulating within the cattle population 
of Sulawesi, if JDV were introduced into the cattle population of Sulawesi it would 
not lead to disease enhancement.  
The lack of any evidence of a protective immunity against JDV as a consequence of 
previous BIV infection was unexpected, considering the extensive antigenic cross-
reactivity of JDV and BIV proteins and evidence of an antibody response to BIV at 
the time of superinfection with JDV. It will be necessary to determine if protection 
against JDV can be achieved by altering the parameters of the superinfection.  
Perhaps if the dose of BIV used to infect the cattle was increased this would affect 
the result: higher doses of SIVmacC8 provided greater protection against challenge       133 
with SIVmac (Cranage et al., 1998). Alternatively, the time interval between BIV and 
JDV infection could be important: greater protection has been provided by a 
decreased time of 21 days between superinfection with closely related simian 
lentiviruses (Stebbings et al., 2004) but it is also possible that a longer interval may 
be required for the development of a cell-mediated immune response. Although 
desirable, analysis of cell-mediated immune responses was not possible and so the 
type of immune response required to control infection could not be adequately 
assessed.  
An important technical requirement for immunosurveillance of JDV infection in 
Indonesia is the development of reliable and specific serological tests. JDV and BIV 
contain an extensive array of cross-reactive epitopes on several proteins (Desport et 
al., 2005; Kertayadnya et al., 1993) and using serological assays, differentiation of 
infection by the 2 viruses using serological assays is currently not possible. The 
investigation reported in Chapter 6 where a series of overlapping peptides spanning 
the MA, CA and SU regions of JDV was used to identify epitopes that would react 
specifically to JDV and not BIV has identified potential peptides that could be used 
for this purpose. Seven peptides were identified within the MA-CA and the CA-NC 
junctions, while 5 were identified in SU, that reacted with >75% of sera from JDV-
infected cattle. Unfortunately, these peptides also reacted with some sera from BIV-
infected cattle and could not therefore be used for the development of a JDV-specific 
serological assay. A combination of these peptides could, however, be used as an 
alternative antigen for the development of a broadly-reactive bovine lentivirus 
serological test. A number of peptides were identified which reacted with sera from 
JDV-infected cattle only and hence have potential for development of a JDV-specific 
serological assay. These peptide combinations must now be tested using an extensive       134 
array of sera from naturally infected cattle from areas of Indonesia where infection 
with both BIV and JDV have been suspected, such as Bali, and in regions where 
infection with a non-pathogenic BIV is suspected and where Jembrana disease has 
not been detected, such as Sulawesi. A longitudinal series of serum samples from 
individual cattle also needs to be tested to determine how the antibody response to 
the peptides changes over time.  
In conclusion, the results reported in this thesis have made a significant original 
contribution to our understanding of BIV infection in Bali cattle that indicate BIV is 
unlikely to be a significant pathogen in these cattle.  The results obtained have also 
provided insights into the interaction of BIV and JDV in Bali cattle which suggest 
that previous BIV infection will not provide significant cross-protective immunity 
against subsequent JDV infection, and that BIV infection is unlikely to provide a 
simple method of vaccinating cattle against JDV infection. The results have also 
provided information about epitopes of the Gag and SU proteins of JDV that indicate 
there are potential epitopes on these proteins that could be used for the development 
of JDV-specific serological tests needed in Indonesia.       135 
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